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There is a substantial need among clinicians for health-related, evidence-based recommendations. 
Evidence-based recommendations help distill research findings and aid health care providers in 
making clinical decisions. However, it is infeasible for providers to sort through thousands of 
available guidelines, and heterogeneity among recommendation developers (e.g., composition, 
processes, outputs) can make it difficult for clinicians to identify which recommendations are 
trustworthy, feasible, and applicable to their patient population. Even when there is broad 
consensus about the quality and utility of recommendations, a range of contextual factors (e.g., 
the health care system, patient characteristics, enabling resources) can impede implementation. 
This study examined the diffusion of evidence-based recommendations through professional 
societies to clinically-trained members, and explored knowledge, attitudes, beliefs, and behaviors 
regarding evidence-based recommendations and practice. The study had three aims:    
1) Describe the role primary care professional societies play in developing and/or 
disseminating evidence-based reports and recommendations. 
2) Determine if the needs of primary care providers and their professional societies for 
evidence-based reports and recommendations are being met. 




To achieve these aims, content analysis was used to examine transcripts from 34 semi-structured 
telephone interviews of leaders and members from eight health-related professional societies. 
Nonprobability, purposive sampling of knowledgeable experts enabled in-depth exploration of 
phenomena. An interview guide was developed using theory-driven concepts and theoretical 




included theory-and data-driven codes and was revised through an iterative process that included 




There were differing views on the meaning of “evidence-based”, but there was broad agreement 
on its scientific underpinning and the importance of conducting “evidence-based practice.” 
Professional societies can play several roles (i.e., disseminator, liaison, developer, and/or 
facilitator) in the promotion of evidence-based recommendations and practice. Views varied on 
whether the needs of primary care providers and their professional societies for evidence-based 
reports and recommendations were being met. Federally-sponsored recommendation developers 
were viewed as valuable contributors to evidence-based practice because of their objectivity, 
transparency, balance, methodological rigor, and prioritization. Study participants offered many 
suggestions for improving the development, feasibility, readability, acceptability, and 
dissemination of evidence-based recommendations. Participants also offered input on how 
federally-sponsored recommendation developers could strengthen their partnerships with 




The issue of trust was central to participants’ attitudes and beliefs; therefore, recommendation 
developers should integrate transparency and three factors that bolster trust (ability, benevolence, 
and integrity) into their processes. Federally-sponsored recommendation developers should 
consider collaborating with professional societies in a variety of ways to develop and disseminate 
recommendations to facilitate evidence-based practice. The federal government can also promote 
the use of evidence-based recommendations by improving its guideline clearinghouse, expanding 
health insurance coverage to more Americans, requiring that recommendations be covered by 
insurance, and supporting research on point-of-care decision support tools, electronic health 
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CHAPTER 1: INTRODUCTION 
 
 
The lead investigator for this study is an employee of the National Institutes of Health (NIH), 
Office of Disease Prevention (ODP) and a doctoral candidate at the Johns Hopkins School of 
Public Health. This study was initiated to: 1) provide a formative evaluation of an ODP program 
and 2) contribute original research to the social and behavioral sciences. This dissertation couples 
both efforts in order to promote a broad understanding of the diffusion of evidence-based 
recommendations and describes a federal program that sponsors the development of 
recommendations as well as the perspective of stakeholders that accept or reject those 
recommendations. 
Formative Evaluation for the NIH Office of Disease Prevention 
The formative evaluation was intended to provide the ODP with information to assist 
decision-making and improve the design and outcomes of its Consensus Development Program 
(CDP). The CDP convened scientific panels to produce unbiased, evidence-based assessments of 
controversial and complex medical issues and offered evidence-based recommendations to 
advance research and clinical practice. The CDP assembled 159 panels from 1977-2013 and 
disseminated panel assessments and recommendations to a variety of stakeholders (e.g., 
researchers, health care providers, policymakers, patients).  
Many at NIH voiced support for the CDP, but by 2010, senior NIH leadership was 
questioning the program’s methods and utility. In response, the ODP began a formative 
evaluation focused on the CDP’s structure, methods, and dissemination of recommendations to a 
key stakeholder constituency (i.e., primary care providers and the professional societies that 
represent them). The study was designed to explore many issues, including: 
• Panel composition and processes 




• The usefulness of CDP recommendations in promoting evidence-based care 
• Suggestions for improving the CDP, enabling it to provide more trustworthy, pertinent, 
and feasible recommendations for its stakeholders. 
Despite efforts to evaluate and improve the program, the CDP was retired in 2013 following 
an office reorganization. In its place, the ODP created a new, but similar program, Pathways to 
Prevention (P2P). The P2P program also convenes scientific panels, but these panels primarily 
make research, not clinical, recommendations. Additionally, the P2P program was built to 
accommodate cost-saving measures and have more timely processes than the CDP.  
The retirement of the CDP did not end the program evaluation; rather, it served to broaden its 
scope. To gain a better understanding of how scientific panels can be effective in developing and 
disseminating evidence-based recommendations, research questions were expanded to collect 
information about other panels supported by federal agencies, nonprofit organizations, disease 
specific societies, and medical specialty societies. While the findings of this study identify the 
CDP’s strengthens and weaknesses, it also notes these characteristics in other panels as well, 
providing the ODP with insights for enhancing P2P and other programs and initiatives. 
Furthermore, the evaluation offers guidance for improving other federally-sponsored panels (e.g., 
U.S. Preventive Services Task Force, Community Preventive Services Task Force), which are 
ODP partners. 
Contributing Original Research to the Social and Behavioral Sciences 
This study contributes original research to the social and behavioral sciences by applying 
well-known theories and theoretical frameworks to examine phenomena from the perspective of 
professional society leaders and members. Everett M. Rogers’ (2003) Diffusion of Innovations is 
used to examine professional society characteristics, activities, perceived innovativeness, and 
promotion of evidence-based assessments and recommendations. Ronald Andersen’s (1995) 




influence the implemenation of evidence-based recommendations. Eliot Freidson’s (1984) work 
on professional practice and control is used to analyze tensions between those that develop 
recommendations and those asked to carry them out. The study explores individual and social 
environmental factors that impact the translation of research into practice. 
The Need for Evidence-Based Recommendations and Obstacles to Their Implementation 
 
This study examined the diffusion of evidence-based recommendations—through 
professional societies to their clinically-trained members—in order to promote quality, evidence-
based practice. There is a substantial need among clinicians for health-related, evidence-based 
recommendations. There are thousands of randomized controlled trials (RCTs) published 
annually, and evidence-based recommendations help distill research findings and aid health care 
providers in making clinical decisions (IOM, 2011). However, it is infeasible for providers to sort 
through the approximately 6,500 published guidelines (GIN, 2013), that have been developed by 
a variety of scientific panels from over 200 organizations (NIH-CDP, 2010b). Moreover, 
heterogeneity in panel composition, processes, and outputs can make it difficult for clinicians to 
identify which recommendations are trustworthy, feasible, and applicable to their patient 
population. Even when there is broad consensus about the quality and utility of recommendations, 
a range of contextual factors (e.g., the health care system, patient characteristics, enabling 
resources) can impede implementation (Andersen, 1995). With so many obstacles hindering the 
translation of quality research into clinical practice, the lag time between scientific discovery and 
when most Americans benefit from research findings has been estimated to be 17 years (Clancy, 
2006).  
 
Using the Topic of Colorectal Cancer Screening to Anchor the Study 
Examining the diffusion of evidence-based recommendations can become unwieldy with 




colorectal cancer screening, to anchor the study and serve as a starting point for discussion with 
study participants. Focusing on this topic was useful for the following reasons:  
1) Colorectal cancer (CRC) screening was the focus of a 2010 CDP panel, which provided 
recommendations on the topic. 
2) The Institute of Medicine (2011) highlighted CRC in a report because of the 
heterogeneity in screening recommendations provided by a variety of scientific panels. 
3) CRC is of broad public health importance and the implementation of screening guidelines 
has been shown to save lives (AHRQ, 2010). However, researchers at the National 
Cancer Institute found that only 19.1% of physicians made “guideline-consistent 
recommendations across all CRC screening modalities” (Yabroff et al., 2010).  
The topic of CRC screening exemplifies complexities surrounding the development of evidence-
based recommendations and permits examination of how life-saving innovations (CRC screening 
modalities, packaged in recommendations to direct use) are accepted or rejected by professional 
societies, disseminated to membership, and utilized by clinicians. Although CRC screening 
served as a starting point for discussion, it often led to comments about other topics (e.g., breast 
cancer screening, prostate cancer screening, cholesterol screening) tackled by both federal and 
non-governmental panels.  
Study Aims and Methods 
 
The overall goal of this study was to identify the role of scientific, federally-sponsored panels 
in promoting evidence-based practice and determine how these panels can better meet the needs 
of primary care providers and their professional societies for evidence-based reports and 
recommendations. The study aimed to: 
1) Describe the role primary care professional societies play in developing and/or 




2) Determine if the needs of primary care providers and their professional societies for 
evidence-based reports and recommendations are being met. 
3) Describe the value that the federal government contributes to evidence-based practice. 
To achieve these aims, content analysis was used to examine 34 semi-structured interviews of 
leaders and members from eight health-related professional societies. 
Study Findings Related to Aims and Dissertation Structure 
This study found that professional societies play a variety of roles in promoting evidence-
based practice, including those of information disseminator, partnership liaison, direct developer 
of recommendations or measures, and facilitators of evidence-based programs and initiatives. 
Professional societies aim to change health provider practice through a variety of mechanisms 
(e.g., journal articles, official guidelines, conferences, strategic programs and initiatives) and the 
federal government could work more closely with these organizations to leverage resources and 
promote evidence-based practice. 
Scientific panels sponsored by federal agencies and non-governmental organizations are 
meeting some of the need for evidence-based reports and recommendations. However, there are 
gaps in the topics covered, confusing heterogeneity among recommendations, many poor quality 
recommendations, and a lack of transparency that inhibits a clinician’s ability to directly and 
accurately evaluate and compare recommendations. The federal government can address these 
issues by bolstering national clearinghouse criteria for guidelines, identifying research gaps, 
funding new applicable research, and partnering with others to harmonize recommendations.  
Federally-sponsored scientific panels are valuable contributors to evidence-based practice, 
bringing objectivity, transparency, balance, methodological rigor, and effective prioritization to 
the development of evidence-based reports and recommendations. Moreover, the federal 





This dissertation comprises five chapters. Following the introduction, Chapter 2 provides 
information about the NIH Office of Disease Prevention and the Consensus Development 
Program; colorectal cancer and its screening; health-related reports, recommendations, and the 
scientific panels that create them; health professions; and Rogers’ (2003) Diffusion of 
Innovations. Chapter 3 provides a description of study methods, including study population, 
sampling, recruitment for semi-structured interviews, guiding qualitative approaches, data 
collection and analysis, and human subjects considerations. Chapter 4 reports the study’s results, 
with illustrative quotes from interviewees. Chapter 5 discusses the study’s findings, limitations, 



































CHAPTER 2: LITERATURE REVIEW 
2.1 Overview 
This chapter begins with a review of the NIH Office of Disease Prevention and its Consensus 
Development Program (CDP), including the creation, guiding principles, outcomes, critiques, and 
retirement of the CDP. This is followed by an examination of colorectal cancer screening, an 
important public health topic the CDP assessed in 2010, which also elucidates the complexities of 
diffusing evidence-based recommendations (e.g., quality and heterogeneity of scientific panels 
and their recommendations, contextual factors which impede the implementation of evidence-
based strategies). The next section addresses the need for trustworthy panel processes and outputs 
and proposed standards for developing them. This is followed by a review of health professions 
(i.e., their control, determinants of provider practice, practice change, and tension among 
professionals) and the functions professional societies serve—including translating evidence into 
practice. The chapter concludes with a review of Everett M. Rogers’ theoretical framework, 
Diffusion of Innovations, and the specific aims and research questions of this study. 
2.2 NIH Office of Disease Prevention (ODP) and Evaluation of an ODP Program 
The ODP was created in 1986 to promote and coordinate disease prevention and nutrition 
research activities and to conduct evidence-based assessments of the state of the science and 
medical practice. (ODP, 2014). To help fulfill this mission, the ODP inherited the NIH Consensus 
Development Program, which was intended to produce unbiased, evidence-based reports of 
controversial or complex medical issues to advance understanding among health professionals 
and the public (NIH-CDP, 2011a). 
Beginning in late -2010, the ODP sought a formative evaluation of the CDP to identify ways 




provide an understanding of the CDP’s strengths and weaknesses, but they also provide the ODP 
with valuable insights for enhancing other programs and initiatives.  
The ODP, which has been reorganized several times (most recently in 2012), released a 
strategic plan in 2014 which centered on efforts intended to: 
• Extend the value of ODP as a resource to the NIH and broader prevention research 
community 
• Provide guidance in prevention research methodology  
• Identify gaps in existing evidence  
• Facilitate coordination of new activities to address those gaps 
• Promote quality improvements in the review of prevention research 
• Increase the impact and visibility of prevention research. (ODP, 2014c). 
The results of this study support several of the efforts listed above and directly assist the ODP in 
achieving a key strategic priority:  
Identify and promote the use of evidence-based interventions and promote the conduct of 
implementation and dissemination research in prevention. (ODP, 2014d) 
2.3 NIH Consensus Development Program 
 
Impetus for Creating the CDP 
In the 1970’s, there was substantial public pressure to increase medical accountability due to 
rising health care expenditures and the perception that “these increases were at least partly due to 
the premature application of expensive technical innovations in medicine before their safety, 
efficacy, and costs had been adequately evaluated” (Perry, 1987, p. 485). In 1976, the 
Congressional Office of Technology Assessment concluded that reviews of medical innovations 
would be useful in decision-making, and Senators Jacob Javits (R-N.Y.) and Edward Kennedy 




societal impacts of medical technologies (Perry & Kalberer, 1980; Wortman et al, 1988). In 
response, the NIH created the CDP in 1977. 
Principles and Mechanics of the CDP 
The CDP sought to improve the translation of biomedical research into knowledge that could 
be used effectively in the practice of medicine and public health (Lowe, 1980). To achieve its 
aim, CDP processes were designed to be objective, evidence-based, and involve the public. (NIH-
CDP, 2010c). See Figure 1.  
Figure 1: Foundation of NIH Consensus Development Program Processes. (NIH-CDP, 2010c) 
 
 
Topic proposals were developed by NIH scientists—sometimes in collaboration with other 
federal partners, such as the Centers for Disease Control and Prevention—in response to research 
gaps or the failure of strong evidence to be widely translated into clinical practice (NIH-CDP, 
2012b). Topic proposals were submitted to the ODP for initial consideration and later reviewed at 
an organizational meeting with staff from relevant NIH Institutes and Centers and other federal 




• Have clinical and broad public health importance - the severity of the problem and the 
feasibility of interventions were key considerations 
• Be controversial or unresolved and amenable to clarification, or reflect a knowledge and 
practice gap that could be narrowed 
• Have an adequately defined base of scientific information from which to answer topic 
questions. (NIH-CDP, 2012b) 
Once a topic was accepted at an organizational meeting, a planning committee of federal and non-
federal experts would be convened to: 1) finalize key questions to be addressed, 2) set a date and 
agenda for a CDP conference, 3) nominate conference speakers, and 4) nominate panelists to 
weigh the evidence and develop a consensus statement (NIH-CDP, 2010c).  
After the planning committee meeting, a systematic evidence review would be performed by 
one of the Agency for Healthcare Research and Quality’s Evidence-based Practice Centers. The 
resulting evidence report would be examined by an independent panel, which had been carefully 
screened to ensure members had no financial or intellectual conflicts (NIH-CDP, 2011b).  
Six to eight weeks after the panel received the evidence report, a two-and-a-half day 
conference would be held, consisting of expert presentations and town hall forums to facilitate 
open discussion among panelists, speakers, and the general public. Lowe (1980) argued that these 
conferences differed from standard scientific state-of-the-art meetings in that CDP panels had to 
consider specific sets of questions and issue recommendations framed around those questions. 
CDP conferences were likened to a “judicial process or ‘science court’ procedure”; the 
conference questions constituted the charge, the evidence report, speakers’ presentations, and 
audience comments provided the evidence, and the panel served as a jury to weigh the evidence 
and reach a verdict (Wortman et al, 1988, p. 471). The verdict, in the form of a consensus 
statement, was presented on the third day of the conference for audience commentary. Federal 
officials were not directly involved in the deliberations of the panel, as NIH staff served only as 




the conference and disseminated to a variety of stakeholders, including professional societies and 
their members.  
By its retirement in 2013, the CDP had sponsored 159 conferences. The CDP held two types 
of conferences: State-of-the-Science Conferences and Consensus Development Conferences. 
Both had the same structure and methodology; they differed only in the strength of the evidence 
surrounding the topic in question (NIH-CDP, 2010d).  
When it appears that there is very good evidence about a particular medical topic, but that 
the information has not been taken up into widespread clinical practice, a Consensus 
Development Conference is typically chosen, in order to consolidate, solidify, and 
broadly disseminate a strong evidence-based recommendation for general practice. 
Conversely, when a medical issue has weak or contradictory evidence, or practice habits 
not based in high-quality evidence are widespread, a State-of-the-Science Conference is 
chosen in order to highlight what evidence about a topic is available, the directions future 
research should take, and to alert physicians that certain practices do not have good data 
to support them. (NIH-CDP, 2010d, p. 1) 
CDP Outcomes 
Portnoy et al. (2007) found that CDP conferences appeared to stimulate new, relevant 
research activities, including NIH-issued initiatives (e.g., requests for applications, program 
announcements, notices) and investigator-initiated grants. However, the influence of CDP 
conferences on health providers appeared to be mixed. For example, after a conference on 
computed tomography scans of the brain, “only about one third of neurosurgeons or neurologists 
knew of the conference and less than half of these were aware of the conclusions” (Perry, 1987, p. 
487). In contrast, conferences on burn care and liver transplantation appear to have influenced 
provider practice and Medicare coverage policies (Burke, 1981; Perry, 1987). Kosecoff et al 




821), but that conferences mostly failed to stimulate changes in clinical practice (Kosecoff et al, 
1987). 
Critiques of the CDP 
Lowe (1980) pointed out that NIH Consensus Statements, which were authored by 
independent panelists, were not regulations; they simply represented “the best current thinking by 
those in the best position to know” (p. 1584). However, since program inception, some medical 
groups voiced concern that panel recommendations might become regulations, which could turn 
physicians into “automatons” whose actions were dictated by a small group (Perry, 1987).  
The lure of consensus is powerful. Once a consensus is defined—correctly or 
otherwise—there will be those in academia, in public health, in the insurance fields, in 
health maintenance organizations, and most surely and most terribly in the fields of law 
and government who will desire and will move to require strict conformity of practice to 
the presumed ideal…We must protect the individual choices of each physician from the 
potential tyrannical domination of consensus. (May, 1985, p. 1077) 
The Director of the American College of Surgeons questioned whether CDP conferences should 
be boycotted (Hanlon, 1980) and one medical professional society threatened to sue the NIH and 
its panelists (Perry, 1987). 
An NIH-funded evaluation of the CDP in the 1980s found that the program was “arguably the 
most visible and influential medical technology assessment activity in the United States” 
(Wortman et al, 1988, p. 495); however, there were flaws that undermined its credibility, 
including: 
• The potential for selection bias - particularly with respect to the choice of questions, 
which “generally reflect the substantive concern of the institute staff responsible for the 
conference” (p. 476), and panelists, who in the “absence of a systematic, formal 
procedure…are often suggested and selected by NIH staff (including planning committee 




• Insufficient time during conferences to adequately review the evidence, manage 
disagreements, and draft consensus statements. 
Ferguson & Sherman (2001) echoed concerns over time constraints. They surveyed panelists 
from 69 conferences and noted substantial criticism of the short window of time to draft the 
statement, which required late evenings of writing after long days of conference presentations.  
Kosecoff et al (1987) argued that CDP conferences were an important education tool. 
However, it was also noted that better selection of topic questions might have increased the 
relevancy and effectiveness of conferences and that follow-up programs should have been 
encouraged for the purpose of dissemination and implementation (Kosecoff et al., 1987 & 1990).  
When the ODP was reorganized in 2012, NIH leadership voiced concern that the CDP was 
expensive, lacked nimbleness, and was duplicative since other organizations were conducting 
evidence-based assessments. In 2013, the NIH retired the CDP, noting: 
The CDP was created during a time when few other organizations were providing 
evidence reviews.  Today, there are many other organizations that conduct such reviews, 
including other federal agencies, academic institutions, and private organizations.  
Examples include the U.S. Preventive Services Task Force, the Community Preventive 
Services Task Force, the Institute of Medicine, and The Cochrane Collaboration.  The 
CDP has served a very useful role, but one that is now served by other able parties. (NIH-
CDP, 2013) 
In place of the CDP, the ODP has developed a new program to conduct evidence-based 
assessments of complex public health issues. The Pathways to Prevention (P2P) program 
convenes workshops similar to the ODP’s former State-of-the-Science Conferences in that both 
were designed to address topics having weak or contradictory evidence. The P2P program is 
focused on identifying research gaps in a selected scientific area, identifying methodological and 
scientific weaknesses in that area, and suggesting research needs to move the field forward (NIH-




Science Conferences, and they focus on research gaps not being addressed by other scientific 
panels. This study, while helping to evaluate the CDP, will also provide the ODP with 
stakeholder input for strengthening the P2P program. 
2.4 Colorectal Cancer Screening 
 
Evidence-based recommendations have been developed for numerous topics. To elucidate 
important issues in developing and implementing recommendations, this study focused on 
colorectal cancer screening. This topic was the focus of a 2010 CDP conference (NIH-CDP, 
2010a) and was highlighted by the Institute of Medicine in 2011 for its complexity and 
heterogeneity of recommendations (IOM, 2011). Colorectal cancer screening served as a starting 
point for discussion, and often led to insightful comments about other screening 
recommendations in primary care practice. Background information on colorectal cancer 
screening is provided below.  
Disease Burden 
Colorectal cancer (CRC) is the third most common nonskin cancer and the third highest cause 
of cancer death among men and women in the United States (NCI, 2011). There were an 
estimated 142,820 new cases and 50,830 deaths in 2013 (NCI, 2014). Before age 50, men and 
women have similar incidence and mortality rates; however rates are higher in men after the age 
of 50 (NCI, 2011).  Non-Hispanic blacks have the highest incidence and mortality rates of any 
racial or ethnic group and are more likely to develop colorectal cancer at an earlier age (IOM, 























In addition to the burden of illness and tragedy of lives lost, there are tremendous economic costs 
related to the disease; approximately $14.1 billion is spent annually for CRC medical 
expenditures (NCI, 2013). 
Natural History and Risk Factors 
Colorectal cancers begin as benign adenomatous polyps (Winawer, 1999), or adenomas, and 




This slow progression of disease permits clinicians to identify and remove adenomas before they 
develop into invasive cancers (IOM, 2008).  
Both hereditary and environmental factors play important roles in the development of CRC 
(Fearon and Vogelstein, 1990). Between 25% and 30% of people with CRC have hereditary 
factors that put them at increased risk for this disease (Fearon and Vogelstein, 1990; Winawer, 
1999).  
The increased risk is related to inflammatory bowel disease in 1%, to familial 
adenomatous polyposis in 1%, and hereditary nonpolyposis colorectal cancer (HNPCC) 
in 5%. The remaining 15%-20% of high risk individuals have a family history of 
colorectal cancer in close relatives without an identified genetic predisposition. 
(Winawer, 1999, p. 4S) 
The risk of CRC increases with age; there is a progressive rise from age 40 and a sharp 
increase after age 50 (Haggar & Boushey, 2009). Modifiable factors, such as diet, physical 
activity, obesity, smoking and alcohol intake, have also been associated with the development of 
colorectal cancer (Watson & Collins, 2011). Diets high in animal fat and meat are a major risk 
factor for disease (Boyle and Langman, 2000; Larsson & Wolk, 2006; Santarelli et al., 2008). 
Two “interrelated risk factors, physical inactivity and excess body weight, are reported to account 
for about a fourth to a third of colorectal cancers” (Haggar & Boushey, 2009, p. 195). Cigarette 
smoking is linked to the development of adenomas (Botteri et al. 2008) and it is estimated that 
12% of CRC deaths are attributed to smoking (Zisman et al., 2006). Lastly, heavy drinking, 
defined as 4 or more drinks a day, has been found to increase CRC risk by 52% (Pelucchi et al., 
2011). 
Screening Methods & Trends 
Death rates for CRC have fallen since the mid-1980s for both men and women (Edwards et 
al., 2010) and the decline accelerated in the last decade (annual decline between 2002-2005 was 




screening for the disease (Hanley, 2011; Pignone et al., 2002). There is substantial evidence that 
cancers diagnosed in average-risk asymptomatic individuals through screening are found at a 
more favorable stage and have lower mortality than cancers diagnosed in unscreened controls 
(Kronberg et al., 1996).  In general, there has been an upward trend in CRC screening rates 
among adults age 50 and older; for example, screening rates which were 20% to 30% in 1997, 
increased to nearly 55% by 2008 (Kahi et al., 2009). There are several screening tests for CRC, 
including the guaiac-based fecal occult blood test (gFOBT), fecal immunochemical test (FIT), 
flexible sigmoidoscopy (FS), and colonoscopy (NIH-CDP, 2010a). The use of two other 
screening methods, digital rectal examination and double contrast barium enema (DCBE), has 
precipitously declined in recent years, and two newer tests, fecal DNA and computed 
tomographic colonography (CTC), are not in widespread use (Cardarelli & Thomas, 2009). Fecal 
DNA screening may increase since the FDA’s Medical Devices Advisory Committee 
unanimously approved the use of a multi-target stool DNA screening test in March 2014 (Bin 
Han Ong, 2014). Screening tests can be divided into two categories: 1) tests that primarily detect 
CRC (gFOBT, FIT, fecal DNA) and 2) those that detect both CRC and precancerous colonic 
polyps (FS, colonoscopy, CTC, barium enema) (AHRQ, 2010a).  
Despite a range of screening methods, only gFOBT has been tested in full randomized 
controlled trials (RCTs) of CRC screening (AHRQ, 2010a). In the last 20 years, four RTCs of 
screening with gFOBT found a “relative reduction of 16 percent to 33 percent in CRC mortality 
(absolute risk reduction = 2.9 deaths/1,000 over 13 years in the U.S. trial), first appearing 5 to 7 
years after start of screening” (AHRQ, 2010a, 11). A good quality case-control study in the mid-
1990s bolstered the case for FS (Coughlin & Thompson, 2005). Some studies have indicated 
colonoscopy reduces CRC death rates (Kahi et al., 2009); however, the recommendation for 
colonoscopy has been largely based on extrapolated benefits from studies of FOBT and FS 




Colorectal Cancer Screening Issues 
Three issues have been cited that compromise the beneficial impact of CRC screening: 
underuse, overuse, and misuse. 
1) Underuse of Screening - Scientific panels have recognized the importance of CRC 
screening for asymptomatic average-risk adults, and the value of screening has also been 
“prioritized by the National Commission on Prevention Priorities as an important service 
with high public health value” (NIH-CDP, 2010b, p. 31). However, underuse of CRC 
screening among adults age 50-75 is a serious public health issue (NIH-CDP, 2010b).  
Although screening rates for CRC have increased in the last ten years for most population 
subgroups, disparities in screening exist.  Colorectal cancer screening rates are 
“significantly lower among minority, low SES [socioeconomic status], and rural 
populations” (NIH-CDP, 2010b, p.41). Moreover, screening rates have not significantly 
increased for individuals with no usual source of care, no physician visits in the past year, 
or who lack health insurance (NIH-CDP, 2010b). A number of factors contribute to low 
CRC screening rates; see Table 1 for a listing of factors cited in the literature (NIH-CDP, 
2010b; Zapka, 2008; Klabunde et al., 2005). 
Table 1: Patient, Provider, and System Level Factors that Contribute to Low Colorectal Cancer Screening 
Rates. (NIH-CDP, 2010b; Zapka, 2008; Klabunde et al., 2005) 
 
Patient Level Factors Provider Level Factors System Level Factors 
Lack of provider 
recommendation for screening 
Lack of knowledge or 
disagreement with guidelines 
Lack of reminder and 
tracking systems 
Lack of awareness and 
knowledge 
Concern over efficacy of the 
screening tests 
Lack of patient education 
and support 
Cultural attitudes, beliefs, and 
norms Forgetfulness 
Lack of insurance Lack of time 
Embarrassment Norms 
Inconvenience Reluctance to order screening due to cost 
Lack of time Perceptions of patient compliance 
Fear of cancer Competing medical priorities 
Perceived discomfort or pain 





2) Overuse of Screening - Overuse of CRC screening occurs when: 
• There is a preferential use of one test, such as colonoscopy, when less risky (e.g., 
fewer colonic perforations) and more convenient procedures are available, such 
as FOBT or sigmoidoscopy plus FOBT 
• Screening is used for older persons who are likely to receive insufficient benefit 
compared to potential harms (e.g., perforations, bleeding) 
• Surveillance colonoscopy (after removal of polyps) is conducted more frequently 
than guidelines suggest—resulting in greater potential harm than benefit (NIH-
CDP, 2010b). 
3) Misuse of Screening – Misuse refers to screening that is of low quality (e.g., 
colonoscopy that is poorly conducted or in-office FOBT—a test which should be 
conducted with three samples collected at home). Dreyfuss wrote that “in-office FOBT 
[of a sample collected during a digital rectal examination (DRE)] misses 95% of cases of 
advanced neoplasia, giving patients a false sense of reassurance” (Dreyfuss, 2005, p. 
275). 
Reducing underuse, overuse, and misuse are critically important to improving CRC screening 
outcomes, and some argue that appropriate screening recommendations are an important first step 
in improving screening practices. Ransohoff (2010) stated that because “practice guidelines 
provide a kind of starting place or ‘set point’ often used to judge overuse, underuse, or misuse, 
consideration of the quality of guidelines themselves is required” (NIH-CDP, 2010b, p. 45).   
Heterogeneity in Screening Recommendations 
The availability of evidence-based reports and recommendations is critical to health care 
providers and patients who face a range of screening options. However, the heterogeneity, 
quality, and trustworthiness of recommendations have been questioned (Shaneyfelt T.M. & 




Of concern is the more than 200 recommendation-developing organizations, covering a range 
of medical conditions (NIH-CDP, 2010b), with substantial differences in their processes and 
recommendations. 
Guidelines may differ not only in their recommendations but also in the process used to 
generate recommendations. Differences in process may occur in the composition of the 
groups of persons who assess evidence and make guidelines; in the process by which the 
evidence is weighed; and in the fundamental principles or goals that direct the guideline-
making process, for example, regarding whether patient outcome is the main focus.  
While guidelines ideally might be intended to “do what is best for the patient”, recent 
commentary has pointed out that that ideal may be compromised by conflicting interests 
of physicians or professional groups who participate in making guidelines (who may 
want to maximize economic outcome or professional activity) or from payer or 
governmental participation (who want to minimize economic costs). Because guidelines 
play such an important strategic role in practice and in overall quality of care, it is 
necessary to understand and manage the process of guideline making itself. (NIH-CDP, 
2010b, p. 45) 
A search in January 2012 using a free, online database of clinical practice guidelines—the 
National Guideline Clearinghouse (NGC) funded by AHRQ—with the term “colorectal cancer 
screening”, yielded 19 results from 17 organizations. See Appendix 1. Differences in CRC 
screening recommendations were highlighted at a 2010 CDP conference, where it was noted that 
recommendations varied regarding target age group for screening and type of screening test. 
Table 2 highlights the differences between two sets of recommendations that were discussed at 
the conference (1. United States Preventive Services Task Force [USPSTF] and 2. American 







Table 2: Colorectal Cancer Screening Recommendations from the U.S. Preventive Services Task Force and 
the American Cancer Society-U.S. Multisociety Task Force-American College of Radiology. (NIH-CDP, 
2010a) 
 
* Positive findings require follow-up colonoscopy. 
In 2011, the Institute of Medicine’s Committee on Standards for Developing Trustworthy 
Clinical Practice Guidelines noted that the divergent CRC screening recommendations from the 
USPSTF and ACS-MSTF-ACR contributed to confusion among clinicians and patients (IOM, 
2011). The IOM committee argued that differences in these recommendations were likely the 
result of disparate development methodologies and committee composition (IOM, 2011). 
Screening Test  Description  USPSTF  
  
ACS-MSTF-ACR  
Fecal occult blood test 
(FOBT)* and fecal 
immunochemical test 
(FIT)* 
Examination of the 
stool for traces of blood 
not visible to the naked 
eye 
Recommends high- 
sensitivity FOBT and 
FIT annually for ages 
50-75 
Recommends high-
sensitivity FOBT and 
FIT annually for  
ages ≥ 50 
Sigmoidoscopy* 
Internal examination of 
the lower part of the 
large intestine 
Recommends every 5 
years with high- 
sensitivity FOBT 
every 3 years for ages 
50-75 




X-ray examination of 
the colon -- 
Age ≥ 50, every  
5 years 
Colonoscopy 
Internal examination of 
the entire large 
intestine 
Recommends every 
10 years for ages 50-
75 




Examination of the 
colon and rectum using 
pictures obtained using 
a computed 
tomography scanner 
-- Age ≥ 50, every  5 years 
Fecal DNA* 
Examination of the 
stool for traces of 
colorectal cancer DNA 




To inform its work, the USPSTF drew on findings of a commissioned systematic review 
and benefit/risk simulation modeling (Pignone and Sox, 2008). The USPSTF methods 
were predefined, rigorous, and quantitative and they separated the systematic review 
process from that of guideline development (Imperiale and Ransohoff, 2010). However, 
Pignone and Sox (2008, p. 680) describe “some surprising choices” and missing analyses 
(e.g., cost/Quality Adjusted Life Years [QALY]) in the data modeling…In the joint ACS-
MSTF-ACR guideline...“the process of evidence review was not clearly separated from 
the process of guidelines-making” and “no pre-stated process [was] used to translate 
evidence into recommendations, nor was the strength of recommendations graded” 
(Imperiale and Ransohoff, 2010, p. 5). The joint ACS-MSTF-ACR guideline document 
codifies two guiding principles that informed their recommendations: (1) the importance 
of one-time test sensitivity…given poor adherence to lower sensitivity program 
approaches, and (2) the primacy of colon cancer prevention in screening efforts (Levin et 
al., 2008). Commentaries on the guideline raise concerns about oversimplifications 
inherent in these decisions (Imperiale and Ransohoff, 2010) and note that this is the only 
guideline in which the American Cancer Society has adopted and expressed such guiding 
principles (Goldberg, 2008). 
The USPSTF panel was composed of generalist physicians and methodologists 
(Imperiale and Ransohoff, 2010); the ACS-MSTF-ACR committee consisted of medical 
specialists and experts in the fields of radiology, gastroenterology, and oncology (Bottles, 
2010; Goldberg, 2008). Bernard Levin, a member of the joint panel, remarked in The 
Cancer Letter, “It is extremely hard to bring disparate professional groups together, to 
have them operate totally out of objectivity, not because they are bad people, but because 
they see the world through different lenses. Everyone, in some respects, has their vested 
interests” (Bottles, 2010; Goldberg, 2008, p. 3; Jacques, 2010). Such sentiments have 
been echoed in multiple commentaries relating to clinical practice guidelines, with 
authors recognizing that bias extends beyond financial interests to include intellectual and 
emotional interests as well (Lederer, 2007). (IOM, 2011, p. 58-59) 












Independent Panel of 
Generalist Physicians and 
Methodologists  
 
Disease Specific Society and  
Medical Specialty Society Whose Members 
are Medical Experts in the Fields of 
Radiology, Gastroenterology, and 
Oncology 
 
Source of Funding United States Government 
American Cancer Society, 
American College of Radiology, and  
US Multisociety Task Force on Colorectal 
Cancer 
Reported Financial 
Conflicts with Panel 
Members 
No Financial Conflicts 
Report Financial Conflicts Reported 




Systematic Review with 
Evidence Tables 
Review 
Method of Validating 
Recommendation 
Comparison with 
Guidelines from Other 
Groups, 
External Peer Review, and  




A recent study by Yabroff et al. (2010) examined physicians’ recommendations for colorectal 
cancer screening and found that only 19.1% of physicians made “guideline-consistent 
recommendations across all CRC screening modalities.” Clinician confusion linked to 





2.5 Health-Related Reports, Recommendations and Scientific Panels 
 
Need for Synthesized Research Evidence Reports and Health-Related Recommendations 
Despite the confusion caused by recommendation heterogeneity, there is a substantial need 
for recommendations and synthesized research evidence reports among many clinicians given the 
enormous volume of findings in the health literature. The number of randomized controlled trials 
published in MEDLINE grew from 5,000 annually in the early 1980s to 25,000 annually by the 
late 1990s (IOM, 2011). Furthermore, many “physicians have less than one hour per week to 
devote to reading the literature and limited skills in evaluating the quality of the research” 
(Albanese et al, 2009a, p. 1044). 
Scientific panels can provide an invaluable service to clinicians by analyzing copious 
amounts of data, distilling research findings, and creating synthesized research evidence reports 
and health-related recommendations that “reduce inappropriate practice variation, enhance 
translation of research into practice, and improve healthcare quality and safety” (IOM, 2011, p. 
xi). Evidence reports and recommendations can also promote a more cost-effective use of health 
care resources (Grilli & Lomas, 1994), encourage discussion among caregivers about best 
practices, and serve to strengthen the professionalism of medicine (Khorasani, 2010). 
Types of Reports, Recommendations, and Other Resources 
There are different types of reports, recommendations, and other resources geared toward 
assisting not only health care providers, but also patients and their families, policymakers, and 
researchers in making better informed decisions. Although there is no universal agreement on 
their definitions, the following descriptions are used for the purposes of this study. 
• Clinical Practice Guideline – A statement “to assist practitioner and patient decisions 




• Consensus Statement or Report – A document developed by a “panel of experts, usually 
multidisciplinary, convened to review the research literature for the purpose of advancing 
the understanding of an issue, procedure, or method” (O'Toole, 2003). 
• Expert Advice – Guidance based on an individual expert’s experience or knowledge 
(Katzburg et al., 2009).  
• Quality or Performance Measure – A criterion that can be used to “measure and quantify 
healthcare processes, outcomes, patient perceptions, and organizational structure and/or 
systems that are associated with the ability to provide high-quality care” (NQF, 2012). 
• Recommendation – Guidance developed by a panel of experts that “highlights the 
opportunities for improving delivery of effective services” (AHRQ, 2013). 
• Systematic Review – “A critical assessment and evaluation of all research studies that 
address a particular clinical issue. The researchers use an organized method of locating, 
assembling, and evaluating a body of literature on a particular topic using a set of specific 
criteria. A systematic review typically includes a description of the findings of the 
collection of research studies. The systematic review may also include a quantitative 
pooling of data, called a meta-analysis.” (AHRQ, 2014) 
Additionally, although the term “evidence-based” is ubiquitous in the literature, its meaning 
varies. The description below will be used for this study. 
• Evidence-based – “Applying the best available research results (evidence) when making 
decisions about health care” (AHRQ, 2014).  
There is disagreement about what constitutes evidence, but the CDP utilized an evidence pyramid 








Figure 3: Evidence Pyramid for the NIH Consensus Development Program. (NIH-CDP, 2011a) 
 
 
Using definitions supplied by AHRQ (AHRQ, 2014) and ODP lecturer W. Scott Richardson, 
M.D. (Staus, Richardson, Glasziou, and Haynes, 2011, p. 1), this study will consider evidence-
based clinical practice to be an integration of 1) the best research evidence available, 2) clinical 
expertise and, 3) the patient's unique values (i.e., preferences, concerns, expectations) and 
circumstances (i.e., individual clinical state and clinical setting). (AHRQ, 2014; Staus, 
Richardson, Glasziou, and Haynes, 2011, p. 1). 
Sponsoring Organizations, Their Scientific Panels, and Recommendations 
The National Guideline Clearinghouse has CRC screening recommendations from 17 
organizations (see Appendix 2), eight of which are included in this study (see Table 3). The eight 
organizations are U.S.-based, national in focus, provide recommendations for people at average 
risk of colorectal cancer, and consider mechanisms to support common CRC screening modalities 
(i.e., FOBT, sigmoidoscopy, double-contrast barium enema, colonoscopy, computed tomography 
colonography). 
In addition to these eight target organizations and their panels, three other groups are 
considered in this study based on their recently published work on CRC screening and their 
visibility among experts in the field. 




(2) Centers for Disease Control and Prevention (CDC)/Community Preventive Services 
Task Force  
(3) Institute of Medicine (IOM)/ National Cancer Policy Forum  
These 11 organizations and their scientific panels can be divided into four categories based 
on their “major designation or function” (NGC, 2012): 1) independent expert panel, 2) nonprofit 
organization, 3) disease specific society, and 4) medical specialty society. See Table 4. 
Table 4. NCG-Listed Panels/Groups Included in the Study 
 
Organization/Panel  Categories 
1. National Institutes of Health, Consensus 
Development Program/State-of-the-Science Panel 
Independent Expert Panel 
2. Agency for Healthcare Research and Quality/U.S. 
Preventive Services Task Force 
3. Centers for Disease Control and 
Prevention/Community Preventive Services Task 
Force 
4. American Cancer Society/Colorectal Cancer 
Advisory Group: Disease Specific Society 
5. American Academy of Family Physicians/ 
Commission on Health of the Public and Science 
Medical Specialty Society 
6. American College of Radiology/Colon Cancer 
Committee 
7. American Gastroenterological Association,  
8. American Society for Gastrointestinal Endoscopy, 
9. American College of Gastroenterology/U.S. 
Multisociety Task Force on Colorectal Cancer 
10. The Cochrane Collaboration/The Cochrane 
Colorectal Cancer Group 
Nonprofit Organization 
11. Institute of Medicine/National Cancer Policy 
Forum 
 








Issues Regarding Recommendations 
In 2011, an IOM report cited several factors that can erode confidence in health 
recommendations, including: 
• Failure to convene a multi-stakeholder, multidisciplinary panel 
• Unmanaged conflicts of interest among panel members 
• Lack of transparency of panel methodologies  
• Overall failure to use rigorous methodologies. (IOM, 2011)   
The report also stated that “the quality of CPG [clinical practice guideline] development 
processes and guideline developer adherence to quality standards have remained unsatisfactory 
and unreliable for decades. Non-standardized development results in substantial variation in 
clinical recommendations” (IOM, 2011, p. 2).   
Hutchinson et al. (2002) echoed concerns about the quality and transparency of panel 
processes by noting considerable variation in how evidence is appraised and how it is linked to 
subsequent recommendations. “At times, there was a lack of clarity in the information reported, 
such as a lack of clear distinction between evidence and expert opinion. Taken together, this 
meant that direct and accurate comparisons could not be drawn across the guidelines without the 
effort of going back to the original source evidence” (Hutchinson et al, 2002, p. 693). 
Another factor that can attenuate the impact of recommendations is the issue of evolving 
evidence. Updates and changes to recommendations “as a result of new evidence suggest a 
certain level of uncertainty at any one time about the absolute efficacy…and may inadvertently 
contribute to poor compliance among physicians” (Holmes et al., 2004, p. 467). Moreover, 
Albanese et al. (2009b) stated that “vacillating practice guidelines, especially those that 
subsequent research reveals were harmful or unnecessary, are not uncommon and can demoralize 
physicians and their staff, dampening enthusiasm for making future changes...How can a 




Some clinicians are concerned that recommendations, specifically clinically practice 
guidelines, are ‘cookbook medicine’ (Conroy & Shannon, 1995) and question whether 
recommended interventions—tested under ideal circumstances with patients who met strict and 
narrow eligibility criteria—are relevant to certain practice settings and subpopulations (e.g., 
patients with comorbidities, patients who are socially and economically disadvantaged) (IOM, 
2011; Lomas,1994; Freidson, 1984).  
“We have actually invented terms such as “effectiveness” versus “efficacy” research to 
capture the importance of the real world as opposed to that somewhat artificial, well-
equipped, information-rich optimal practice world in which most research is 
conducted…There has been little regard, some would say overwhelming disregard, of the 
contexts from which patients come or the context in which the physician will practice” 
(Lomas, 1994, p. S95-S96).  
Issues of importance, relevance, and appropriateness are particularly salient for primary care 
providers faced with an overwhelming number of recommendations, but with a paucity of clear 
evidence showing clinical effectiveness (Hutchinson, 2002). Grilli and Lomas (1994) also found 
that clinicians in more isolated primary care settings (e.g. family physicians, dentists, 
obstetrician-gynecologists) were less likely to follow guidelines than practitioners in specialty 
areas (e.g. cardiology, oncology), who often serve in secondary or tertiary centers where the 
transfer of research knowledge is ongoing. 
There is also tension regarding the relationship between clinical guidelines and professional 
autonomy (Rappolt, 1997). “Despite being the quintessence of medical knowledge at the 
corporate level, guidelines diminish the clinical autonomy of individual practitioners, and 
therefore threaten medicine’s justification for its autonomy” (Rappolt, 1997, p. 977). Although it 
has been reported that guidelines reduce clinical freedom and physician satisfaction, others argue 
that resistance to guidelines, on the pretense of autonomy, may be used to mask inappropriate and 





Lastly, the impact of health recommendations is often attenuated by a scientific panel’s 
failure to consider and address implementation issues (Conroy, 1995). 
The failure of clinical practice guidelines to achieve their potential in changing clinical 
practice to date can therefore be attributed, in part at least, to the fact that most current 
development processes do not treat implementation of the guidelines as an integral part of 
the development procedure. It is therefore now important to shift the focus from guideline 
development and to emphasize the need for guideline integration, which encompasses 
dissemination and implementation strategies, with provision made for evaluation, audit, 
feedback, and outcome measurement. (Conroy, 1995, p. 372) 
Implementation plans are rarely incorporated or appended to recommendations and the context of 
their utilization has been largely ignored. However, understanding the relationships among 
patient, provider, and environmental factors is critically important, particularly from a 
programmatic or policy perspective (Phillips et al., 1998). Holmes et al. (2004) argued that the 
adoption of clinical guidelines may be affected by “the structure of the service delivery system 
and the degree to which decision supports exist to encourage and reward the practice of evidence-
based medicine” (p. 467). This argument is supported by the research of Haggstrom & Bindman 
(2008) who found that physicians in HMOs were more likely to receive and follow guidelines 
than physicians in independent or medical group practices.  
Although “the importance of research evidence in guiding clinical decision making is 
generally unquestioned intellectually, at a practical level patterns of medical practice often 
diverge from evidence-based recommendations, robbing patients of the benefits of medical 
research” (Oxman et al, 1995, p. 1424). Grilli and Lomas (1994) found a high degree of variation 
in compliance with practice guidelines and an average compliance rate of just 55%. In 2004, 
Holmes et al. noted that 56% of physicians reported that guidelines affected their practice of 
medicine, and of those affected, 66% reported the effects as positive. 
The development of panel recommendations is an expensive and time-consuming process 




disseminated to stakeholders (Davis & Taylor-Vaisey, 1997). In response to “strong indications 
of the need to improve clinical decision making and healthcare quality” the IOM formed the 
Committee on Standards for Developing Trustworthy Clinical Practice Guidelines (IOM, 2011, p. 
xii). The 2011 IOM committee report, Clinical Practice Guidelines We Can Trust, included eight 
proposed standards for panels to follow, which address: 
(1) Transparency 
(2) Management of Conflict of Interest 
(3) Guideline Development Group Composition 
(4) Clinical Practice Guideline-Systematic Review Intersection 
(5) Establishing Evidence Foundations for and Rating Strength of Recommendations 
(6) Articulation of Recommendations 
(7) External Review 
(8) Updating. 
A summary of the eight IOM standards is in Appendix 4. Although the IOM report focuses on 
clinical practice guidelines, the standards are often applicable to other types of reports, 
recommendations, and other resources.  
2.6 Professional Practice and Control  
Colorectal cancer screening recommendations are largely implemented by health 
professionals (e.g., physicians, physician assistants, nurse practitioners). This section covers 
literature on professions and professional control, provider practice and practice change, and 
professional societies—which work to educate, and advocate on behalf of, their members. 
Professional practice and control issues are included in this study because they can influence a 







Professions   
There is no consensus on the definition of profession (Bureau & Suquet, 2009). Max Weber 
distinguished priests from sorcerers in the early 1920’s using 11 defining characteristics of 
professions, including:  
(1) Power (ability to convince using rationale authority) 
(2) Doctrine, or general systematic knowledge 
(3) Rational training 
(4) Vocational qualifications 
(5) Specialization 
(6) Full-time occupation 
(7) Existence of a clientele 
(8) Salaries 
(9) Promotions 
(10) Professional duties 
(11) Distinctive way of life (professional culture). (Ritzer, 1975, p. 631) 
In the 1930’s Sir Alexander Morris Carr-Saunders and Paul Alexander Wilson identified the 
following professional properties:  
Professions were organized bodies of experts who applied esoteric knowledge to 
particular cases. They had elaborate systems of instruction and training, together with 
entry by examination and other formal prerequisites. They normally possessed and 
enforced a code of ethics or behavior. (Abbott, 1988, p. 4) 
Scholars today find attributes identified in the 20th century useful in understanding professional 
work. Gorman and Sandefur (2011) argue that four recurring professional attributes from the 
sociological ‘golden age’ of the study of professions are applicable to contemporary research. 
These attributes include 1) expert knowledge, 2) autonomy, 3) a normative orientation grounded 






Professional Control and Tensions  
Eliot Freidson wrote extensively on the nature of professional control (who does what, under 
which circumstances, and for what purpose). In 1984, he argued that professional control was 
becoming more formalized, that stratification was paramount in the control of everyday 
professional practice, and that tensions were growing among the knowledge elite, administrative 
elite, and rank and file professionals.  
• Knowledge Elite – An important difference between modern professions and crafts/guilds 
is the way the former systematically developed a relationship with universities and 
innovated through research, experimental practice, and theorizing. The knowledge elite 
of a profession conduct research, teach professionals in training, and produce the 
technical knowledge that is required to direct the work of the rank and file (Freidson, 
1984). 
• Administrative Elite – This group is comprised of executives, managers, and supervisors 
with official authority to issue directives to their subordinate rank and file colleagues. 
They “are accountable for the aggregate performance of the workers under them and they 
tend to have an organizational perspective… [They are] in a position to assert economic 
and administrative, but not technical or cognitive power” (Freidson, 1984, p. 15). 
• Rank and File Professionals – These professionals are practitioners who are primarily 
concerned with “performing their work according to their own view of the intrinsic 
practical problems and of the necessary means of coping with them on a day-to-day-
basis” (Freidson, 1984, p. 15). 
Freidson (1984) noted that the knowledge elite is responsible for providing state-of-the-art 
information to public policy decision-makers and is often called to serve on committees that 
develop guidelines to govern professional practice. The administrative elite, which lack cognitive 
power or authoritative expertise, must rely on guidelines developed by the knowledge elite to 
formulate and evaluate the work of rank and file practitioners (Freidson, 1984). Resentments can 




practitioners) and the administrative elite, which tends to have a strong allegiance to the 
organization they serve. Additionally, there is tension between ‘town and gown’, practitioner and 
academic: 
Since the standards of the knowledge elite are grounded in the abstract world of logic, 
scientific principles, and statistical probabilities rather than the concrete world of work, in 
experimental designs and controlled laboratory findings rather than in the untidy, 
uncontrolled arena of practice, and in circumstances that are considerably less subject to 
the constraints of time, money, equipment, and other resources than is true of everyday 
practice, it is not hard to understand the skepticism of the rank and file professional 
(Freidson, 1984, p. 16).     
Determinants of Provider Practice 
It has been estimated that there is a 17-year lag between scientific discovery and when most 
Americans benefit from research findings (Clancy, 2006). Even when strong scientific evidence 
supports certain practices (e.g. secondary prevention via cancer screening and detection) 
providers frequently do not perform those (Zapka et al, 2003). Many scholars argue that studying 
the context in which professional work is performed is key to understanding which professional 
procedures are implemented (Battista et al. 1986; Lomas, 1994; Davis & Taylor-Vaisey, 1997). 
Lu Ann Aday and Ronald Andersen (1974) included contextual factors in a framework to 
study access to medical care. This model was initially developed to understand how and why 
families use health services (Andersen, 1995). Andersen revised the framework in 1995, creating 
an updated Behavioral Model for Healthcare Utilization. See Figure 4. This subsequent model 
shifted the unit of analysis to the individual and can be used to examine both patient and provider 






















Although the model is “one of the most frequently used frameworks for analyzing the factors 
associated with patient utilization of healthcare services”, its potential “for examining the context 
within which utilization occurs”—the role of the environment and provider-related factors—has 
been largely neglected (Phillips et al, 1998, 571). And yet these contextual variables are critical to 
understanding clinician practice. 
The Behavioral Model for Healthcare Utilization identifies four domains: 
1) Environment – This domain focuses on the milieu in which health care access occurs and 
is divided into two groups of variables (Davidson et al, 2004). 
• Health Care System – These variables involve the labor and capital dedicated to health 
care (e.g., volume and distribution of providers, equipment, and health facilities) and 
their organization, or the manner in which resources are coordinated in the process of 
providing care (e.g., waiting times for appointments, office waiting times in reception 
areas) (Aday and Anderson, 1974). 
• External Environment – These variables relate to broader social, physical, political, and 
economic conditions, such as societal norms, national health policies, and economic 




Studies concerning environmental variables focus on systems or organizations as the unit 
of analysis (Aday & Andersen, 1974). However, because there has been a historical 
emphasis on individual factors in utilization studies, the result is “a dearth of information 
on the role of environmental factors” in influencing utilization (Phillips et al., 1998, p. 
573). 
2) Population Characteristics - This domain includes both patient and provider elements and 
can be divided into three groups of variables (Andersen, 1995). 
• Predisposing Characteristics – These variables include age, education, ethnicity, gender 
(Stein et al, 2012), occupation, religion, and health knowledge and beliefs (Andersen, 
1995). For patients, these variables describe the ‘propensity’ of individuals to use [or not 
to use] services (Aday and Anderson, 1974). For providers, predisposing characteristics 
“are intrinsic to who they are as people and how they view themselves and their roles in 
the system” (Albanese et al., 2009a, p. 1050). Zapka et al. (2003) noted that predisposing 
factors also include provider “knowledge of and agreement with clinical guidelines and 
protocols and assumptions about patients and their adherence” (p. 7). 
• Enabling Resources – These reflect a patient’s means of obtaining needed health care 
using personal, family, and community resources (e.g., health insurance, income, regular 
source of care) (Lemming & Calsyn, 2004; Stein et al, 2012). For clinicians, enabling 
resources influence their capacity to provide care and include items such as reminder 
systems and decision-support tools (Oxman et al., 1995; Heltevik et al. 2000; Zapka et 
al., 2003; Haggstrom & Bindman, 2007). 
• Need – This involves perceived need (i.e., a patient’s self-perception of a health 
condition) and objective or evaluated need (i.e. a provider’s medical diagnosis, which 
provides external validation) (Aday & Andersen, 1974; Honda, 2004).  
Evaluated need is not simply, or even primarily, a valid and reliable measure 
from biological science. It also has a social component, and varies with the 




training and competency of the professional expert doing assessment (Andersen, 
1995, p. 3). 
Clinical guidelines and recommendations can also affect the determination of need, by 
setting expectations that can influence a provider’s judgment (Andersen, 1995).  
3) Health Behavior - This domain refers to the direct actions taken by both patients and 
providers to maintain or improve health and is divided into two elements (Andersen, 1995). 
• Personal Health Behaviors – Variables in this group include diet, exercise, and self-care 
among patients (Andersen, 1995) and physician recommendations for screening and other 
services (Phillips et al., 1998). 
• Use of Health Services – This refers to the utilization of health services (e.g. number of 
doctor visits and total services provided) (Andersen & Aday, 1978). 
4) Outcomes - This domain captures key subjective and objective outcomes.  
• Perceived Health Status – This involves a patient’s perception of well-being relative to 
the care they have received or to an illness they have experienced (Andersen & Aday, 
1978). 
• Evaluated Health Status – This involves the objective measurement of an individual’s 
well-being (Andersen & Aday, 1978). 
• Consumer Satisfaction – Consumer satisfaction concerns “attitudes toward the medical 
care system of those who have experienced a contact with it” (Aday & Andersen, 1974, 
p. 245). Dimensions of satisfaction may include perceptions about convenience of care, 
courtesy shown by clinicians, and the quality of the care received (Aday & Andersen, 
1974). 
Andersen (1995) noted that health care access is effective when utilization improves health status 
or consumer satisfaction; access is efficient when levels of health status or satisfaction increase 
relative to the amount of services received.  
Access is equitable to the extent that predisposing demographic variables such as age and 
sex and the illness variables explain health services utilization. The demographic 




patterns and age and sex. Conversely, access is inequitable when use is explained by 
social variables such as race or education or by any of the enabling variables such as kind 
of health insurance coverage or number of physicians (Andersen & Aday, 1978, p. 535).  
The Behavioral Model for Healthcare Utilization is useful from a programmatic or policy 
perspective because it explores the relationships among mutable and immutable patient, clinician, 
and environmental factors that facilitate or impede utilization (Andersen, 1995; Phillips et al. 
1998). Demographic variables and social structure are considered to have low mutability, health 
knowledge and beliefs have medium mutability, and enabling factors (including insurance 
coverage and provider management tools) have high mutability (Andersen, 1995). By 
understanding which variables are most amenable to change, decision-makers can better plan 
interventions directed at providers, patients, and the environment (Andersen, 1995). 
Practice Change 
Health provider behavior is influenced by many factors. Battista et al. (1986) examined 
primary care physicians and their preventive practices (i.e. counseling, teaching, and screening) 
for breast, cervical, colorectal, and lung cancer. They found that colorectal cancer screening 
practices by physicians were influenced by mode of reimbursement (higher for salaried vs. fee for 
service), continuing education (higher among those who read journals and participated in classes), 
provider-related barriers (lower among those with lack of knowledge, or who perceived 
ineffectiveness or risk of procedures), and gender (women screened more frequently than men). 
Davis & Taylor-Vaisey (1997) argued that the adoption of guidelines was influenced by provider 
characteristics, patient factors, practice setting, incentives, and regulation. Among nurses 
specifically, Piper et al. (2008) noted that numerous provider, patient, and system-related factors 
affected the translation of guidelines into practice. 
With the complex influence of multiple factors on clinician behavior, practice change 




Education about an innovative health care recommendation may increase awareness and 
predispose providers to change, but “it is not sufficient to bring about actual behavioral change in 
the absence of an active implementation strategy appropriate to the setting concerned” (Conroy & 
Shannon, 1995, 372). Oxman et al. (1995) examined 102 studies of interventions aimed at 
changing provider practice, including: 
• Educational Materials (distribution of recommendations using print, electronic, or 
audiovisual materials) – most studies showed that educational materials failed to 
influence change 
• Conferences (participation of clinicians in conferences, workshops, lectures, or 
traineeships) – studies showed that conference participation failed to influence change 
• Outreach Visits, also known as academic detailing, (use of trained individuals who 
provide information in the clinician’s practice setting) – studies showed that outreach 
visits reduced inappropriate prescribing and increased the delivery of preventive services 
• Local Opinion Leaders (use of clinicians identified by their colleagues as educationally 
influential) – studies of the effectiveness of opinion leaders were mixed 
• Patient-Mediated Interventions (interventions directed to patients with the aim of 
changing provider behavior [e.g., direct mailing to patients, patient education,  and 
counseling]) – patient education improved management of diabetes mellitus; studies of 
other patient-mediated interventions were mixed 
• Audit and Feedback (summaries of clinical performance obtained from medical records, 
electronic databases, observation, or patient comments) – studies showed mixed results 
• Reminders (manual or computerized interventions that prompt clinicians to take an 
action) –  studies showed mixed results 
• Multi-faceted Interventions (a combination of two or more interventions) – “The use of a 
variety of interventions, such as audit and feedback, reminders, outreach visits, patient-
mediated interventions or opinion leaders, has demonstrated changes in professional 




The authors determined that while most interventions were not successful in isolation, a 
combination of interventions improved provider performance, and to a lesser extent, health 
outcomes (Oxman et al., 1995). 
In an evidence report for AHRQ, Marinopoulos et al. examined a variety of continuing 
medical education (CME) activities that “serve to maintain, develop, or increase the knowledge, 
skills, performance, and relationships a physician uses to provide services for patients, the public, 
or the profession” (AHRQ, 2007, p. 1). The CME interventions studied included the use of media 
(e.g., print, audio, video, internet), various educational techniques (e.g., academic detailing, 
demonstration, case-based learning, mentor/preceptor, programmed learning), and simulations 
(e.g., standardized patient, role play, task simulation, computer simulation). Of these activities, 
Marinopoulos et al. found that: 
• Print interventions are either not beneficial or very weak in their ability to improve 
knowledge or attitudes. 
• A multimedia approach is better than a single media intervention for improving 
knowledge, attitudes, and practice behaviors. 
• Multiple techniques, that most commonly include case-based learning, are more likely to 
be associated with improvements in knowledge, attitudes, and practice behaviors than 
single techniques. 
• Multiple exposures to CME activities produce better knowledge gains and attitudinal 
change. (AHRQ, 2007) 
Davis & Taylor-Vaisey (1997) also found that a combination of two or more interventions had a 
greater impact on improving physician behavior and health care outcomes than single 
interventions. 
Albanese et al. (2009a) reviewed many models of health provider change (e.g., Context-
Input-Process-Products (CIPP) Model, Input-Transformation-Output Model, Coordination 




Change, Innovation Decision Process). Albanese et al. (2009b) argued that the further a provider 
moved along Everett M. Rogers’ Innovation Decision Process, the more likely he or she is to 
adopt change. The authors also argue that CME is most likely to change behavior when: 
• Barriers to implementation and maintenance are identified and providers are given the 
opportunity to develop solutions for their own practice 
• The evidence in support of change is compelling and durable 
• Respected colleagues, ideally local opinion leaders, adopt a change and encourage others 
to do so. (Albanese et al., 2009b) 
Rogers’ Innovation Decision Process is discussed in Chapter 2.7. 
Professional Societies  
Jordan, Espey, & Godfry (2010) noted that while guidelines issued from federal agencies are 
important, these recommendations alone are insufficient for improving patient care; “A strategy 
for widespread distribution and adoption of recommendations by relevant professional 
organizations and teaching institutions must be part of the plan from the start” (p. 1). 
Many primary care providers are members of professional associations or societies, which 
“create networks of professionals through which information about innovations in a particular 
field are disseminated” (Newell & Clark, 1990, p. 199) and promote the exchange of ideas and 
foster “scholarship, research, teaching, policy development, professional development, and 
collegiality” (Nelson & Weeks, 2006, p. 411).  
Frankel (1994) noted that professional societies, as organized self-governing institutions, 
“play a vital role in negotiating the boundaries of scientific freedom and responsibility” (1764) 
and serve the following functions:  
• Mediate between their members and the social environment 
• [Are] a strong voice in educating outsiders about the values and norms of the discipline 




• Serve as custodians of their discipline’s distinct body of knowledge, traditions, and 
professional norms 
• Adopt standards and guidelines accompanied by a complementary program of education 
designed to reinforce those standards. (p. 1764) 
Lowe (1972) asserted that the education of members, through annual meetings, scientific 
forums, and the publication of peer-reviewed journals, is a routine and traditional activity of the 
professional society. The education of professionals covers not only clinical issues, but broader 
ethical issues as well since professionals often have multiple and conflicting responsibilities (e.g., 
personal conscience, professional norms, and loyalties to colleagues, institutions, and larger 
society) and the public is increasing ambivalent about the “growing interdependence among 
science, government, and industry…and suspicious of the scientific community’s commitment to 
police itself” (Frankel, 1994, p. 1759). 
Although professional societies profess strong support for ethical conduct, at both individual 
and organizational levels, many scholars identify conflict of interest as a key concern. Albanese et 
al. (2009a) argued that boundaries were becoming blurred between practice and industry and that 
the profit motive was putting physicians in conflict with their duty to provide quality care. Lomas 
(1994) reported that physicians who have a proprietary interest in a therapeutic or diagnostic 
facility prescribe 2-3 times more for such services than a physician with no proprietary interest. 
Kassirer (2005) wrote about the “complex web of financial conflicts of interest between 
professional societies and industry” noting that:  
Conflicts occur at multiple levels. Some professional society officers and editors of 
official society journals are ongoing consultants to the pharmaceutical, biotechnology, 
and device industries. Some societies’ clinical practice guideline committees are funded 
by industry and some of the participants in the guideline development process are paid 
industry consultants or speakers. Some official professional society materials are written 




Partnerships between professional societies and the NIH are highly decentralized and vary 
based on NIH Institute or Center. Many of these collaborations support educational workshops, 
conferences, and scientific meetings (Butterfield et al. 2011), and are often funded through grant 
mechanisms (e.g., R13, U13). The National Cancer Institute (NCI) Office of Advocacy Relations 
frequently schedules meetings between leaders of professional societies and the NCI. One of the 
most structured models for public-private partnership was developed by the National Heart, Lung, 
and Blood Institute (NHLBI). The NHLBI invited representatives of professional societies, 
voluntary health organizations, and community programs to serve on program coordinating 
committees, such as the National Asthma Education and Prevention Program, the National 
Cholesterol Education Program, and National High Blood Pressure Education Program (NHLBI, 
1999, 2012a, 2012b). Public-private partnerships can serve as a catalyst for practice change and 
promote the implementation of evidence-based recommendations. 
2.7 Diffusion of Innovations  
 
The creation of health care recommendations to improve clinical practice is a sterile exercise 
if significant attention is not given to their adoption (Davis et al. 2003). 
Competing demands in a time-and resource-stressed system, coupled with profound 
external and internal changes in the structure of the organization and leadership, all work 
against process improvement. Efforts to redesign delivery systems, improve decision-
support systems, and implement clinical information systems and patient self-
management strategies must be undertaken within the broader understanding of diffusion 
as a social process. (Zapka et al., 2003, p. 8)   
Elements of the theoretical framework, Diffusion of Innovations, by Everett M. Rogers can be 
used to explore the pathway from recommendation development to sustained adoption.  
Diffusion and Dissemination 
Rogers (2003) saw diffusion as a kind of social change and defined it as “the process in 




a social system. It is a special type of communication, in that the messages are concerned with 
new ideas” (p. 5). Some scholars differentiate the terms diffusion (a spontaneous and passive 
spread of ideas) and dissemination (a planned and active process of spreading ideas to target 
audiences) (Lomas, 1993; Ciliska et al., 2005). Rogers; however, did not make this distinction 
and used diffusion to capture both the spontaneous and planned spread of new ideas.  In this 
study, dissemination is used to describe the planned and active communication of new ideas 
from: 1) scientific panels to professional societies and 2) professional society leadership to 
membership.  Diffusion will describe a broader process, which includes the development of new 
ideas, the communication of these ideas, and the five-stage process to adopt or reject them 
(Rogers, 2003). 
Diffusion Elements 
Rogers (2003) identified four main elements to diffusion: 
(1) Innovation – an idea, practice or object that is perceived as new by an individual or other 
unit of adoption (p. 12). Perceived attributes of an innovation include: 
a. Relative Advantage – The degree to which an innovation is perceived as better 
than the idea it supersedes 
b. Compatibility –  The degree to which an innovation is perceived as being 
consistent with the existing values, past experiences, and needs of potential 
adopters  
c. Complexity – The degree to which an innovation is perceived as difficult to 
understand and use 
d. Trialability – The degree to which an innovation may be experimented with on a 
limited basis 
e. Observability – the degree to which the results of an innovation are visible to 
others. (p. 15-16) 
Rogers argued that innovations with less complexity and greater relative advantage, 




other interventions (2003). Other scholars have agreed with this position (Grilli & Lomas, 
1994; Davis & Taylor-Vaisey, 1997; Albanese et al. 2009) 
(2) Communication Channels – These are means by which messages are passed from one 
individual to another. These channels can include mass media (e.g., newspapers, radio, 
television), interpersonal channels (which involve direct exchanges), and interactive 
communication channels, such as the Internet. 
(3) Time – This dimension involves the passage of individuals or groups through the 
innovation process.  
(4) Social System – Is “defined as a set of interrelated units that are engaged in joint problem 
solving to accomplish a common goal. The members or units of a social system may be 
individuals, informal groups, organizations, and/or subsystems” (p. 23).  
Adopter Categorization  
Innovativeness is “the degree to which an individual or other unit of adoption is relatively 
earlier in adopting new ideas than other members of the social system” (p. 37). Individuals in a 
social system adopt innovations at different times, and can be classified into one of five adopter 
categories based on their relative innovativeness: 1) Innovators, 2) Early Adopters, 3) Early 
Majority, 4) Late Majority, and 5) Laggards. “The adoption of an innovation usually follows a 
normal bell-shaped curve when plotted over time on a frequency basis”  (Rogers, 2003, p. 272). 
See Figure 5. 
















“If the cumulative number of adopters is plotted, the result is an S-shaped curve”  (Rogers, 2003, 
p. 272). See Figure 6. 
 
 





Innovation-Development Process  
Rogers (2003) identified six steps in the trajectory of an innovation: 1) recognition of a need 
or problem, 2) basic and applied research, 3) development, 4) commercialization, 5) diffusion and 
adoption, and 6) consequences.  He also specifically identified the point at which the NIH 
Consensus Development Program entered the process—step 5, diffusion and adoption. 
Gatekeeping is controlling the flow of messages through a communication channel.  One 
of the most crucial choices in the entire innovation-development process is the decision 
to begin diffusing an innovation to potential adopters (p. 155). 
Innovation Gatekeeping – controlling whether or not an innovation is diffused to an 
audience of potential adopters – can occur in variety of ways…In medical diffusion there 
is a strong concern with exerting “quality control” over new technologies that spread to 
practitioners. This concern is understandable, given the possible threat to human life that 
might be involved in diffusing unsafe medical innovation to practitioners.  The National 




scientists, practitioners, consumers, and others in an effort to reach general agreement on 
whether or not a given innovation is both safe and effective…An NIH consensus 
conference typically ends with preparation of a brief consensus statement, which is then 
published by the U.S. government and widely disseminated to physicians in medical 
journals and by other means (p. 156). 
Innovation-Decision Process  
Individuals undergo a process when deciding to accept or reject an innovation.  Rogers 
(2003) cites five sequential stages of behavior in the innovation-decision process: 1) knowledge, 
2) persuasion (perceiving an innovation’s attributes and forming a favorable or unfavorable 
attitude), 3) decision, 4) implementation, and 5) confirmation (reinforcing or reversing the 
decision to innovate). See Figure 7. 












Innovation in Organizations   
Organizations, like individuals, also undergo a five-stage process when deciding to accept or 
reject an innovation; however, the process for organizations is more complex because of 
organizational size and institutional bureaucracy (Rogers, 2003). 
Rogers further categorized the five- stage process into two broad activities: 
(1) Initiation—consisting of all the information gathering, conceptualization, and planning 
for the adoption of an innovation, leading up to the decision to adopt use (Rogers, 2003, 
p. 421) 
(2) Implementation—consisting of all of the events, actions, and decisions involved in 
putting the innovation into use  (Rogers, 2003, p. 424). See Figure 8. 
 








Rogers (2003) also identified independent variables related to organizational innovativeness, 
including leader characteristics, internal characteristics of organizational structure, and external 
system openness. See Figure 9. 












2.8 Study Goal, Specific Aims and Research Questions 
The overall goal of this study was to identify the role of federal scientific panels in promoting 
evidence-based practice and how federally-sponsored panels can better meet the needs of primary 
care providers and their professional societies for evidence-based reports and recommendations. 
The study had three aims: 
(Aim 1)   Describe the role primary care professional societies play in developing and/or 
disseminating evidence-based reports and recommendations. 
(Aim 2)   Determine if the needs of primary care providers and their professional societies for 
evidence-based reports and recommendations are being met. 
(Aim 3)   Describe the value that the federal government contributes to evidence-based 
practice.  




Research Question #1— What do professional society leaders and members know about 
organizations, scientific panels, and evidence-based reports and recommendations? 
Research Question #2 — How do professional society leaders and members view 
organizations, scientific panels, and evidence-based reports and recommendations?  
Research Question #3 — How do professional societies develop, support, and disseminate 
evidence-based reports and recommendations and what factors influence these activities?  
Research Question #4 — What factors influence primary care provider implementation of 
evidence-based recommendations?  
Research Question #5 — What role, if any, do professional society leaders and members 



























 Research questions and study aims were addressed through content analysis of semi-
structured telephone interviews conducted with 34 leaders and members from eight professional 
societies. Nonprobability, purposive sampling of knowledgeable experts enabled in-depth 
exploration of phenomena. The interview guide was developed using theory-driven concepts and 
theoretical frameworks, and pilot tested using cognitive interviewing techniques. The codebook 
included theory- and data-driven codes and was revised through an iterative process that included 
intercoder reliability assessments.  
     3.2 Study Population 
 
The study population included leaders and members of U.S.-based primary care professional 
societies (or primary care segments of broader associations) that are national in focus and which 
address colorectal cancer screening issues through position statements or clinical 
recommendations.  
An internet search of professional societies using the terms “health, professional organization, 
professional society, primary care, physician, nurse, medical, and nursing” yielded 26 medical 
and 27 nursing professional societies. See Appendix 5. Information was collected about each 
organization’s background, mission, position statements and clinical recommendations. Of these 
53 organizations, only six medical societies had online documentation that they met the study’s 
eligibility criteria. The remaining 47 organizations were contacted by email. Within a week, 37 
professional societies replied with information that disqualified them from the study. The 
remaining organizations (seven medical and three nursing societies), which did not respond to the 




organization, it was determined that none of these professional societies met the study’s eligibility 
criteria. See Appendix 5. 
The six physician professional societies that met the study’s eligibility criteria are listed in 
Table 5. Although no physician assistant or nursing organizations met all the study criteria, it is 
important to understand how physician assistants and nurse practitioners view recommendation 
developers, how their professional societies disseminate recommendations, and how federally-
sponsored panels can better design and communicate their recommendations to these 
stakeholders. Therefore, the largest nurse practitioner and physician assistant societies identified 
through the internet search were also included in this study and are listed in Table 5.  







American Academy of Family 
Physicians (AAFP) 
American Academy of 
Physician Assistants (AAPA) 
American Academy of Nurse 
Practitioners (AANP) 
American College of Physicians 
(ACP)   
American College of 
Obstetricians and Gynecologists 
(ACOG) 
  
American Medical Association 
(AMA)   
American Medical Women's 
Association (AMWA)   
American Osteopathic 





The study used nonprobability, purposive sampling of individuals within the professional 
societies listed in Table 5. In purposive sampling, the emphasis is on in-depth understanding, not 
generalization from a sample to a population (Trochim, 2006, Patton, 2002). Purposive sampling 
involves the selection of information-rich or illuminative cases that provide insight about a 
phenomenon; in the case of this study, it included persons with known expertise in their field and 




Trochim (2006) divides purposive sampling methods into five subcategories: 1) expert, 2) 
quota, 3) snowball, 4) modal instance, and 5) heterogeneity. This study utilized expert and 
snowball sampling of professional society leaders and members.  
3.4 Recruitment 
 
The President/Chief Executive Officer (or a Board Member) of each professional society was 
mailed: 
• An invitation letter  
• A description of the study 
• Letters of support signed by the Director of the NIH Office of Disease Prevention and a 
lead researcher from the NCI Division of Cancer Control and Population Sciences  
• Two copies of the consent form (one to sign and return; one to keep) 
• A response sheet to indicate interest and/or willingness to participate in the study 
• A pre-stamped envelope to return the consent form and response sheet. See appendices 6-
11. 
Those who did not respond within six weeks were sent a follow-up email and telephone calls 
were placed to nonrespondents at ten weeks.  
Each interviewee was offered a $60 stipend in appreciation for their time and participation in 
a one-hour interview. Twenty-six leaders were invited to participate in the study; one did not 
respond and seven (all of whom were Presidents or Chief Executive Officers) provided the names 
of staff members who would be willing to participate. Leaders also identified one or more 
members of their professional society who would serve as information-rich cases for the study. 
Eighteen members were invited to participate; two members (from different organizations) did 







Table 6. Sampling for Each Professional Society in this Study  
Professional Society Leader  Interviews Member Interviews 
American Academy of Family 
Physicians 3 3 
American College of Physicians 3 2 
American College of Obstetricians 
and Gynecologists 3 3 
American Medical Association 3 1 
American Medical Women's 
Association 1 1 
American Osteopathic Association 2 2 
American Academy of Physician 
Assistants 2 2 
American Association of Nurse 
Practitioners 1 2 




3.5 Qualitative Approach  
 
Qualitative inquiry is not a monolithic approach to research; there are several qualitative 
theoretical traditions (e.g., positivism, symbolic interaction, grounded theory) (Patton, 2002). 
This study was guided by systems theory.     
Systems Theory 
Patton (2002) notes that systems are greater than—and different from—their interconnected 
and interdependent parts. Although it is useful to analyze parts in isolation, it is insufficient if the 
goal is to understand the real-world complexities of whole entities and what influences them (von 
Bertalanffy, 1950; Patton, 2002; Bonn, 2005). Rather than examining an entity as a “splintered 
conglomerate of dissociated parts” (Bonn, 2005, p. 338), systems theory is a holistic perspective 
which seeks to answer: “How and why does this system as a whole function as it does?” (Patton, 




In this study, the professional society was the primary system to be examined. Interviewing 
leaders and members provided insight into the “internal and external dynamics of organizational 
life”, as well as how organizations are embedded within the larger, more complex system of 
health care (Bonn, 2005, p. 338). The study’s use of Diffusion of Innovations (to explore 
organizational systems, i.e. professional societies) and the Behavioral Model for Healthcare 
Utilization (to explore the broader environment that influences provider practice) dovetailed well 
with a systems theory approach.  
3.6 Data Collection and Analysis  
Data Collection 
Data was collected through semi-structured interviews with open-ended questions; the 
researcher set an initial agenda in terms of the topics discussed, but the interviewee’s responses 
determined the kinds of information gathered about these topics  (Green & Thorogood, 2006). 
The semi-structured interviews also permitted new questions based on interviewee responses and 
enabled the exploration of perceptions and opinions about complex issues (Barriball & White, 
1994). The process provided the freedom to explore issues that emerged in discussions which 
might have been missed through more tightly scripted interviews (Beatty & Willis, 2007, p. 297).  
The study involved a cyclical process of sampling, data collection, and analysis. As 
information was gathered and scrutinized for themes, it provided guidance regarding additional 
questions and participants. This process continued until no new concepts emerged from the 
data—a point of saturation was reached (Green & Thorogood, 2006).  
The semi-structured interview guide was pilot tested with three leaders and two members 
using cognitive interviewing techniques utilized by the NCI, Division of Cancer Control and 
Population Sciences, Applied Research Program. These techniques involve administering the 




with the interview questions (Beatty & Willis, 2007). As part of the pilot testing, cognitive probes 
were used to assess: 
• Clarity of interview guide questions (e.g., What does this term mean to you?) 
• Difficulty or appropriateness of questions (e.g., Was it easy or difficult to answer this 
question? Please tell me more about that.) 
• Respondent knowledge (e.g., How much would you say you know about this topic? Are 
you involved in this process? If so, how?) 
• Respondent computation (e.g., What factors did you think about when answering this 
question?) 
Two changes were made to the interview guide based on feedback from the cognitive interview 
participants: an eighth item was added to a list of issues facing providers during clinical decision-
making, and one question was changed to ask what characteristics made federal recommendation 
developers untrustworthy as well as trustworthy.    
Since many interview participants were outside the Washington, D.C. metropolitan area, 
interviews were conducted by telephone. Each interview lasted approximately 45 minutes to one 
hour. The first eight interviews were conducted in tandem by the lead investigator and an 
experienced interviewer contracted to the ODP through IQ Solutions, a private firm specializing 
in communications and health information.  The joint interviews provided the lead investigator 
with additional training prior to the broader administration of the instrument. To improve 
reliability, all interviews were recorded and transcribed (Green and Thorogood, 2006) using the 
NIH’s telecommunications contractor, MyMeeting Conferencing Solutions.  
Data Analysis 
Content analysis was used to identify core consistencies and meanings from the data (Patton, 




frameworks (e.g., Diffusion of Innovations, Behavioral Model for Healthcare Utilization), the 
data were also examined for patterns and emergent understandings (Patton, 2002). 
Analysis was conducted following several steps noted by Green and Thorogood (2006) and 
Barnard (2010): 
(1) Familiarization – Fieldnotes or transcripts were re-read “until the researcher is closely 
familiar with them in their entirety” (p. 184) 
(2) Thematic analysis – Themes were identified and served as coding labels 
(3) Indexing – Codes were systematically applied to the entire data set and comparisons were 
made within and between cases 
(4) Charting – Data was rearranged by theme 
(5) Mapping and Interpretation – Relationships among themes and cases were explored 
The following methods were used to bolster the study’s rigor of analysis (Green and 
Thorogood, 2006): 
• A clear account of procedures (an audit trail) was developed to promote transparency 
• Validity was promoted by analyzing deviant cases and disconfirming data, and by 
providing sufficient context so others could judge interpretations 
• Several transcripts were analyzed by two coders at the beginning, middle, and end of the 
study to maximize reliability  
• Data between and within cases were examined to explore the contextual meanings and 
strengthen comparison 
• Theoretical assumptions, how they shaped the study, and how values “have both made 
possible the research…and constrained it” are discussed in Chapter 5 and promote 
reflexivity. (p.195) 
Computer assisted qualitative data analysis software (ATLAS.ti 7) was used for data 
management to assist in coding, retrieving, comparing, and linking data from 900 pages of 
transcripts (Patton, 2002). A codebook was developed using theory- and data-driven codes 
(DeCuir-Gunby, Marshall, &McCulloch, 2011) and included the code abbreviation, code name, 
code definition, and examples for more complex concepts (Berends & Johnston, 2005). 




consensus with any differences; and the codebook was revised three times. After each codebook 
revision, all transcript coding was updated to reflect new or revised codes. Intercoder reliability 
was determined using this formula:  
Reliability =         # of agreements__________ 
Total # of agreements + disagreements 
The coders met four times; Intercoder reliability was 76%, 86% (at the beginning of study), 90% 
(middle of study), 93% (end of study). 
3.7 Human Subjects Considerations 
This research study adhered to the guidelines prepared by the Johns Hopkins Bloomberg 
School of Public Health, Committee on Human Research (CHR) and the National Institutes of 
Health, Office of Human Subjects Research (OHSR). The protocol for this study was vetted by 
CHR and OHSR prior to any contact with human subjects.  
There were no direct benefits for participation in the study. Indirect benefits included the 
improved development and messaging of evidence-based recommendations by the ODP to 
professional societies and primary care providers.  
There was minimal risk associated with being a participant in the study. Some identifying 
information (including name, address, and phone number) was collected; therefore, securing 
confidentiality was a key concern. To guard against breeches in confidentiality, participants were 
assigned a unique study code number and all interview transcripts and notes were enumerated by 
code number. The linkage between code number and identifiable data was maintained on a 
password protected server with access limited to study administrators. Identifying information 
was kept separate from other documents that held participant data (e.g. interview notes, 
transcripts). All hard-copy data were stored within secure offices at IQ Solutions and the NIH. 
At the beginning of each interview, the interviewer referred the participant to the consent 




right to end the interview at any time; steps taken to protect confidentiality; procedures for 
handling data; and whom to contact with any questions regarding the study. Participants were 
asked for their permission to record the interview and if they had any questions. Audiofiles were 
destroyed 30 days after each interview and any mention of indentifying information during an 
interview was stricken from transcripts. De-identified data were used for all analyses and 





























 This chapter presents study results from 34 semi-structured telephone interviews. It begins 
with participant and professional society characteristics and the latter’s association with 
innovativeness. This is followed by an examination of views on, and support for, evidence-based 
recommendations and practice. Next is a report on awareness, knowledge, attitudes, beliefs, and 
utilization of scientific panel reports and recommendations. The chapter concludes with views on 
the value the federal government contributes to evidence-based practice, and suggestions for how 
federally-sponsored panels can improve their composition and processes; make recommendations 
more readable, acceptable, and feasible; and strengthen partnerships with stakeholders. 
4.2 Study Participant Characteristics 
 
The 34 participants in this study came from a variety of geographical regions and held 















 Table 7: Demographic Characteristics of Study Participants 
                                                                                         No. of Participants 
 Leaders n=18 Members n=16 
Sex 
Female 10  9 
      Male 8  7 
Geographical Region 
Midwest 6  2 
Northeast 2  1 
South 10  9 
West --- 4 
Area of Professional Society Leadership 
Executive Vice President 1 --- 
Board Member 1 --- 
Clinical Practice 2 --- 
Science and/or Research 3 --- 
Education 6 --- 
Government Relations or Policy 3 --- 
Other 2 --- 
Type of Clinical Training 
Adult Primary Care --- 1 
Family Medicine --- 5 
Internal Medicine --- 7 
Obstetrics and Gynecology  --- 3 
Career Role of Member 
Academician/Clinician  --- 7 
Academician/Administrator --- 1 
Clinician --- 5 
College Administrator --- 1 
President/Founder of Advocacy Organization --- 2 
 
Among members, years of career service ranged from 1 to 38 years, with a mean of 22 years. 
 
 
4.3 Professional Society Characteristics and Innovation  
 
The professional societies included in this study were membership organizations whose 
objectives largely focused on promoting patient health, enhancing the practice environment and 
education of its members, and advocating for changes in health care policy. Their size ranged 
from a staff of <10 to >900 people, and membership ranged from 3,000 to nearly 218,000 
professionals.  
Professional societies often have shared governance and formalized procedures, and 
maintain highly knowledgeable members. 




• An Executive Board, Board of Directors, Regents, or Trustees 
• Executive staff 
• Official committees, commissions, or subspecialty boards  
(Foci included strategic planning, administration, professional practice, research, ethics, 
education, and advocacy.) 
and  
• A Congress, House of Delegates, or Board of Governors—consisting of members from 
constituent chapters and districts, and sometimes other professional societies and state 
medical associations 
(Their charge was to make recommendations; some had voting authority to endorse or reject 
proposed policies and resolutions.)  
When discussing centralization, or the “degree to which power and control in a system are 
concentrated in the hands of a relatively few individuals” (Rogers, 2003, p. 412), most 
respondents described their societies as being a hybrid, with some decisions (particularly 
administrative ones) made by a few, while other decisions incorporated not only senior executive 
leadership, but also representatives from constituent chapters and districts. Complexity, the 
degree to which an organization’s members possess knowledge and expertise (Rogers, 2003) was 
high across all societies given the education, formal training, and degree of professionalization 
among its members. Formalization, the degree to which an organization emphasizes the following 
of rules and procedures (Rogers, 2003) was high among most organizations.  
Size and system openness varied, but were associated with self-reported innovativeness 
among professional society leaders. 
System openness, the degree to which members of a system are linked to other individuals 
external to the system (Rogers, 2003), varied substantially among societies. Organizations with 
greater staff and financial resources were able to designate official liaisons to several external 
scientific panels and organizations. Size and system openness were also associated with self-




organizations were more likely to be self-described as trailblazers, often because they have the 
resources to develop their own health reports and recommendations or they have processes in 
place to review and endorse the work of others. For example, a leader at a large organization with 
a very sophisticated process for developing clinical recommendations stated: 
Oh definitely, [we’re a trailblazer]. The [professional society] is a very well respected 
organization when it comes to evidence-based medicine and evidence-based clinical 
practice guidelines and other programs as well. I think people are very well aware of 
how closely we stick with the scientific evidence and how rigorous our program is when 
it comes to the development of guidelines. --- Professional Society Leader #1 
Smaller, less open systems were more frequently self-described as “followers” who tended to 
wait for larger organizations to weigh in on clinical issues before taking a position themselves.  
If it’s something that is clinical, we’re probably waiting for endorsements from the more 
reputable or more involved larger organizations—say the Institute of Medicine or the 
American Cancer Society. --- Professional Society Leader #2 
When we make [clinical] recommendations, we feel like they’re kind of tried and true 
already. If there was something new and different that needed to be looked at more in-
depth, we would probably hold back a bit. --- Professional Society Leader #3 
One exception was a smaller society that did not wait before releasing statements on certain 
key issues. 
I definitely feel like the intention is that we’re a trailblazer. We’re not necessarily sitting 
back and waiting for the specialty societies. One example of that is last year there was 
some fuss about ultrasounds before abortion. The [professional society] did not sit back 
and say, “Let’s see where everybody is before we weigh in.” --- Professional Society 
Leader #4 
Although smaller, less externally connected organizations were less likely to take clinical 
positions before larger societies, the smaller groups were proactive in disseminating information, 
often on professional issues important to their members.  
We're very good disseminators of information. Whenever [the USPSTF comes] out with 




disseminate the information to our members, and they can make their decisions as to 
what they want to do. --- Professional Society Leader #5 
The clinical information from [our professional society] tends to be less prescriptive and 
sort of descriptive about what other people are doing. We may contact another society 
and say, “Hey, how is this done?” [The information we produce] is more specific to our 
profession—organizational and structural issues, staffing models, things like that. --- 
Professional Society Member #1 
Many respondents expressed a desire for their organization to become more innovative and noted 
barriers that hindered this objective.   
One of the things that holds us back a little bit, at least in appearance, is that all of our 
recommendations come out via our journal. It’s not an official [professional society] 
position until it’s published there, and the process to get this done takes months. 
Although we know the recommendations we’re going to make, they sometimes are six to 
eight months behind others. Our process [causes] delay, so it appears frequently that we 
are followers for many guidelines. We would rather be leaders, but that’s the way it 
appears sometimes and we get criticized for that from our members. --- Professional 
Society Leader #6 
The democratic process makes us slower and reactive rather than proactive and 
innovative. --- Professional Society Leader #7 
[One barrier] is probably bandwidth. I mean, there’s only so much you can do, and each 
one of these things is difficult.  --- Professional Society Leader #8 
A few participants did not self-identify their organization as either trailblazers or followers. One 
respondent said the focus of their organization was not the propagation of new ideas, but rather to 
focus on “important issues that are needed by our members…we pay attention to our mission.”  
Other respondents echoed a focus on topics important to members or central to their 
organization’s mission.  
It just depends on what you’re talking about. If it’s a topic that’s central to what we’re 
working on, and it’s an evidence-based recommendation, I don’t think we would ever 




our focus, we’re unlikely to push it because we don’t want to become too diffuse. --- 
Professional Society Leader #9 
 4.4 Views on Evidence-Based Recommendations and Practice  
There were differing views on the meaning of “evidence-based”, but there was broad 
agreement on its scientific underpinning and the importance of conducting “evidence-based 
practice.” 
General definitions described evidence-based recommendations and practice as having “some 
scientific merit” and being “based in evidence, things that we have studied”, and “based on good 
science, peer-reviewed publications.” More detailed responses expanded on these descriptions by 
adding procedural or outcome-based components, which often involved the patient.  
I think evidenced-based medicine is actually backed up by data, solid studies…we don’t 
do something just because it seems to make sense, or it sounds right, or other people 
think it sounds right. We do this because there are studies that show this works or works 
better. --- Professional Society Member #1 
Evidence-based recommendations integrate the best available evidence from clinical 
studies with the physician’s experience, knowledge of pathophysiology, and 
understanding of patients’ views and preferences. --- Professional Society Member #2 
 
Evidenced-based practice involves consolidating and compiling various pieces of 
research that are applicable to the question at hand and coming up with the best 
recommended treatment for a patient. --- Professional Society Member #3 
Evidence-based practice integrates the highest level of medical evidence based on 
studies, hopefully—randomized trials and prospective trials, or sometimes expert opinion 
or consensus opinion—into the bedside management of patients. --- Professional Society 
Member #4 
Evidence-based recommendations are based on a systematic, unbiased consideration of 
the available evidence. --- Professional Society Leader #2 
Rather than experiential practice, evidence-based practice is based upon proven 




from individualized practice and experiential practice into epidemiologically-based 
practice and outcome-based practice. --- Professional Society Leader #10 
Although the term “evidence-based” holds different meaning for different people, there was 
wide agreement among participants that conducting evidence-based practice and 
recommendations was very important for most primary care providers. 
For me, personally, it’s is highly important. I just care so much about the care I provide. 
I would feel uncomfortable not providing evidence-based care. --- Professional Society 
Member #5 
It’s absolutely important. We have fallibility in our own thinking, the same as what you 
see in any non-clinician, and evidence-based guidelines help us recognize those frailties 
in our own logic and reasoning. --- Professional Society Member #6 
 
A few participants cited that evidence-based practice and recommendations were less 
compelling to a subset of older, traditionally trained clinicians.  
It’s a big challenge for physicians my age and the Boomer physicians, because all of us 
were educated experientially. The educators provided you with, “This is the way to do 
it” and that's the way you learned to do it. There’s a sector amongst the older 
physicians who really think of what they do as an art rather than a science. --- 
Professional Society Leader #10 
 
Although conducting evidence-based practice was widely viewed as important, some 
respondents noted that standards of care and accessibility of resources influenced the ability of 
clinicians to implement evidence-based recommendations.  
If your professional society says get super-special MRIs on everybody and you don't have 
a super-special MRI in your community, then you wouldn't be applying it. --- 
Professional Society Member #5 
Regional changes in the standard of care are not supported by the evidence. With 
crafting a guideline, we need to be aware of differences in regional resources and allow 





A patient’s values and circumstances should be considered when weighing the benefits and 
harms of evidence-based recommendations.  
Many respondents noted that evidence-based screening recommendations were geared toward 
asymptomatic, at average-risk populations and that clinicians needed to consider the 
individualized needs of their patients when making decisions about implementing evidence-based 
recommendations. 
Is this really going to help? Not everything is going to help every individual in each 
instance—it’s the best practice for the biggest body, the biggest bang for your buck. Then 
you have to individualize the evidence-based guidelines and recommendations at the 
patient level to make sure it’s actually something that’s going to be applicable and 
doable for your patient. --- Professional Society Leader #11 
Sometimes there's some judgment that has to be applied when using evidence in practice 
and using it in the context of an individual patient's life when other priorities might exist. 
--- Professional Society Member #6 
Sometimes the recommendation might make scientific sense, but that does not necessarily 
mean it makes sense for an individual in a particular situation. --- Professional Society 
Member #7 
Some participants discussed how evidence-based recommendations would change with 
evolving technology, from “What should we do for the average person?” to “What should we do 
for individuals with these specific characteristics?” 
We’re now moving into an era that’s going to be more challenging because we will know 
more and more about the individuality of medicine; because we’ll know more about 
genetics, epigenetics, and the influence of specific aspects of the environment. We will 
gradually move into a realm where there is no average person. I don’t think our 
evidenced-based medicine methodologies are up to that at this point. So I often try to 
think about what lies beyond what we now think of as evidenced-based medicine, which is 
very much tied to what should we do for the average person—which we assume is almost 
everybody and then there are these five exceptions. --- Professional Society Leader #9 
 





Some participants noted that high quality evidence, [based on the evidence pyramid] is 
sometimes absent from the literature, especially for rare conditions. This is a challenge for 
primary care providers and patients seeking information and clinical options. 
There have been questions that I’ve had and I’ve looked for evidenced-based answers 
and not been able to find them. --- Professional Society Member #1 
Well, sometimes there's not a lot of evidence, but you don't need to know that if you run 
off a cliff you're going to die when you fall off. Sometimes, we're just going to have to use 
a little common sense. --- Professional Society Member #3 
Evidence-based practice is informed by data, when it exists. I mean, as you know, there's 
not data on everything. --- Professional Society Member #8 
Ideally, randomized trials would be the best. But if not that, then looking at the type of 
trial that was done and how they controlled for as much bias as possible. Unfortunately 
we see a lot of [rare conditions] in my practice, and sometimes you actually have to go 
off case reports. Whether or not it’s evidence-based, I’m not sure that you can actually 
say that, but you’re going off as much information as you have and that’s the best that 
you can do. --- Professional Society Member #9 
There are situations where you cannot find good evidence, but you end up with a patient. 
So the physician does need to know how to take care of that patient at that point in time. 
They can’t just say, “Well, I don’t really have good evidence from randomized controlled 
trials, so I can’t really do anything.” In that case, of course, the evidence from some 
experts may kick in. But that’s only in the absence of good evidence. If there is good 
evidence, I think we need to stick with it and avoid expert-based opinion. --- Professional 
Society Leader #1 
 
One member noted that the scarcity of evidence in certain scientific areas was due in part to 
economic pressures.  
I think some of the difficulty is we fund a lot of research based on a commercial goal. It’s 
just hard to get studies on things where there’s not necessarily a profit for some 





Views varied on what was an acceptable level of evidence, but many supported a 
transparent process to assess the quality of evidence and strength of recommendations. 
I hear somebody say, “This [decision] is based on evidence-based recommendations.” 
And I’m thinking to myself, “It’s just not that good of evidence.” --- Professional Society 
Leader #6 
We do use the term evidenced-based, and what we’re generally referring to are 
recommendations that can be supported by high quality clinical studies. But, of course, 
recommendations have different levels of evidence support—the highest support coming 
from a large number of randomized clinical studies or systematic reviews, and the lowest 
level—and I hesitate to use the word evidence—in terms of expert opinion and consensus. 
We certainly make a real effort to distinguish between the levels of evidence supporting 
our recommendations, and in our guidelines we use the GRADE process in order to do 
that. --- Professional Society Leader #12 
We define evidence-based practice based on the level of evidence from the particular sort 
of study, really aiming for the randomized controlled prospective trial being the gold 
standard. We look at all of the current peer reviewed data that’s out there and then we 
quantitate it based on whether it’s randomized, prospective, retrospective, or whether it 
is a summary of expert opinion, so when people read what we are saying they know what 
the level of evidence was for the statement. --- Professional Society Leader #13 
We look to see the process that was used - was it a Delphi process or consensus? We look 
to see whether they actually rated the evidence. We also look for ratings of their 
recommendations. That is a little tough sometimes because different groups have 
different rating systems. --- Professional Society Leader #14 
I am looking for a transparent process that involves systematically searching for and 
appraising the relevant evidence. I think a systematic review should always be conducted 
with the recognition that oftentimes even the best systematic review is not going to 
answer all of the questions that need to be addressed. --- Professional Society Member #2 
I want someone to tell me how they ranked the evidence, and then follow that 





Several participants discussed concern with expert-based (testimony by a single expert) or 
consensus opinion (testimony and agreement reached by more than one expert).  
When it’s a consensus guideline you really have to be suspectful. By consensus, I mean 
this is our best recommendation as opposed to an evidenced-based guideline. --- 
Professional Society Leader #7 
I think the dilemma is how to be truly evidenced-based and within that—how do you 
capture or consider expert opinion? What place, if any, should it have in the evidence 
tree? --- Professional Society Leader #9 
Some may consider collective expert opinion or common practice to be evidence, but we 
actually don't. --- Professional Society Leader #15 
Some respondents were more accepting of expert-based or consensus opinion as part of the 
evidence tree when combined with higher levels of evidence.  
There are certain levels of evidence and I think that it’s always good to have a mix of 
that. I think that it is valuable to have expert opinions; however, I don’t put as much 
emphasis on that as I would randomized controlled trials. --- Professional Society Leader 
#3 
I tend to like expert opinion…they've already worked with patients, they've been clinical. 
They're looking at the data and thinking about how that data applies to patients. 
Systematic review to me is more cut-and-dry; these are the numbers versus we know 
patients and they have this behavior or this type of outcome. --- Professional Society 
Member #10                   
4.5 Professional Society Support of Evidence-Based Recommendations and Practice  
 
The section below accomplishes Aim 1 of the study: Describe the role primary care professional 
societies play in developing and/or disseminating evidence-based reports and recommendations.  
 
Professional societies can play several roles (disseminator, liaison, developer, and/or 
facilitator) in the promotion of evidence-based recommendations and practice. 
For some societies, the role is that of disseminator, sharing information through: 
 
• Email and other electronic tools 




• Statements, bulletins, committee opinions, practice advice, guidelines, and 
recommendations 
• Meetings and conferences 
• Continuing education and training programs. 
Our official journals always have articles that relate to evidence-based practice. --- 
Professional Society Leader #2 
Our role is mostly as a disseminator. We do it through email, our website, regional 
meetings, and our yearly convention. --- Professional Society Leader #5 
I don’t think there’s a document today that comes out [of the professional society], 
certainly from the practice division, that doesn’t have evidence-based written on it and 
basically we live by it in terms of our recommendations. --- Professional Society Leader 
#6 
[The professional society] is extremely supportive of the principles of epidemiological 
and evidence-based outcomes and practice. We incorporate it significantly into our 
continuing medical education programs. It's incorporated very heavily into our 
continuous certification processes that require competencies in reporting outcomes. 
We've stretched it a little bit to include patient registries, to look at patient safety and 
outcomes as well. So it's an integral part of our planning and our educational processes. 
--- Professional Society Leader #10 
We carry that role out through document production (protocols, guidelines, checklists) 
and educational venues, first at our annual clinical meeting and through district meetings 
we conduct around the country. When putting forth a didactic course for our members, 
they hear the evidence our recommendations are based on. --- Professional Society 
Leader #13 
We offer continuing medical education and we coined the term evidence-based CME to 
differentiate that which was based on expert opinion or consensus panel versus that for 
which there was a research-based infrastructure. --- Professional Society Leader #15 
Our guidelines are published in [our journal] and are freely accessible to all interested 
parties whether or not they are a member or subscriber. They are also available 




one can access our evidence-based guidelines. We also have other products, such as our 
electronic decision-support tool, but this is a members’ only benefit that offers graded 
recommendations for a variety of medical conditions and is designed to be accessed at 
the point-of-care to support decision-making. --- Professional Society Leader #16 
Many professional societies take on a liaison role, appointing members to serve on external 
scientific panels that develop evidence-based findings and recommendations, and/or liaising with 
these external panels. 
We have representatives that sit on the National Quality Forum and we have 
representatives, upon request, appointed to the U.S. Preventive Services Task Force. --- 
Professional Society Leader #13 
So we have, for example, in the past, had an organizational liaison to the National Heart, 
Lung, and Blood Institute’s High Blood Pressure Education Program and the Cholesterol 
Education Program. It’s now been collapsed into the Cardiovascular Risk Coordinating 
Committee. As you probably well know, they have their own guidelines. We have a 
similar arraignment with the NIDDK and CDC for the Diabetes Education Program. We 
also work with the CDC Advisory Committee on Immunization Practices and have a very 
long heritage with the U.S. Preventive Services Task Force. We nominate members to the 
Task Force and I’m happy to say that one our national leaders was recently appointed.    
--- Professional Society Leader #17 
Some of the professional societies take on a more direct role by developing their own 
evidence-based recommendations or measures, often in collaboration with other professional 
societies.  
We have a consortium that brought together all specialties and 13 different provider 
groups (including nursing, podiatry, etc.). We developed quality performance measures, 
and the main point of that work is to determine what the best evidence tells us should be 
occurring for patients with particular conditions. --- Professional Society Leader #14 
We have a commission that empanels guideline groups to develop clinical policies. We 
also work with other professional societies on the development of evidence-based clinical 




Several professional societies facilitate evidence-based practice through their divisions and 
special initiatives.     
There are times when our role in promoting evidence-based recommendations extends to 
legislative advocacy, either at the national, state, or local level, depending on the issue. 
Clearly, one of the shining stars [for the professional society] has been their leadership 
role in tobacco cessation. They have been credited with being instrumental in turning the 
nation around in terms of getting smoke-free environments and setting the stage for the 
tobacco settlements. --- Professional Society Leader #7 
We promote evidence-based practice in many ways. Specifically, we’re very interested in 
promoting patient-centered medical homes. There’s a definite component of this that 
requires evidence-based guidelines, so that’s been a big piece of our promotion effort. --- 
Professional Society Leader #8 
Additionally, three of the professional societies in this study have partnered with over 50 other 
societies as part of the Choosing Wisely® initiative, which shares evidence-based 
recommendations to spur conversations between health care providers and patients about what is 
appropriate and necessary treatment (Choosing Wisely®, 2014). 
4.6 Awareness, Knowledge, Attitudes, and Beliefs about Organizations and Their Scientific 
Panels 
There was general awareness of scientific panels and/or their sponsoring organizations, but 
little in-depth knowledge about panel composition and procedures. 
There was universal awareness of the U.S. Preventive Services Task Force, although many 
study participants were not aware of the connection between the USPSTF and the Agency for 
Healthcare Research and Quality. There was also broad awareness of NHLBI’s Joint National 
Committee on Prevention, Detection, and Treatment of High Blood Pressure (JNC), the Cochrane 
Collaboration, and CDC’s Advisory Committee on Immunization Practices (ACIP). There was 
also broad awareness of the American Cancer Society’s recommendations, but not their specific 




less awareness of CDC’s Community Preventive Services Task Force. Many participants noted 
that professional societies (e.g., AAFP, ACP, ACOG, AMA, ACR, AAP, Endocrine Society, 
American College of Chest Physicians, American College of Cardiology) and advocacy groups 
(American Heart Association, American Diabetes Association) had scientific panels that 
generated findings and recommendations.  
Despite this awareness, except for the USPSTF and a few professional societies’ scientific 
panels (such as those convened by AAFP, ACP, and ACOG—which participated in this study), 
there was limited knowledge among the interviewees of panel composition and processes. 
I must admit to you that I don’t really pay attention to that. --- Professional Society 
Leader #12 
The NHLBI process, I don't know exactly how JNC 8 has been done. But we've been told 
that it is being done in a much more evidence based approach compared to the old days 
where you essentially got a panel together and it wasn't real clear how they had decided 
what evidence to look at, how to grade the evidence, how to move from the evidence to a 
strength of recommendation. --- Professional Society Leader #17 
I’ve heard of [the CDC Preventive Services Taskforce], but I don’t know anything 
specifically… I’m familiar with the name Cochran…I’ve come by their stuff when looking 
up subjects, but I can’t give you a whole lot more beyond that.  --- Professional Society 
Member #1 
Although I don't know the process in any detail with NIH and CDC, they are reputable 
non-biased sources of information. I know the AAFP and USPSTF very well and trust 
what they do. The American Cancer Society - I don't know their process very well, but it 
seems to be scientifically based and without bias. --- Professional Society Member #5 
There was also limited knowledge of the CDP. Many respondents had never heard of the 









Table 8: Awareness and Knowledge of the NIH Consensus Development Program 
 
                                                                    Number and Percent of Respondents with 







Never Heard of the CDP 7 (39%)  6 (38%)  13 (38%) 
Heard of the CDP, but Had No 
Knowledge 5 (28%)  5 (31%) 10 (29%) 
Heard of the CDP, and Had 
Knowledge 6 (33%)  5 (31%) 11 (32%) 
 
*Totals do not equal 100% due to rounding 
Given the recent IOM report, Clinical Practice Guidelines We Can Trust, this study chose to ask 
leaders and members about why they would trust scientific panels. Responses were largely 
shaped by views regarding panel composition, managing conflicts of interest, and methodological 
rigor. 
Conflicts of interest (COI) impacted panel trust, but there were perceived gradations of 
COI and disagreement on whether conflicted, but knowledgeable experts should serve on 
panels.  
When discussing the composition of scientific panels, some respondents reported having the 
most trust in scientific panels that were comprised only of members with no conflicts of interest. 
Participants expressed concern that panel members with financial ties to medications or 
procedures under consideration, or who had published on the topic, could be unduly influenced 
by secondary interests. 
I think people who have potential conflicts are not, in general, the best individuals to be 
part of a panel that’s producing a document or recommendation. While those individuals 
should not sit on the panel, there is opportunity oftentimes for them to testify before the 
panel and for the panel to evaluate and interpret that information. --- Professional 
Society Leader #13 
I would think that for someone who extensively writes on a topic or publishes, it's hard 





Intellectual and financial conflicts of interest are really, really hard to ignore. People 
can be super and have the best of intentions, but I think it's hard to get away from those 
conflicts—there're just too important to people in their careers and their lives. --- 
Professional Society Member #8 
There was also some unease with recommendations developed by clinical subspecialists, who 
were thought to have a greater financial stake in certain recommendations than primary care 
providers. Furthermore, some believed that the clinical orientation of subspecialists could 
influence their analysis of research. 
If their membership is all very deeply involved in doing Procedure A, and they are 
developing a guideline on Procedure A, it’s going to be a natural instinct—regardless of 
the evidence—to make a judgment call that it’s okay to do Procedure A because you’re 
going to see more benefits than harms. --- Professional Society Leader #1 
I’m going to be very frank. When the cardiologists came out saying one in two Americans 
need to be on statins, the recommendation left me very skeptical. One of the first 
questions that comes to my mind is—why are they making this recommendation? This is 
going to make a lot more people have to see cardiologists for managing their care. --- 
Professional Society Leader #7 
I have seen it over and over again. When you get a panel of like-minded specialists 
together, they’ll quibble over ultrasound versus X-ray, or they’ll quibble about one 
surgical approach versus another, but they’ll never sit back and ask the basic question, 
“Should we be doing this at all?” --- Professional Society Member #12 
 
For panels that focus on preventive health care services, such as the USPSTF, some 
respondents argued that primary care clinicians, not subspecialists, are the best or most 
appropriate experts to be at the table. 
The focus [of the USPSTF] is on primary care preventive services, so my personal 
opinion is that the members, who are very well versed in the topics at hand, can really 
speak to the recommendation being discussed at the time. It’s a pretty robust, diverse 




An oncologist gives you almost no expertise in cancer screening. As a matter of fact they 
might make it more difficult for you to understand the concepts of cancer screening. A lot 
of people think that if you're a clinical specialist [versus a generalist] that makes you 
more of an expert, but that's not true at all. What makes you more of an expert is 
understanding something about the clinical content you're making a recommendation 
about. So for example, oncologists don't do cancer screening; they do cancer treatment. 
So they're not going to be useful panel members for cancer screening. Primary care 
physicians do cancer screenings so they would be much more useful panel members as 
such for the clinical content. --- Professional Society Member #13 
However, others mentioned that clinical subspecialists were often considered vital members 
of scientific panels. 
Members of our House of Delegates routinely criticize the U.S. Preventive Services Task 
Force for not having [subspecialist] experts at the table. They would see the Task Force 
as being too controlled by methodologists and would say, “How in the world can the U.S. 
Preventive Services Task Force opine on breast cancer if there is not a breast cancer 
surgeon on the Task Force?” --- Professional Society Leader #9 
The United States Preventive Services Task Force is made up mostly of primary care 
physicians. The major drawback there is they're not seeing consistently the same high 
volume of patients with the same type of disease, like [members of the] American Cancer 
Society panels, which are geared more towards cancer. So I tend to think a little bit less 
of the United States Preventive Services Task Force than I would of an actively 
practicing institution or a society that has more of a direct focus. --- Professional Society 
Member #10                   
 
Some respondents noted that regardless of clinical orientation, all panelists or sponsoring 
organizations come to the table with biases of some kind. 
It’s always been amazing to me that the decisions an organization may make in terms of 
recommendations often parallel the best interest of their members. We’re a membership 
organization…all of these organizations represent members, so obviously they have an 




battle, like we battle, with not doing harm to their members and at the same time doing 
the right thing by patient care. --- Professional Society Leader #6 
Everybody knows that every medical society has some fur in the fight. They're not 
disbelieved, but they're looked at with more of a degree of skepticism. Everybody knows 
that there is a stakeholder position buried in that. We're a representative organization for 
our members. Our job is to advocate for and to advance them. My positions are going to 
be influenced by that. I'm not going to do anything wrong, but I'm going to be shaded in 
my recommendations about what's good for my physicians. --- Professional Society 
Leader #10 
You hope that experts can look at this in a fair and balanced way and not let inherent 
bias push them in one direction or another. The problem is a lot of times you don’t even 
realize you’re biased. People with a clinical background—they’re very biased too. A lot 
of times they’re biased by their last case: “Well, I tried this medicine on that person or I 
did this procedure on somebody and it didn’t come out well; therefore, the procedure is 
no good. --- Professional Society Member #14                   
 
Some respondents were accepting of panelists with conflicts of interest, especially those with 
intellectual conflicts, because they were deemed to be the most informed experts to make clinical 
recommendations. 
I have yet to be on a committee where the [published] experts did not have a very good 
point that led to important changes in the guideline recommendation because they are the 
experts. Let’s say you’re an expert in cooking one specific dish. If you’re going to have 
people over, you’re not going to cook something that you may not know at all. If it’s an 
important dinner, you’ll go with something that you’re very well aware of and that has its 
benefits. --- Professional Society Leader #1 
If they’ve published [on the topic under consideration], that gives the panel report more 
weight. --- Professional Society Leader #12 
In general, I personally would prefer to have people that know the topic very well and 
that means that they would have done work in that area and would have some 
publications. I would be careful about someone that may have sort of an extreme point of 




an editorial alone wouldn’t necessarily be a reason to exclude someone. --- Professional 
Society Member #2 
 
Several respondents thought the most effective panels were those with a balance of conflicted 
and non-conflicted members. 
I think it's useful to have some experts that might have some conflicts of interest as long 
as they don't dominate the panel. And it's one thing to be at a medical school and have 
funding from certain industries and be part of a panel. It's another thing to be an 
employee of the industry itself. I have a little more problem if I think if it's actual industry 
representatives on the panel as opposed to researchers who may have had support from 
industry. --- Professional Society Member #7 
I would have more confidence in the recommendations if there was a good mix. Certainly 
people that have done a lot of research in the field can bring a lot to a panel. But they 
may not have the practical experience to say how this is really translated in a clinical 
setting. We need to know that there are also some generalists or at least some practicing 
clinicians that bring practicality and relevance to the recommendations. --- Professional 
Society Member #11 
 
Some were concerned that generalists on a panel might defer to published experts in the field. 
To ensure these experts did not dominate panel discussions or unduly influence decision-making, 
one interviewee suggested having a strong panel chair. 
The chair plays an important role because, one of the big issues is, [published] experts 
can dominate the committee since they are so comfortable with the topic. But, you don’t 
want just the expert talking—you need to hear from other folks as well. So that’s the role 
of the chair, to make sure that experts are conveying their points and important concerns, 
but they don’t end up dominating the group. --- Professional Society Leader #1 
 
There was support for panel diversity, but respondents noted caution and caveats when 




Respondents wanted panel diversity, which could be accomplished in different ways. Some 
supported panelists from multiple organizations as compared to panelists from a single 
association. 
So single specialty group recommendations, for me, immediately feel less free of bias. I’m 
sure they try to eliminate all the bias, but as a consumer of those recommendations I feel 
more comfortable when it’s not coming from a single association. --- Professional 
Society Leader #7 
It's always more powerful if multiple organizations get together and make a 
recommendation. If you can get all those people to agree on what should be done, that 
would be a pretty good recommendation. Then physicians don't have to struggle with 
different ones. I feel like CDC has made good recommendations in the past and they've 
partnered with organizations I trust—it absolutely enhances credibility. --- Professional 
Society Member #5 
There was also support for panelists to reflect multiple disciplines (e.g., medicine, nursing, 
allied health fields, research methodology), to include clinical generalists and subspecialists, and 
to maintain diversity in geographic location (e.g., urban, rural), sex, race, and other attributes. 
Within medicine, diversity also meant including more Doctors of Osteopathic Medicine (D.O.s), 
not just different types of allopathic physicians.  
I would say [our needs are] mostly met, but I’d like nurses and other professions to be 
represented on more panels…I would like to admonish [panels] and ask them to include 
other health care providers (P.A.s, physical therapists, occupational therapists) who 
team treat patients. And then also have a patient advocate. --- Professional Society 
Leader #2 
I would like to see a panel involving people that have an appropriate balance of 
perspectives. So, geographic balance, specialty input, and I would be paying attention to 
race, ethnicity, and gender. --- Professional Society Leader #7 
If you look at a 20-physician panel, there’s often not a single D.O. on it. We’ve got 
people that are teaching at every level of every specialty and I think [panels] can do a 




Generalists add a lot to the group, whereas those that are experts [in their subspecialty] 
add their own unique attributes. So I think there's a role for both, and I think balancing 
that is a really good way to go about creating a guideline. --- Professional Society 
Member #6 
I think a mixture is good. When you get too highly specialized you can’t see the forest for 
the trees and things are just really different if you are a specialist. They don’t consider 
the difference in approach from someone in primary care who has a long-term 
relationship with a patient. You have a very different patient-provider relationship when 
you’re a specialist, seeing from a consulting standpoint, and when you’re in primary 
care, taking care of their mother when she’s dying and taking care of their babies when 
they’re born. You really have more of a personal relationship with them. --- Professional 
Society Member #15 
Regardless of clinical focus, many reported a preference for panelists with clinical experience 
because they share the practical perspective of those who are asked to implement panel 
recommendations.  
I want somebody who has a lot of clinical experience who can practically say, “Hey, you 
know, that’s a good idea. But if we recommend this, we’re going to add $100,000 to the 
patient’s hospitalization.” --- Professional Society Leader #12 
I’ll admit my bias. I have a world of respect for methodologists, but I prefer the experts 
who actually deal with patients because I find oftentimes a big disconnect from people 
who are say epidemiologists or experts in their own right, but don’t see patients and 
don’t have that practical bent of mind or experience when they’re making 
recommendations. --- Professional Society Member #4 
[It’s important to have] someone able to say, “Okay—well that’s all well and fine, but 
that just doesn’t happen in primary care. There’s no point going there.” --- Professional 
Society Member #15 
 
There were differing views on including lay persons on scientific panels. 
They’d have to be pretty sophisticated or they’ll just be lost. But, there are groups of very 
sophisticated lay people who bring interesting approaches and thoughts. Often they 




considering the questions that are important to patients.” --- Professional Society Leader 
#9 
I do think there is value in having one or more people that can represent the patient’s 
perspective. It can be a little tricky because sometimes patient advocacy organizations 
don’t understand evidence-based medicine and sometimes won’t even listen to evidence if 
it goes against their prior beliefs about what should be done. I think the patient or 
consumer organizations are best if they’re folks that understand a little bit about 
evidence-based medicine. --- Professional Society Member #2 
I think having a layperson is a particularly good idea if you’ve got broad topics, very 
common conditions like asthma or COPD. A lot of what goes into recommendations has 
to do with patient education, knowing what the patient’s needs are and what they’re 
willing to do. I think that having non-clinicians brings a further layer of richness to that. 
If it’s a surgical kind of recommendation, maybe not. It really depends on whether it’s a 
technical skill versus a broad recommendation. --- Professional Society Member #11 
Some patient advocates want something done at all costs regardless of the evidence. --- 
Professional Society Member #12 
There was support for internal and external reviews, but some concern about asking the 
general public for comments. 
Respondents also described the benefits of recommendation reviews (both internal and 
external to the sponsoring organization) to evaluate the panel’s characterization of the evidence 
and recommendation rationale.   
I think both an internal and external review are good. --- Professional Society Member 
#6 
I kind of like an external review, because those are the people who are really taking the 
information and putting it into practice and deciding whether or not it's going to fly in the 
real world. --- Professional Society Member #10                   
 
A handful of respondents discussed the risk or questioned the value of an external review, 




I want my recommendations to be scientifically-based and not necessarily emotionally-
based. When you ask to cue the public, it’s going to be a rare public citizen that really 
analyzes the science of it. --- Professional Society Member #5 
I like both internal and external review. I think there's a risk with public comment—that it 
can be so negative or so threatening that it can be intimidating or scary to guideline 
committees. But, it's probably good to have both. --- Professional Society Member #8 
Clinicians often felt overwhelmed by information, but electronic support systems lessen the 
burden. 
I think what's happened with some of these guidelines is your primary care provider is at 
a total loss about what they're supposed to be doing. They now know what they're not 
supposed to be doing, but they don't know what they're supposed to be doing anymore. --- 
Professional Society Member #3 
It's pretty overwhelming. It's hard for a physician to keep up. --- Professional Society 
Member #6 
Where I am, we’re completely electronically run, and I think that’s really helpful. We 
have a lot of built-in reminders and you can check [for recommendations] very easily in 
our system. I work for a big organization and we’re constantly being updated. When 
recommendations change, we’re notified by email and that helps a great deal. I imagine 
it would be more difficult if you were in private practice or in a really small group that 
didn’t have an organized system with that sort of back up. --- Professional Society 
Member #9 
Honestly, medical literature turns over so much now that it’s almost impossible for 
anybody to keep up, even people who are expert in the field. --- Professional Society 
Member #14          
It’s not possible to read through the hundreds or thousands of studies that come out every 
month and also to do the deeper analysis of the study - to whom they apply and whether 
they've been validated. I find it intimidating and overwhelming. --- Professional Society 
Member #16 
The National Guideline Clearinghouse (NCG) has the potential to support providers, but 




The mission of the NGC is to “provide physicians and other health professionals, health care 
providers, health plans, integrated delivery systems, purchasers, and others an accessible 
mechanism for obtaining objective, detailed information on clinical practice guidelines and to 
further their dissemination, implementation, and use” (NGC, 2014). However, some respondents 
noted that the inclusion criteria for the NGC needed strengthening.  
There is a move to strengthen the criteria for being [listed in the NGC], to be more 
transparent and more evidence-based. --- Professional Society Leader #17 
It’s a huge problem. There are too many guidelines [in the NGC], there are too many bad 
ones, and at times they conflict. For the Guideline Clearinghouse right now, you have to 
have the equivalent, in human terms, of a pulse to get on there. I think the Institute of 
Medicine’s report that came out recently is going to drive them to elevate the bar. It’s 
maintained at AHRQ, which ought to have higher standards. --- Professional Society 
Member #12 
Evidence-based recommendations can affect professional practice and satisfaction, but 
providers believe there is often latitude within recommendations to incorporate clinical 
expertise and patient factors. 
Respondents reported that panel recommendations affected professional practice and 
satisfaction—sometimes enhancing them and at other times serving as an impediment. 
I know that there are some physicians that feel [guidelines] impede [professional 
practice] by bringing it to cookbook medicine, but I think there's so many ways to be 
artistic in medicine that guidelines only enhance it…We know that evidence-based 
protocols enhance patient safety because you don't forget things. I get a few complaints 
from the older physicians that never had to follow protocols before. I think the majority 
of physicians really appreciate it. It makes them remember things that they need to do. It 
actually makes their life easier. --- Professional Society Member #5 
It really depends on how a physician takes that information and uses it to the best 
advantage of his or her patients. I think that there are physicians that feel that a 





It's so dependent upon the particular issue. I think in general clinical recommendations 
improve the quality of practice, but, it could interfere with a physician-patient 
relationship. So from that perspective, it could impede the practice of medicine, but the 
quality of that practice is probably improved by clinical recommendations. --- 
Professional Society Member #7 
I would say that [guidelines] do enhance practice by summarizing large amounts of data. 
Do they make it easier? I would say no. I think in some ways they make it potentially 
harder. There's a lot of guidelines, making it confusing, which might reduce satisfaction. 
And, there’s another part to it. There's an article, oh gosh, like 12 years ago in JAMA 
that showed if you did everything recommended in guidelines, it would take like four 
hours for a patient visit. So, in that way, I think it makes practice harder. --- Professional 
Society Member #8 
I think it enhances practice and satisfaction because you’re not struggling on a daily 
basis to figure out what to do. --- Professional Society Member #11 
If they’re well-done clinical guidelines, I think they’re very useful because it gives you an 
objective summary of the current state of the evidence which is very hard to stay up on as 
a clinician. However, if a guideline is done poorly and all of a sudden that becomes the 
standard of practice and now the standard of practice is a non-evidence-based, 
somewhat expensive, potentially harmful intervention, and you’re held to that standard, 
now it’s become a hindrance. --- Professional Society Member #12 
I think some providers feel that with too many recommendations medicine becomes 
cookbook and they like the freedom to think and apply the stuff they know. But there's still 
so many nuances that, if you consider the study population and the different risk groups, 
there's still a lot of room for interpretation. As to whether that affects satisfaction, I think 
that it gives people more confidence; feeling like what they're doing has been validated, 
and the confidence increases satisfaction. But, at the same time, people are concerned 
that it's taking away some of their autonomy, so it may be a little bit of a balancing act. --
- Professional Society Member #16 
To hone in on aspects of professional practice, study participants were asked if panel 




You always have the tension of "cookbook" medicine. In our country, we’re being raised 
where the individual is supreme. That's why we moved away from the oppression we had 
with England. We've always worshipped the individual, which is somewhat in conflict 
with epidemiologically-based medicine. When I walk into a patient room and shut the 
door, it is me and that patient. There’s always that conflict between population and 
individual. I don't see it ever going away, because as a physician, I have a commitment to 
try to do everything that's deemed appropriate for my patient. --- Professional Society 
Leader #10 
No, and I say that because at the end of the day—at this point anyway—you’re free to 
accept them or not. I think [my professional society] does a particularly good job of 
stressing that their recommendations are not the standard of care and that if you don’t 
follow them, you’re not going to be subject to a lawsuit. They’re there just as a guide, as 
a help, but they certainly don’t cover every scenario. --- Professional Society Member #4 
I think they do in a good way. Professional autonomy allows you to be a bad doc. “Sure, 
I want to protect my autonomy to do out-of-date, harmful and ineffective practice!” 
That’s professional autonomy. To the extent you want to protect that, then don’t do 
anything. But guidelines, if done properly, keep you current. There are always 
allowances for individual considerations in guidelines and almost every guideline starts 
with that caveat. --- Professional Society Member #12 
I think it actually makes you a lot more autonomous. In the past, some primary care docs 
might not have known about screening women for breast cancer. Before the age of 
guidelines, a physician might have said, “Oh, I don't know- let me go ask my local 
oncologist.” With these guidelines, it allows primary care physicians to look at things 
themselves and make their own decisions based on the evidence…A lot of physicians say, 
“Oh well, it's telling me I have to do this and I can't do this and that's stepping on my 
autonomy.” That's not what guidelines do at all. There's no guideline that says you 
always have to do this or you never should do that. The guideline always says in general 
you should do this, but if there's something about that particular individual that makes 
them different from the general population then you might care for them differently. 
That's an issue of interpretation so physicians who think that guidelines are impeding 




Of course recommendations affect autonomy. Nobody likes to say you’re supposed to do 
it this way. Because when you’re looking at population-based recommendations it really 
is not 100% applicable to the patient sitting in front of you. You have all these other 
things that are intervening. People say these are guidelines, they’re not written in stone, 
but if you don’t follow those guidelines or you’re not following enough people with those 
guidelines then they say that you’re not practicing standard of care. So people get 
infuriated by these things. Sometimes it’s legit and sometimes it’s just a lame excuse for 
really not doing the job they should be doing. But you can always fall back on that as an 
excuse. I think experts, clinicians, and public health people have to come together to 
come up with something that’s reasonable and then have enough latitude within that to 
use common sense. --- Professional Society Member #14 
Professional tensions were noted, most frequently between academicians involved in 
developing recommendations and the rank and file clinicians involved in implementing 
them. 
Definitely, I would say there is tension. Some of the guideline writing bodies craft 
recommendations that are especially based on their personal experience, their own 
perspectives, and the limitations thereof. Some of the guidelines are written with the 
belief that everybody has an academic medical center at their disposal, and has this 
perfect patient population to try and apply the guidelines to. I think that there's an 
increasing understanding that's not the best way to write a guideline. And especially with 
randomized controlled trials, I would say that's an area where a lot of physicians look 
with skepticism, because they weed out all the comorbidities and then you don't have any 
real patients. --- Professional Society Member #6 
When patients are enrolled in a study, obviously there are drop outs, but the patients that 
remain are compliant, they have a vested interest, whether it's for the drug, for their 
honorarium, or even just their interest in the study. The problem is that sometimes boiling 
down those recommendations and then telling physicians, PAs, NPs, whatever, to put 
them into practice is hard because the patients we see on a regular basis aren’t like the 
patients being followed in the study. Our patients have other comorbidities, but in 
academia and research it's more of a controlled environment. For us it’s more of a free-
for-all. While we realize these might be good recommendations, they may not be realistic 




Oh, absolutely, absolutely [there’s tension]. People who are on the front-line, seeing 
patients, trying to pay the bills, trying to keep the lights on, trying to keep their patients 
alive, recognize the realities and when some recommendations come out, they just seem 
sort of esoteric and don’t really fit the realities of practice. I hear people say, and I have 
felt this when I was pretty disconnected from academic sorts of practices, that it seems 
like a sort of mandate from the mount. --- Professional Society Member #15 
One respondent described tension between administrators and rank and file clinicians. 
There's a lot of tension there because physicians are in a tough spot. We've got a clinical 
integration program here where we do measurements and reimburse physicians for the 
quality of the results that they get. When patients are sicker, administrators don't always 
understand how hard it is to implement these things. I believe as a physician, who's also 
an administrator, it's important for me to keep my hand in clinical practice for that 
credibility. Those that have stepped out of clinical practice can lose that credibility pretty 
quickly. --- Professional Society Member #6 
One participant noted a tension between academics and specialists. 
I think there’s more tension between the specialists and the academics who are making 
the recommendations, because often the recommendations that I’ve seen have fallen 
more in line with what the primary care doctors are seeing. It’s the specialists who, just 
by the very sake of being specialists, get a skewed view of things, and so I see much 
more tension there—at least with the recent PSA and mammography recommendations 
that have come out. --- Professional Society Member #9 
Others identified a tension between generalists and specialists.  
In our House of Delegates there was quite a debate about the urology guideline.  The 
primary care physicians were the ones that said, “This recommendation came from the 
U.S. Preventive Services Task Force and we think this is a very credible organization 
and a credible recommendation.” The urologists were fighting this on the House floor 
saying, “We didn’t like the panel; we don’t think they were expert enough. Who are 
these people anyway?” --- Professional Society Leader #7 
 
The section below accomplishes Aim 2 of the study: Determine if the needs of primary care 
providers and their professional societies for evidence-based reports and recommendations are 





Views varied on whether scientific panels were meeting the needs of professional societies 
for evidence-based recommendations. 
When asked if scientific panels were meeting the needs of professional societies and their 
members, some participants reported a qualified yes.  
I think generally, for many of the professional societies, yes. But the burden is on us to 
make sure that these recommendations are coming from a valid source, that they are 
evidence-based, and that they’re trustworthy enough that we feel confident in spreading 
the word. --- Professional Society Leader #4 
I think in general the answer to that is yes. I mean there are always other things that we 
might want to have looked at, but I think overall we’ve been fairly pleased. --- 
Professional Society Leader #13 
Some respondents noted that when external scientific panels left gaps, their own professional 
societies would develop recommendations.  
Yes - I think in most areas [our needs are met]. When we see an unmet need, where our 
members express consternation in not knowing which recommendations are the best or if 
all of the recommendations that are out there appear to come from conflicted 
constituencies, then we tend to pull things together to make our own recommendations.    
--- Professional Society Leader #15 
Well I think that the USPSTF is doing a great job. And I would say, when coupled with 
the guidelines that we produce ourselves, we’re meeting the needs of our members. --- 
Professional Society Leader #16 
Other respondents voiced frustration with available guidelines.  
There's inconsistency. There's stakeholder conflicts that are involved in it, and guidelines 
frequently are not followed up well enough. A guideline will be issued to a great degree 
of publicity, and then it kind of goes away and nobody hears anything further about it 
until the next crisis. --- Professional Society Leader #10 
It’s difficult when a panel does not rate the evidence or their recommendations. It’s 




outcome. It’s difficult when the guideline is not accompanied by an implementation plan. 
--- Professional Society Leader #14 
I think some guidelines have been very helpful and influential in practice. I think the 
problem is that there are so many of them that it makes it difficult for busy practitioners 
to keep up with them and to know which ones to pay attention to. --- Professional Society 
Member #2 
4.7 Provider Utilization of Scientific Panel Reports and Recommendations  
Clinicians tried to follow panel recommendations, with the caveat that there were always 
exceptions for patients with unusual circumstances or characteristics.  
I am one of those physicians that rely heavily on [clinical guidelines]. I call myself a 
guideline girl and whenever the five of us in my practice are trying to make individual 
decisions, we always rely on them heavily. --- Professional Society Member #5 
I try to follow panel recommendations. If it’s from a reliable source, I would rarely not 
follow it because I disagree. It would be because the patient doesn’t fit into that 
guideline. An example is the CT scan for lung cancer. The people who should be 
screened are patients that are well enough to benefit from therapy. If they've got heart 
failure and so forth, they're probably not going to be able to benefit from having part of 
their lung removed. They might die from that surgery. To follow a recommendation, the 
patient must benefit. --- Professional Society Member #8 
The right thing can change from person to person. So that’s where I think being an expert 
clinician comes into play. Where you balance these recommendations against the patient 
in front of you knowing the limitations they might have, to make the best decisions for 
that patient, using an evidence base to support it. --- Professional Society Member #14 
Clinicians resolve the heterogeneity of recommendations in different ways and often share 
decision-making with their patients.  
You really have to go back and make it a doctor-patient relationship. Instead of me 
telling you what to do, it’s me educating you in the differences and us reaching the 




All the work is done on electronic medical records, so you are prompted to check for 
certain things given a certain situation, and prompted on which actions to take. Usually 
the stuff there is straightforward. I tend to look up things that are not typical. --- 
Professional Society Member #1 
We saw a lot of [heterogeneity] with mammography recommendations: the U.S. 
Preventive Services Task Force, [our professional society], the American Cancer Society, 
and the American College of Radiology. So when I do see [differences], I usually will 
look towards [my professional society] then look at those other recommendations and try 
to find out why there’s a difference. Sometimes I can see why and explain that to my 
patients, and other times there is frustration. --- Professional Society Member #5 
Well, I have to say that in my own mind I'm very aware of the harms that can result from 
excessive testing, excessive use of medications, and things. So I tend to err on the side of 
less is more in terms of medical care. That would probably be a bias that I bring. When I 
see conflicting pieces of information and really feel stumped about it, I go to where I 
believe the best information comes from which would be the U.S. Preventive Services 
Task Force or [my professional society]. --- Professional Society Member #6 
The way that I dealt with [mammography recommendations] was talk with my 40 to 50 
year olds about it. We talk about the risks and the benefits. We talk about their family 
history, their concerns. And then we decide what they want to do. I try to inform them and 
let them be involved in making that decision because the evidence is somewhat 
conflicting. So for things like that, I tend to try and involve the patient more. If it’s 
something where I feel there’s less conflict, I’m more likely to decide what I’m going to 
follow, like pap smears, and how frequently to do them. --- Professional Society Member 
#9 
I would go online and I'd do some research and I'd look at reputable websites - Mayo 
Clinic, Cleveland Clinic, John Hopkins;  I'd see what they say. I'd talk to peers in my 
field or talk to peers who are specialists. --- Professional Society Member #10                   
I think in those instances it probably is a systems issue because people mostly practice in 
systems now, which adopt one group’s recommendations over another’s for various 
reasons. For instance, if you practice in Cigna in Arizona, they have their own set of 




Task Force and some accommodation to some really outspoken specialty groups who 
disagree with the USPSTF. --- Professional Society Member #12 
I think that everybody looks at it with their own bias. So if you’re looking for an answer 
it’s sort of like shopping for a consult. If you want a specific thing you can probably go to 
a number of people until you get the answer you want and that’s the one you believe. And 
then you can verify that because so and so said it. --- Professional Society Member #14 
Typically I, however naïvely, assume that the organizations with the least agenda are 
perhaps the more reliable and so often for a lot of the preventive screening 
recommendations I will turn to the United States Preventive Services Task Force. I tend 
to prefer that over individual societies like the American Neurologic Association because 
they have less of a vested interest in a particular area. However, I do take into 
consideration some of the deeper analysis that is done by these societies; the USPSTF 
gives a very blanket recommendation. Some of these societies have looked at 
subpopulations, whether its minority groups or certain high risk groups, and they give 
recommendations that the USPSTF does not address. So I try to look at it, weigh the 
evidence, see who's involved and what seems reasonable and unbiased. --- Professional 
Society Member #16 
Contextual factors (e.g., access to facilities, regional practices, patient beliefs, enabling 
resources, perceived need, provider preferences) impacted the utilization of evidence-based 
recommendations.  
Although the health care system did not influence provider support for recommendations, it 
did influence patient access to recommended services, especially among rural populations. 
We are the primary care providers of health care in rural and remote communities, so 
access to the things that we recommend are substantial considerations. For example, if 
you live 200 miles from nothing, a colonoscopy can be kind of hard to get. --- 
Professional Society Leader #15 
We’re a rural state. I’m seeing patients in a town two hours away this afternoon and 
there are certainly patients who cannot access what I recommend or what the consensus 





Some respondents said that access to providers, equipment, and health facilities was not a barrier 
in their work because of connections to large, university-based, multispecialty practices or the 
U.S. Veterans Health Administration. 
Many participants observed that the external environment, particularly regional practices and 
controversial recommendations (either socially or scientifically) impacted providers.  
If it’s [scientifically] controversial, to me that’s a warning that there may be different 
points of view. It would push me to look harder regarding why it’s controversial. Is it 
because the data is not good? Is it because the findings are a threat to certain people’s 
livelihood? I’d do more fishing. --- Professional Society Member #1 
Any issue around abortion would be a topic that we would probably stay away from. --- 
Professional Society Member #3 
You kind of practice the way people in that region practice, and if you're not doing it the 
way they're doing it, they might judge you to be practicing poor medicine. And so you 
adapt, and yet it's not necessarily appropriate. We have an excessive amount of regional 
variation. --- Professional Society Member #6 
What’s common in our geographic area is definitely a big influence on our standard of 
care…If it’s controversial, [clinicians in my area] are afraid of the liability. --- 
Professional Society Member #10                   
Part of its buy-in for patients. If patients are reading up on it and it’s controversial, that 
can cause a problem. I might be more leery to do it. --- Professional Society Member #9 
 
Many clinicians stated that if a guideline was trustworthy, they would still recommend it 
regardless of any surrounding controversy. 
If it was a reputable entity and a scientifically based, good guideline I would still make 
the recommendation. --- Professional Society Member #5 
 
Predisposing characteristics also have an important impact on utilization of health 




greatly influence whether or not a service was recommended, but these characteristics did 
influence patient-provider discussion, shared decision-making, and consideration of alternatives.  
[Patient knowledge, attitudes, and preferences] would not change my recommendations. 
I wouldn’t forgo telling someone to stop smoking just because I don’t think they’ll do it.   
--- Professional Society Member #1 
Obviously it’s a patient’s choice what kind of treatment to accept, but that would not 
change our algorithm. We would just move the patient further down the algorithm if they 
declined a recommended therapy. --- Professional Society Member #3 
I recite [recommendations] to patients whether they’d like to hear it or not. They can 
choose not to do it, but they should have the education and know that’s the 
recommendation. --- Professional Society Member #5 
[Patient knowledge, attitudes, and preferences] affect my ability to implement a 
recommendation, but I really like to give patients the choice. I make a recommendation 
based on what I think is the very best thing in that situation, then let them apply their own 
values to make the decision about whether to follow through. --- Professional Society 
Member #6 
 [Patient knowledge, attitudes, and preferences] definitely come into play and should. It’s 
a tricky one; however, because somebody comes in and they really want something that’s 
totally unindicated, harmful, and useless. It’s a discussion that needs to occur. --- 
Professional Society Member #12 
If the patient doesn’t buy into it, they’re not going to do it. Colon cancer screening is a 
very good example since many patients are reluctant to be invaded in that way. We 
encourage them to do it and try to find and facilitate ways for them to get what they need. 
If they won’t take the gold standard recommendation, we encourage them to do the next 
best thing. We try to modulate patient compliance to provide the best possible care for 
patients on an individual basis. --- Professional Society Leader #15 
 
Provider preferences were cited by some study participants as influential in their 




I’d like to think all my clinical work is based on best evidence, not my own preferences, 
but I realize it isn’t. I like to minimize my own personal preferences as much as possible, 
but there’s a certain level of familiarity in certain things that drives a lot of decisions. --- 
Professional Society Member #1 
[As a provider] I have preferences, but they don’t go outside the recommendations. I 
think if reputable organizations said this, that, or that, and they are equal in all senses, 
then I would probably share my preference with the patient on which of the three I would 
do. --- Professional Society Member #5 
There’s no question. If I have had a particular treatment or test in my own life, I play out 
my discussion [with patients] slightly differently. --- Professional Society Member #6 
Most providers reported that a patient’s enabling resources, such as health insurance, were an 
important factor influencing utilization of health services. 
Yes, absolutely [coverage influences utilization]. Some things just aren’t covered or a 
patient can’t afford it based on what the copay it. This happens very frequently. --- 
Professional Society Member #4 
I ran into that today, in fact, where the best view of the pancreas was going to be with an 
MRI to see if the person has cancer, because we’re very concerned about that. But the 
insurance company wanted a much cheaper test, which was an ultrasound, that’s far 
inferior. We ended up with a compromise, the CAT scan, which is still not the best view. 
So you end up with these battles that can go back and forth between the doctor and the 
insurance company. --- Professional Society Member #9 
When asked if providers would discuss a recommendation for which there was no insurance 
coverage, all respondents acknowledged they would. 
 Yes, I would bring it up, but if it’s not covered then I need to let my patient know that they 
might be on the hook for it. --- Professional Society Member #2 
 I would make the recommendation, whether it was covered or not. But then certainly, the 
patient would be informed if it was covered. I would still make that recommendation if it 




I wouldn't not bring it up. Sorry for the double negative. I would bring it up. I feel like 
that's something I have to do. And that's something I thought about over the years 
realizing that it's not a good thing to let that excessively influence your recommendations. 
--- Professional Society Member #6 
Some participants discussed how a patient’s self-perception of need and a clinician’s 
evaluation of need have impacted primary care providers and their professional societies. 
We did such a wonderful job of inculcating in women the need for a yearly Pap smear 
when they first came out years ago. Now many women feel like if they don’t get a Pap 
smear every year, regardless of the circumstances, that they’re not being treated with the 
greatest respect and utmost care. [The professional society has] been working on getting 
that message out to our members, but it’s not easy. Patients expect a Pap smear every 
year, and the second thing is that the physician’s bottom line may be affected if women 
don’t come in for these annual visits because they see no reason to. So it’s things like 
this, where we wrestle with what we know and preach is good medicine, medicine that 
certainly is changing because our recommendations today are certainly much different 
than our recommendations on Pap smears 5 to 10 years ago, and our support for the 
interest of the members of our society. --- Professional Society Leader #6 
As you know, not all providers follow immunization recommendations. So often that’s 
why there are a lot of vaccine preventable illnesses that are occurring in the U.S. I hate 
to say this, but with vaccine preventable illnesses, people sometimes do not see the value 
of prevention. They don’t see the value of immunizing because they’ve not seen the 
disease. And so I think we need to improve the provider knowledge base—they need to 
always be inquiring about the patient status for immunizations. --- Professional Society 
Leader #11 
 
Clinicians have some influence in modifying contextual factors, but barriers remain and 
inhibit utilization of health care services.   
Patient knowledge, yes; we can certainly influence it. Insurance coverage- only to a 
certain degree; you can fight and fight - so sometimes you can influence insurance 
coverage. Patient access, that's a tougher one, too. You know, we do our best. If a patient 
can't access, we would assist them in accessing it. I think it would just be more a matter 




Some of my patients have been from the inner-city. They are Medicaid or self-pay, and so 
access to specialists can be a problem. I’ve called Catholic Charities and tried to cajole 
my colleagues. But there's a limit to how much you can do that. It doesn't necessarily 
mean you're going to be successful, but you tried your best. --- Professional Society 
Member #6 
I do think that the insurance companies in general have learned and that they're pretty 
decent in terms of how they apply the science and approve a recommendation. What I run 
into more so has to do with just coverage in general. So if a patient has no insurance 
that's a challenge. I have had to sometimes try and find resources for them. I try my best 
to really let them know this is a strong recommendation. We need to figure out a way to 
do it, or else, accept the fact that we're taking that risk. --- Professional Society Member 
#6 
If the insurance won’t pay for it, my patients generally can’t and so I try to find a way to 
work around the resources that they have. But [a workaround] is not always possible. 
Medication can be denied, and I’ve had this happen where I just cannot get it approved 
and it’s the only thing I can use. And that’s really tough, because then it’s out of pocket 
which means it’s probably not going to happen. --- Professional Society Member #9 
4.8 Value Federal Government Contributes to Evidence-Based Practice 
The section below accomplishes Aim 3 of the study: Describe the value that the federal 
government contributes to evidence-based practice.  
 
Although there were some criticisms of specific federally-sponsored panels, the majority of 
respondents believed the federal government substantially contributes to evidence-based practice 
by facilitating the development of high quality, evidence-based reports and recommendations that 
guide clinician practice.  
Federally-sponsored panels are valuable contributors to evidence-based practice because of 
their objectivity, transparency, balance, methodological rigor, and prioritization. 
With the U.S. Preventative Services Task Force, for instance, we expect that the 
recommendations are held to a really rigorous standard. The process is highly vetted and 
taken very seriously. The data is reviewed very carefully. I'm not sure this is necessarily 




lends it some weight. You expect that the government is trying to do right by its citizens.   
--- Professional Society Leader #4 
Well, my most direct and personal experiences are with the USPSTF, and I would say 
they're absolutely trustworthy, unquestionably trustworthy. I'm in the room when they 
listen to evidence reviews from the practice centers and they take great care in digesting 
the information. They ask a ton of questions, and it's a very thorough process. --- 
Professional Society Leader #5 
I have to give the federal government a lot of credit in really trying to deal with balance 
and diversity, and that would be all the forms of balance that you might hope for 
whenever possible. So, geographic balance, specialty input, race, ethnicity, and gender. I 
feel like it’s about as good as it can be. --- Professional Society Leader #7 
People do not feel you're necessarily taking a stakeholder position. They can disagree, 
but they disagree intellectually, and not because they think that you're taking a 
stakeholder position. That's a huge advantage. --- Professional Society Leader #10 
There are two biggies that [federally supported recommendation developers] bring to the 
table—transparency and a rigorous process. --- Professional Society Leader #14 
My experience is that the federal government has done a good job of concentrating on 
things that are a high priority, visible, and that "make a difference." The reality is that 
there isn't enough money to do everything and so the federal government has to focus and 
prioritize what it does, and I think that a lot of very bright and responsible people have 
worked very hard to make sure that the right prioritization takes place. I tend to be fairly 
cynical when the government is concerned, but I’ve had enough contact with it to know 
they try very hard to be conscientious about that sort of thing. --- Professional Society 
Leader #15 
The federal government tends to go out of its way to ensure that the diversity of relevant 
constituencies all have input on any given subject. They cast a very broad net and so the 
likelihood of any leveraged recommendations coming out of a federal group like that is 




If it's a panel that NIH puts together it's inherently trusted because the assumption is 
there's a great amount of rigor in the assembling of the data or the individuals involved.  
--- Professional Society Member #7 
The federal government also contributes to evidence-based practice by covering certain USPSTF 
recommendations (i.e., those graded A and B) through the Affordable Care Act (ODP, 2014e). 
4.9 Comments and Suggestions for Federal Scientific Panels  
Study participants offered many suggestions for improving federal scientific panels. These 
suggestions were related to panel composition and processes; the feasibility, readability, 
acceptability, and dissemination of evidence-based recommendations and reports; and 
strengthening partnerships with stakeholders. Key portions of quotes are underlined below to 
highlight suggestions for federally-sponsored panels. 
Improving Panel Composition and Processes 
You need to get rid of this variation with multiple, different panels. Honestly, if I had to 
pick one - I would probably go with the Task Force model—but include experts. A 
standing panel provides coherence of a sort - the same thinking, same guideline process 
and same methodology. Variation can be a big problem because of training your panel 
members. If you’re going to have multiple panels, multiple committees—I strongly think 
you need to have training. If it’s a single panel and you’re going to be slowly graduating 
(a slow turnover like two or three members rotating up every year and then the new 
members come in) it’s easier to control the training. You need to have a two or three day 
program where people understand evidence-based clinical practice guidelines, definitely. 
--- Professional Society Leader #1 
I would increase the capacity of the USPSTF. Now that it’s become written into ACA 
there are so many issues and its processes are very meticulous; it cannot possibly 
address all the issues in a timely fashion so it’s going to be woefully inadequate. --- 
Professional Society Leader #9 
I was always frustrated as a pediatrician [on the USPSTF] because the sort of studies 




children’s issues because you would need to have a randomized controlled trial for which 
the findings take you out 40 or 50 years. It’s just never going to be done. So I think a lot 
of the pediatricians on the panel have been frustrated by the marriage of the Task Force 
to the large randomized controlled trial. I think they have been looking at some other 
methodologies that are very helpful. But the question about what advice we should give 
on topics that don’t have that level of research, or whether we should just stay away from 
those topics completely, is a conundrum that needs to be solved. --- Professional Society 
Leader #9 
If you start getting into politics, then you're going to become untrustworthy. The country 
is so radically divided, 35% to the far right and 35% to the far left and, you know, 30% in 
the middle. You can't stay away from controversial issues, but as long as you keep 
[recommendations] purely evidential, with the emphasis on patient care and outcomes, 
then you'll remain respected. You may be disagreed with, but you’ll be respected. --- 
Professional Society Leader #10 
I think it would be helpful for [federally-sponsored panels] to make clear the diversity of 
input and the efforts that they've gone to ensure that all relevant viewpoints have been 
taken into account and that responsible, researched, peer reviewed sources have been 
consulted. Articulating the conscientiousness of process would be helpful. --- 
Professional Society Leader #15 
We're optimistic, guardedly, that NIH Institutes are going to move forward with being in 
a manner similar to the CMSS and IOM recommended processes. --- Professional Society 
Leader #17 
I know it's nice to have an event and release the recommendations right after the jury has 
huddled, but maybe launch a process where you have a more apparently thoughtful 
processing of what's been heard. --- Professional Society Leader #17 
I would pay attention to the IOM standards for guidelines now and I certainly would 
want the consensus panels to follow that. --- Professional Society Member #2 
I think there’s always going to be that specialist versus non-specialist argument. I think 
making sure that there is a specialist on panels helps silence those critics. I think that the 




mammography or PSA. But at the same time, I wouldn’t want to see a panel that was just 
specialists by any means, so more of a balance. --- Professional Society Member #9 
[The federal government] should try and build more consensus throughout the 
community. What I would like to see is more consensus, support or conversation from 
government funded groups with other organizations that make recommendations. --- 
Professional Society Member #10                   
I think in general panels should include more members at the grass roots level. It would 
enhance their credibility and [their recommendations] would seem more real, 
approachable, and applicable to their part of their world. --- Professional Society 
Member #15 
Making Recommendations More Feasible to Implement 
The American Academy of Family Physicians has a website for physicians to answer 
common questions and often it will have a patient handout with it, and it’s embedded 
within my EHR. When I’m in an EHR, it’s not easy for me to get out of that EHR and get 
into CDC’s website. But, within my EHR I’ve got Up to Date and AAFP. So the challenge 
at the real level of the practicing physician is to look at how to get [recommendations] to 
point-of-care, apps maybe, but I don’t know how many physicians within their offices are 
actually using a mobile tablet. --- Professional Society Leader #7 
I do think apps are very applicable—put an app in place and work with the electronic 
health record companies for good decision support functionality. You really need to build 
that into the care process more so than anything. --- Professional Society Member #6 
I think considering the insurance side of it is probably the most important. When making 
recommendations, be explicit about exceptions or you can really tie the hands of the 
provider. --- Professional Society Member #9 
Make sure they're covered [by insurance]. Connecting the recommendations with a 
covered ICD9 Code would be awesome, versus me just saying, “You've got to get this 
screen” and then the insurance company comes back saying, “No.” Have some type of 
preventive code for major recommendations that the insurance companies are already 




I would like to see new guidelines come out, and then also see the government step 
forward and say, “These are new guidelines and we support practitioners who implement 
them”—making a statement about liability. For example, the US Preventive Services 
Task Force, I think, offers a grade D for PSA testing. We're still doing it on a regular 
basis because some [panels] recommend it. If I'm getting sued and referencing the US 
Preventive Services Task Force, others will cite organizations with different guidelines. 
What I would like to see is more consensus from organizations that make 
recommendations. That's what I would like to see because, again, liability is always 
concerning to me and there’s a risk to my patent’s health if they don’t get a test. --- 
Professional Society Member #10                   
Right now it’s all procedurally based as far as remuneration. That’s why it’s so hard to 
get people to go into primary care because you’re just not paid for your time. You’re 
paid for a procedure. I talk to my patients and educate them, and I'm not paid very well 
for that. I think that’s where the federal government can play [an important role}—start 
incentivizing people to do these other things. --- Professional Society Member #14 
Improving Readability, Acceptability, and Dissemination  
Perhaps more outreach activities. I work in a big academic institution and we tend to get 
this stuff filtered through to us pretty quickly because there's always somebody in our 
organization who's connected with these panels in some way and wants to get the word 
out. But, I wonder if there's a better way to do outreach for private practitioners or 
community based practitioners or people who work in smaller academic environments, 
where basically, these new recommendations may not be handed to them as readily. So, 
maybe outreach efforts that focus less on some of the major academic players and more 
on, most of the providers in the country, really community based or sort of smaller 
organizations. Reaching out, starting smaller, more locally/regionally, as well as 
nationally. --- Professional Society Leader #4 
I think that if you get out of D.C. and out of Bethesda, and go get involvement in Chicago 
and Dallas and Kansas City and Denver, you will expand your market tremendously. 
Things that come out of D.C. appear to disseminate much slower than something that 
comes out of Stanford, or something that comes out of Washington University in St. 




Sometimes the recommendations that come from the U.S. Preventive Services Task Force 
may be very legitimate from a statistical evidence basis. But they could use some help 
from a communications firm to help them communicate their recommendations in ways 
that are less inflammatory to the public. --- Professional Society Leader #15 
When I look at some of the recommendations, with the exception of the United States 
Preventative Services Task Force, I don’t think they’re as reader friendly, generally 
speaking, for our members. Some of the recommendations tend to be quite long and are 
not as accessible to our members because of their length. --- Professional Society Leader 
#16 
Put your recommendations in a table at the front of the manuscript. That’s basically what 
I’m going to look at. I’m not going to read the text and that’s what our members are 
telling us too. --- Professional Society Leader #16 
One strategy that could be used by the NIH panel to make their recommendations more 
assessable to the general public [is to] make it accessible electronically so one could use 
it on a mobile device and access it at any point in time that they needed it. --- 
Professional Society Leader #16 
If the AHRQ Guideline Clearinghouse does strengthen their criteria for entry, that'll help 
[with dissemination]. --- Professional Society Leader #17 
Professionals have national certification exams. We do this exam and have to maintain 
our license so we’re still proficient with things. People study for the exam, but I think if 
there’s some type of push to make guidelines a bigger component, it might be beneficial 
because people will prepare specifically for them. I think when people put effort into 
things, they stick. --- Professional Society Member #1 
There should be more of an emphasis on readability. I’m ashamed to admit it - I’ve been 
part of a group that did a lot of work and it was so wordy and so detailed that it really 
didn’t get used that much. --- Professional Society Member #4 
I think that too often the results are marketed by and large to academicians and not to 
practitioners in the field. Because when I talk about a recommendation or a panel, a lot 




always get disseminated to the people who really need to get them, because private 
practitioners aren’t reading a lot of literature. --- Professional Society Member #4 
Periodicals like OB.GYN.News and Contemporary OB-GYN—you know, people in 
academics look down at those because they’re glossy and they’re more like a magazine 
than like a journal. Some people think they’re not very serious. But when you go talk to a 
private practitioner, go see what’s on their desk, what’s on their table. It’s those things. 
It’s not the journals. So look at the venues that people are actually reading, and it’s not 
who’s subscribing. --- Professional Society Member #4 
I think it’s definitely how it’s presented to the public. Mammography was not presented 
well and that was part of the problem. If it’s not presented well the media can take over 
and people who are celebrities can start getting equal say or greater say than the Task 
Force themselves. We've seen this with vaccines and autism. Really trying to take control 
and planning out your message beforehand is so important. I saw it happen with 
mammograms; I started seeing young celebrities who had breast cancer coming out 
saying, “Oh, this is so horrible,” and I can guarantee they probably had not read the 
recommendations completely or the entire report and what it was based off of, and they 
probably didn’t have expertise to read the research in the first place. So - that’s a 
problem with all of the specialty societies - making sure that we get out there ahead of 
non-medically based media. --- Professional Society Member #9 
The American Cancer Society has a nice little screening card and one is pink for women, 
and one is blue for men and they're different ages. It’s a pull down card and says women 
at this age should have this, and you pull it down and you line it up with your age and it'll 
say, annual breast exam, mammogram, PAP, pelvic, at age fifty colonoscopy, routine eye 
exam. I think those are great and some insurance companies send that out. It helps us out 
a lot because I do see it increasing patient compliance because they bring it in. My time 
with them is limited only because patients have multiple concerns. I'm addressing their 
meds, their insurance, refills, you know, new complaints. So it's not just the 
recommendation, it's having certain tools to go along with it and I like giving those out. I 
like to pull stuff off-line. You know, someone says, “Why do I need a colonoscopy?” I go 
on the American Cancer Society website, pull it up, and say “Here you go. Here's your 
information. Here's why, here's why not, here's what your options are.” Then they can 




still want them to think about it, I give it to them. So the tools are useful. --- Professional 
Society Member #10                   
Do not use the term physician unless it’s something that only a physician can do. --- 
Professional Society Member #11 
Well I think that mutually agreed-upon recommendations, a consensus opinion, through 
task forces or conferences would be the ideal scenario. Alternatively, maybe some of the 
more general societies could present not only their recommendations, but set them side-
by-side with recommendations by the specialist societies and list them with the pros and 
cons to say, “You know, the panel came up with this recommendation, but the society still 
recommends this for these reasons.” People could see them side-by-side and understand 
with better transparency each of the options. --- Professional Society Member #16 
 
Strengthening Partnerships with Stakeholders 
Well, I honestly feel like [federally-sponsored panels] already have good credibility. So 
how do you make that better? I think what nurse practitioners would like is to be 
recognized that they deliver quality care and that they appreciate good guidelines or 
recommendations and clinical resources. So I think it’s really to reach out, to target 
nurse practitioners as an audience member, and to maybe include them.  As new 
recommendations are coming out, or as things are being produced or developed, I think 
to have a nurse practitioner on the panel or at least as an advisor or consultant would be 
very helpful. Most know and trust most of these panels, so it’s not really a hard sell. But 
they do appreciate being acknowledged and having the opportunity to be involved. --- 
Professional Society Leader #3 
Work more on building consensus among organizations to harmonize recommendations. 
--- Professional Society Leader #6 
I think there might be [opportunity for] specific linkages with professional societies 
around things that are new or important for people to pay attention to. And partner on 
continuing professional education. It seems like as long as you’ve got it on your website 
why not give CME credit. You do a pretest and a posttest and really make sure that 
you’ve read it and that they aren’t just opening up and claiming credit for it. That would 




Conduct your process with the specific inclusion of people that have to disseminate 
whatever you produce. If we had known that you guys were doing this to start with we 
would have helped with the implementation. --- Professional Society Leader #8 
I think that there’s a lot to ask [professional societies], “How is this going to be received 
and how can we talk about it in a way that maximizes its positive receipt? How does this 
land on you and how is this going to land on your members? What are their concerns and 
questions going to be?” It’s always helpful not to be surprised. --- Professional Society 
Leader #9 
I think that one of the things that is very helpful is for folks to actually observe the 
process—describing the process doesn’t usually do it. But my experience is if someone 
gets close to the process, participates in some way, pretty soon they’re drinking the Kool-
Aid. --- Professional Society Leader #9 
I would just say in the spirit of promoting collaboration, we should align with the 
schedules of new recommendations coming out. In other words, we fully respect that 
those committees need to do their work without any external pressures. You know, they 
need to remain independent, objective, and do their work. But as organizations, can we 
sort of talk to each other and say, “Okay, you know, the schedule is these three 
guidelines will be updated in 2014, these in 2018. Can we plan now or let’s try to pilot a 
way to rapidly spread the information? Could we be more team-like in the design of 
translation while in no way tampering with the credibility of the guideline development 
work?” --- Professional Society Leader #14 
Don’t know how realistic this is, but perhaps add some sense of how the guideline would 
be carried out in practice. I know that’s difficult, right? I guess you would call it 
implementation, interpretation, translation examples and that’s part of where we want to 
try to be helpful. Maybe we could bring some of that to bear, recognizing the guideline 
panels. [Clinicians] commit an awful lot of their time and energy; how much more can 
you ask them to do? Maybe it’s a different expertise if you think translation. Could we be 
the arm that tries to supplement that work with some real world implementation 
translation approaches? --- Professional Society Leader #14 
I think to the extent that professional organizations are involved in the creation of 




simply reviewing and commenting on draft recommendations. --- Professional Society 
Leader #16 
Well, one I think you're already doing now, which is understanding what the specialty 
societies are doing and what they feel are appropriate evidence-based clinical practice 
guideline methods. Second would be to look to us as perhaps being able to nominate 
people for panels. --- Professional Society Leader #17 
Get input from [professional societies] during the process and then follow up with them 
when the reports are ready for release. That could help with dissemination and impact. --
- Professional Society Member #2 
You get this big disconnect in the recommendations that are made and the people that are 
on the ground practicing every day. So, if you could figure out a way to enhance that 
relationship—between those individuals that are creating guidelines and those that 
practice day-to-day—I think it would be really helpful. The problem is that physicians 
consider population-based guidelines just that: they're population based and don't really 
apply to their practice. --- Professional Society Member #3 
The next step in all this is going to be harmonization so that you don’t have different 
groups coming out with different recommendations. So how do you involve these 
disparate groups with different perspectives and values and then come down with a 
common set of recommendations? My feeling is the best way to get people together is on 
the evidence report. Involve professional societies with the technical advisory panel that 
advises the evidence report, so that when an evidence report comes out, there shouldn’t 
be a lot of debate. Now, where you’re going to get disagreement is recommendations that 
come from it. You may very well have primary care docs say “We don’t think we ought to 
be doing this until we get the evidence” and you’re going to have specialists out there 
who make their living doing those things who say, “Oh, we should continue to do this 
until we get the evidence.” But, at least everybody agrees this is the current status of the 
evidence. --- Professional Society Member #12 
I think the people who are most skeptical about accepting [recommendations] feel the 
recommendations go against some of the professional societies. So I think that having 
members of these professional societies on an advisory board or panel to contribute to 




that's probably a pipe dream, but I think that sort of collaboration would enhance 
people's belief in the recommendations. --- Professional Society Member #16 
I think that a big mistake is made when we do top-down dissemination and not getting out 
into the ranks and starting at a grass roots level. Almost all states have annual meetings, 
but there’s a couple of states that don’t and there’s a few states that have two or three. 
There are regions that get together. There’s various ways of sharing a message on a very 
local level that makes people feel included and gets them excited. Some of the big 
national organizations are unwieldy and those boats are really slow to turn. They don’t 
always have time to reach out to their states. --- Professional Society Member #16 
 
4.10 Summary of Main Findings  
 There were differing views on the meaning of “evidence-based”, but there was broad 
agreement on its scientific underpinning and the importance of conducting “evidence-based 
practice.” Professional societies can play several roles (i.e., disseminator, liaison, developer, 
and/or facilitator) in the promotion of evidence-based recommendations and practice. Views 
varied on whether the needs of primary care providers and their professional societies for 
evidence-based reports and recommendations were being met. Federally-sponsored 
recommendation developers were viewed as valuable contributors to evidence-based practice 
because of their objectivity, transparency, balance, methodological rigor, and prioritization. Study 
participants offered many suggestions for improving the development, feasibility, readability, 
acceptability, and dissemination of evidence-based recommendations. Participants also offered 
input on how federally-sponsored recommendation developers could strengthen their partnerships 
with stakeholders, including professional societies and their members. 
  A list of all major study findings is provided below. 
1) There were differing views on the meaning of “evidence-based”, but there was broad 





2) Professional societies can play several roles (disseminator, liaison, developer, and/or 
facilitator) in the promotion of evidence-based recommendations and practice. 
3) Views varied on whether scientific panels were meeting the needs of professional 
societies for evidence-based recommendations. 
4) Federally-sponsored panels are valuable contributors to evidence-based practice because 
of their objectivity, transparency, balance, methodological rigor, and prioritization. 
5) Professional societies often have shared governance and formalized procedures, and 
maintain highly knowledgeable members. 
6) Size and system openness varied, but were associated with self-reported innovativeness 
among professional society leaders. 
7) A patient’s values and circumstances should be considered when weighing the benefits 
and harms of evidence-based recommendations.  
8) High quality, evidence-based recommendations were considered valuable, but not always 
available. 
9) Views varied on what was an acceptable level of evidence, but many supported a 
transparent process to assess the quality of evidence and strength of recommendations. 
10) There was general awareness of scientific panels and/or their sponsoring organizations, 
but little in-depth knowledge about panel composition and procedures. 
11) Conflicts of interest (COI) impacted panel trust, but there were perceived gradations of 
COI and disagreement on whether conflicted, but knowledgeable experts should serve on 
panels.  
12) There was support for panel diversity, but respondents noted caution and caveats when 
considering lay persons as panelists. 
13) There was support for internal and external reviews, but some concern about asking the 
general public for comments. 
14) Clinicians often felt overwhelmed by information, but electronic support systems lessen 
the burden. 
15) The National Guideline Clearinghouse (NCG) has the potential to support providers, but 




16) Evidence-based recommendations can affect professional practice and satisfaction, but 
providers believe there is often latitude within recommendations to incorporate clinical 
expertise and patient factors. 
17) Professional tensions were noted, most frequently between academicians involved in 
developing recommendations and the rank and file clinicians involved in implementing 
them. 
18) Clinicians tried to follow panel recommendations, with the caveat that there were always 
exceptions for patients with unusual circumstances or characteristics.  
19) Clinicians resolve the heterogeneity of recommendations in different ways and often 
share decision-making with their patients.  
20) Contextual factors (e.g., access to facilities, regional practices, patient beliefs, enabling 
resources, perceived need, provider preferences) impacted the utilization of evidence-
based recommendations.  
21) Clinicians have some influence in modifying contextual factors, but barriers remain and 















CHAPTER 5: DISCUSSION 
 
The overall goal of this study was to identify the role of federal scientific panels in promoting 
evidence-based practice and how federally-sponsored panels can better meet the needs of primary 
care providers and their professional societies for evidence-based reports and recommendations. 
In working toward this goal, the principal investigator: 1) collected insights for enhancing current 
and future federally-sponsored panels, programs, and initiatives, and 2) developed original 
knowledge to contribute to social and behavioral sciences research. 
The use of nonprobability, purposive sampling did not permit generalization from the sample 
of professional society members and leaders to the wider population, but it did provide the 
opportunity to gain an in-depth understanding of:  
• Knowledge, attitudes, and beliefs about evidence-based practice and scientific panels 
(including the CDP) 
• Utilization of panel reports and the contextual factors that facilitate or impede the 
implementation of evidence-based recommendations 
• Professional society characteristics, activities, innovativeness, and roles in promoting 
evidence-based practice 
• Professional practice and control (including professional tension, autonomy, and 
satisfaction) 
• The value federally-sponsored panels provide in supporting evidence-based practice 
• Suggestions for improving panel recommendations and promoting their diffusion through 
professional societies.  
Although the topic of colorectal cancer (CRC) screening served as a starting point for 
discussion with study participants, their responses were not limited to issues regarding CRC 
screening recommendations. Leaders and members focused largely on evidence-based 
recommendations in general; therefore, their responses can be viewed as covering evidence-based 




Data were compared across professional societies and between leaders and members. 
Although there were differences among professional societies (i.e., size, system openness, and 
organizational innovativeness), there were no substantial differences noted between the responses 
of leaders and members. This homogeneity may be the result of gatekeeper bias since leaders 
helped identified members who could participate in the study. Leaders may have recommended 
members who were similar to themselves, resulting in congruent perspectives on a variety of 
issues.  
There was a variety of views on the term “evidence-based.” Some federally-sponsored panels 
consider many levels of evidence; therefore, consistent grading of the quality of evidence and 
strength of recommendations would help clinicians distinguish their options. High levels of 
evidence are not always available for rare conditions and other diseases not conducive to large 
RCTs. NIH funding of new research methodologies could help strengthen the evidence available 
to clinicians who need guidance to care for these patients. Evidence-based screening 
recommendations are often geared toward populations that are asymptomatic and at average risk. 
As science provides more information about the individuality of medicine, additional 
methodologies may hold utility for panels and the investigators conducting research. 
The issue of trust was central to attitudes and beliefs about scientific panels and their 
evidence-based reports and recommendations. Mayer, Davis, and Schoorman (1995) developed 
an Integrated Model of Organizational Trust that includes three factors that lead to trust: ability, 
benevolence, and integrity.     
• Ability is a group of skills, competencies, and characteristics within a specific 
domain 
• Benevolence is the extent to which one is believed to want to do good 






Study participants implied that these three factors (which require transparency to be assessed) 
increased the trustworthiness of reports and recommendations.  
First, the participants valued panelists’ abilities (based on a strong scientific background, 
clinical experience, or other pertinent knowledge and skills) to help elucidate the topic under 
consideration. Second, respondents alluded to the issue of benevolence as they expressed 
concerns about conflicts of interest that may put a panel’s primary interest (i.e., to develop good 
recommendations that benefit patients) at risk because of personal interests (e.g., promote 
financial or intellectual gains). Third, participants described the need for a methodologically 
rigorous process steeped in integrity. Many respondents described the importance of following 
principles outlined in the 2011 IOM report on developing trustworthy guidelines and in the 2012 
Council of Medical Specialty Societies report on Principles for the Development of Specialty 
Society Clinical Guidelines. The IOM report proposed eight standards, which address: 
(1) Transparency 
(2) Management of Conflict of Interest 
(3) Guideline Development Group Composition 
(4) Clinical Practice Guideline-Systematic Review Intersection 
(5) Establishing Evidence Foundations for and Rating Strength of Recommendations 
(6) Articulation of Recommendations 
(7) External Review 
(8) Updating 
The Pathways to Prevention (P2P) program and other federal sponsors of scientific panels would 
benefit by adopting IOM or other well-regarded standards. Furthermore, the ODP and other 
federal offices could benefit by incorporating the factors of ability, benevolence, and integrity 




There were conflicting opinions about the inclusion of patient advocates on scientific panels. 
The ODP has a policy of including a public representative on its panels, (e.g., economists, 
attorneys, ethicists, patient advocates) and the lead investigator of this study supports this policy 
after serving six years with the National Cancer Institute, Office of Advocacy Relations. 
Feedback from respondents suggests that if patient advocates are included, it would be beneficial 
if they have an understanding of pertinent medical issues and research methodology in order to 
more fully participate and contribute in panel activities. Patient advocate training programs, such 
as those sponsored by the American Association for Cancer Research, help patient advocates 
develop a stronger understanding of research and related issues (AACR, 2007). Federally-
sponsored panels may benefit from recruiting advocates with similar training. Additionally, a 
short training (similar to that for the USPSTF) on evidence-based recommendations and practice, 
as well as panel processes, could be beneficial to all panelists.    
Many clinicians feel overwhelmed by the high volume of reports and recommendations that 
are released each year. In an effort to assist clinicians, health plan administrators, and others, 
AHRQ has funded a free, online searchable database of clinical practice guidelines—the National 
Guideline Clearinghouse (NGC). However, much criticism has been levied at the NGC, some of 
which was included in IOM’s 2011 report: 
The products listed within are of widely varying quality. The committee has heard 
testimony that the NGC performs a public service, but does not set sufficiently high 
standards to assure users that poor-quality guidelines are not admitted. Given the mixed 
quality of clearinghouse contents, its large volume is also problematic. AHRQ and [its 
NCG contractor] could take several steps to differentiate between trustworthy guidelines 
and others…to increase clearinghouse utility. (p. 196) 
 
In response to the IOM report, the NGC developed new inclusion criteria that take affect 
beginning June 2014 (NGC, 2014b). These criteria include the need to show documentation that 
1) a “guideline is based upon a systematic review of the evidence” and 2) an assessment of the 




2014b).  As one participant noted, the strengthening of inclusion criteria for the NGC will help 
“separate the wheat from the chaff” and assist clinicians in identifying quality recommendations.  
Andersen’s Behavioral Model for Healthcare Utilization was a valuable framework for 
examining the contextual variables associated with the utilization of health care 
recommendations. Respondents noted that the environment, population characteristics, and health 
behaviors of both patients and providers impacted the use of recommendations. Although 
clinicians were resourceful and often successful in facilitating recommended services for those 
with inadequate or no insurance, many patients were unable to receive appropriate care in a 
timely manner. The Affordable Care Act (ACA) is expected to provide quality health care to 
millions of previously uninsured Americans, helping remove a key utilization barrier. 
Furthermore, the ACA covers preventive services recommendations that have an A or B rating 
from the USPSTF (AHRQ, 2014b). Increasing the capacity of the USPSTF and/or providing 
ACA coverage for other federally-sponsored panel recommendations could further reduce 
utilization barriers. 
The large volume of findings in the health literature, coupled with recommendation 
heterogeneity, can be confusing and overwhelming to clinicians. Electronic health records and 
point-of-care decision support tools were helpful to study participants in learning about health 
recommendations and sharing them with patients.  
Weed (1991) argued that clinical decision-making was a difficult and frustrating predicament 
for the ‘physician’s unaided mind’ given the tremendous increase in medical information and the 
complexity of patient needs. Weed (2004) recommended the use of two types of information tools 
[computer software and the medical record] for “1) bridging the gap between the physician’s 
mind and the unbearable burden of coupling patient data with medical knowledge, and 2) 
organizing the multiple processes involved in patient care” (p. 46). 
The coupler principle is simple: gather a large number of variables (medical history 




them into all the diagnostic or treatment possibilities for that patient's unique clinical 
situation. The logic is combinatorial rather than probabilistic or algorithmic. Probabilistic 
logic would cause us to miss the rare possibility, and algorithmic logic forces an either-or 
decision, but in fact, there may be two simultaneous choices (migraine and muscle 
contraction headache) (Burger, 2010, p. 47). 
 
Although knowledge couplers can make clinical care more manageable, in a recent interview, 
Weed dismissed current electronic health record systems (EHR) as inadequate and argued that the 
medical education system continues to perpetuate the myth that physicians can keep up—“In 
medicine, it’s what does the doctor think? It’s pathetic…When are they going to wake up and 
stop moving knowledge through heads and start moving knowledge through tools?” (Conn, 
2013). The American Recovery and Reinvestment Act provided funding to promote electronic 
health records among primary care providers (HRSA, 2014) and Medicare and Medicaid EHR 
Incentive Programs provide payments to eligible professionals and hospitals as they “adopt, 
implement, or demonstrate meaningful use of certified electronic health record technology” 
(ONC-NLC, 2014). These federal efforts are important, but should be combined with more 
research on how to develop better software, training, and workflow adoption (Burger, 2010).  
Scientific panels are meeting some of the need providers have for evidence-based reports and 
recommendations. However, there are gaps in the topics covered, confusing heterogeneity among 
recommendations, many poor quality recommendations, and there is a lack of transparency that 
inhibits a clinician’s ability to directly and accurately evaluate and compare recommendations. 
The federal government can play an important role in addressing these issues by bolstering the 
National Guideline Clearinghouse; identifying evidence gaps; funding new, applicable research; 
and partnering with professional societies and other sponsoring organizations to harmonize 
recommendations. 
Diffusion of Innovations was another useful framework for this study, as it permitted the 




promotion of evidence-based practice. The data collected in this study supports Rogers (2003) 
assertion that certain independent variables, specifically organizational size and external system 
openness, are associated with perceived organizational innovativeness. Federally-sponsored 
panels may benefit from approaching larger, more externally connected professional societies 
when seeking either official endorsements of their recommendations or opportunities to 
collaborate on joint recommendation development (Initiation Activities). For dissemination 
efforts (Implementation Activities), these larger societies, as well as smaller, less open 
organizations, can serve as excellent partners.  
Professional societies play a variety of important roles in promoting evidence-based practice 
among their membership. Whether serving as disseminators, liaisons, direct developers of 
recommendations and measures, or as facilitators of evidence-based programs and initiatives, 
professional societies have resources which federally-sponsored panels could leverage through 
public/private partnerships. Professional societies aim to change provider practice through a 
variety of mechanisms:  
• Journals and newsletters 
• Official statements, bulletins, committee opinions, practice advice, guidelines, measures, 
and recommendations 
• Conferences and meetings 
• Strategic programs and initiatives.  
 
Federally-sponsored panels should consider collaborating with professional societies on a 
combination of interventions to facilitate practice change. Panels and organizations may also 
want to work with state or regional chapters and key local opinion leaders to develop 
implementation plans for broader dissemination and to empower more rank and file clinicians to 
integrate evidence-based panel recommendations with their clinical expertise and patient values 




Friedson (1984) noted conflict among the knowledge elite, administrative elite, and rank and 
file professionals. Study participants also described this tension and identified an additional 
tension between generalists and clinical subspecialists. An understanding of this tension is 
particularly helpful when navigating the often contentious debates regarding screening 
recommendations (e.g., prostate-specific antigen [PSA] testing, mammography for women aged 
40-50 years). Efforts should be taken to help translate academic, epidemiologic recommendations 
into guidance that rank and file professionals can use when serving individual patients. It is 
important for panels to highlight any caveats, so clinicians are not asked to follow a ‘cookbook’, 
but rather, integrate the best available research with their clinical expertise. Furthermore, by 
fostering agreement on evidence reports, tension between generalists and subspecialists can be 
reduced as the two find common ground regarding the state of the science.  
The lead investigator for this study is a former staff member of the Consensus Development 
Program and was admittedly disappointed when the 35-year old program was retired without an 
official evaluation to justify the decision. The investigator approached this study with the 
assumption that most professional society leaders, and many members, valued the CDP and its 
contributions to evidence-based practice. However, the results of this study indicated that only 
one-third of leaders and members had knowledge of the CDP. These well-respected experts most 
frequently sought evidence-based reports and recommendations from panels supported by other 
federal agencies, non-profit organizations, professional societies, or disease specific societies. 
Many that did have knowledge of the CDP were exposed to the program through an existing, 
collaborative relationship between the society and an NIH Institute or Center that had sponsored a 
CDP conference. The ODP should consider building on these existing public/private partnerships 
in order to successfully implement portions of its new strategic plan.  
The CDP was created partly in response to a 1976 conclusion by the Congressional Office of 
Technology Assessment (OTA) that reviews of medical innovations would be useful in decision-




duplicated the work of other federal agencies, academic institutions, and private organizations 
(NIH-CDP, 2013). Interestingly, the OTA was also de-funded in part because it appeared to 
duplicate the work of others.  
The Union of Concerned Scientists has argued that other entities (e.g., National Academy of 
Sciences, Congressional Research Service, and the Government Accountability Office) do not 
satisfactorily fill the role of the OTA.  
• The [National Academy of Sciences] NAS provides excellent consensus 
recommendations from groups of the nation’s most respected scientists and experts. But 
advising Congress is not its primary function and while it tries to be responsive to 
congressional requests, it can and does say no at times. Furthermore, the NAS is not 
always attuned to the needs and timelines of legislators and its reports are very expensive 
to produce. As a non-governmental agency, the NAS lacks sufficient high-level access to 
other parts of the federal government. 
• The [Congressional Research Service] CRS is highly respected for its rapid response, but 
it is not accustomed to working with stakeholders or outside experts. It does not have the 
necessary technological or analytical capacity of the OTA, nor does it have experience 
with peer review. 
• The [Government Accountability Office] GAO has very recently begun to undertake 
technological assessments of the type formerly done by OTA, but that program is bound 
by the rules and culture of a financial auditing agency. While the GAO has extensive 
access to all parts of the federal government and has produced numerous reports that have 
proven extremely useful for oversight, it has little experience with forward-looking 
assessments. Given the GAO’s core mission, it is unlikely that technology assessment 
will find a permanent home at GAO. (UCS-2010) 
 
It is unclear if the U.S. Preventive Services Task Force, the Community Preventive Services Task 
Force, the Institute of Medicine, The Cochrane Collaboration, and other entities will fill the 
vacuum that might have been left by the retirement of the CDP. Some federal and non-federal 
researchers have expressed concern that the rigorous, transparent, and objective processes of the 
CDP are not followed by other entities, especially when assessing treatment modalities. However, 




unlikely to reverse course in the near future. For example, NHLBI announced in June 2013 that it 
will no longer develop clinical practice guidelines and will instead focus on generating high-
quality systematic reviews to support the “development of clinical practice guidelines through 
partnerships with professional societies and other organizations” (NHLBI, 2013). The NIH is 
shifting its focus away from clinical guideline development back to its core mission—scientific 
discovery—and relying more heavily on partnerships to support diffusion. This shift may be 
appropriate for the ODP, given that the influence of the CDP with health providers was mixed 
(Kosecoff et al. 1987 and 1990), while CDP statements appeared to stimulate new, relevant 
research activities, including NIH-issued initiatives and investigator-initiated grants (Portnoy et 
al., 2007). It is hoped that the P2P program will successfully identify important prevention-related 
research gaps using a less expensive and more facile process than its predecessor and that the 
ODP will help bridge those gaps by supporting prevention research and working with key 
stakeholders to move research into practice.  
The recommendations in this study can advance public health with their attention to both 
individual and social environmental factors (McLeroy, Bibeau, Steckler, & Glanz, 1988). 
Professional society leaders and members addressed intrapersonal factors (e.g., multi-faceted 
interventions aimed at changing provider practice), institutional factors (e.g., changes in program 
policies regarding panel composition and processes), community factors (e.g., enhancing 
relationships among federally-sponsored panels and professional societies), and public policy 
(e.g., expanding insurance coverage for preventive services and counseling) (McLeroy, Bibeau, 
Steckler, & Glanz, 1988). Beyond its support of scientific panels, the federal government can 
promote evidence-based practice across a range of health determinants at both individual and 
population levels.  
 




Tuckett (2004) notes two limitations that were applicable to this study: sample frame bias and 
gatekeeper bias. The study population included leaders and members of U.S.-based primary care 
professional societies (or primary care segments of broader associations) that are national in focus 
and which address colorectal cancer screening issues through position statements or clinical 
recommendations. This study population was chosen because it captures organizations that were 
the target of CDP outreach efforts. However, there are many health-related professional societies 
(serving generalists and subspecialists from different areas of the country) which were not 
eligible for this study, but who at times were also involved with CDP conferences. A larger 
sampling frame might have captured more variation in stakeholder perspectives and added to the 
richness of the data.  
The study involved expert and snowball sampling of professional society leaders and 
members. Society Presidents, Chief Executive Officers, and a Board Member served as 
gatekeepers for recruitment and therefore had control of sampling. Over half of the members 
invited to participate in the study were involved in academia, and only one member served as an 
administrator to rank and file clinicians. A more diverse selection of participants may have added 
additional perspectives about professional tensions, determinants of provider practice, and how to 
make recommendations more feasible to implement.  
Telephone interviews permitted access to leaders and members from across the country, 
enabled discussion to be easily recorded, and eliminated travel time and expense. However, the 
telephone interviews reduced social cues, such as body language, which can be used as additional 
sources of information. Interview data limitations also included possibly distorted responses due 
to personal bias, reactivity of the interviewee to the interviewer(s), and self-serving purposes 
(Patton, 2002).  
Lastly, the lead researcher came to this study with her own biases, which included 
disappointment in the retirement of the CDP, belief that the federal government substantially 




panels. She continues to support public representatives on panels, so long as the panelists have 
pertinent knowledge to elucidate the topic under consideration and training to facilitate their 
successful participation. The researcher’s belief that the federal government adds value to 
evidence-based practice is supported by this research, and although feedback from many leaders 
and members challenged some of her views about the CDP, the study findings have fostered 
optimism about the potential impact of the new Pathways to Prevention program and other ODP 










































Appendix 1: Listing of Initial 19 National Guideline Clearinghouse Entries and Sponsoring 
Organizations 
 
19 National Guideline Clearinghouse Entries 
 
(1) NIH State-of-the-Science Conference Statement on enhancing use and quality of colorectal cancer 
screening. 2010 Feb. NGC:008272 
National Institutes of Health Consensus Development Conference - Independent Expert Panel. 
(2) Colorectal cancer screening clinical practice guideline. 2006 Nov (revised 2008 Dec). NGC:007213 
Kaiser Permanente Care Management Institute - Managed Care Organization. 
(3) ACR Appropriateness Criteria® colorectal cancer screening. 1998 (revised 2010). NGC:007920 
American College of Radiology - Medical Specialty Society. 
(4) Colorectal cancer screening. 1995 May (revised 2010 May). NGC:007960 
Institute for Clinical Systems Improvement - Nonprofit Organization. 
(5) Colorectal cancer screening. 2007. NGC:006244 
World Gastroenterology Organisation - Medical Specialty Society. 
(6) Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. 
1996 (revised 2008 Oct). NGC:006722 
U.S. Preventive Services Task Force - Independent Expert Panel. 
(7) Guideline Synthesis Screening for Colorectal Cancer. 
(8) Preventive services for adults. 1995 Jun (revised 2010 Sep). [NGC Update Pending] NGC:008086 
Institute for Clinical Systems Improvement - Nonprofit Organization. 
(9) Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 
2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology. 2001 (revised 2008 May-Jun). 
NGC:007214 
American Cancer Society - Disease Specific Society; American College of Radiology - Medical 
Specialty Society; U.S. Multisociety Task Force on Colorectal Cancer - Medical Specialty 
Society. 
(10) Adult preventive services (ages 50 - 65+). 2005 Jul (revised 2011 Apr). NGC:008506 
Michigan Quality Improvement Consortium - Professional Association. 
(11) Endoscopy by nonphysicians. 2009 Apr. NGC:008327 
American Society for Gastrointestinal Endoscopy - Medical Specialty Society. 
(12) Adult preventive services (ages 18 - 49). 2005 Jul (revised 2011 Apr). NGC:008505 
Michigan Quality Improvement Consortium - Professional Association. 
(13) Diagnosis and management of primary sclerosing cholangitis. 2010 Feb. NGC:007676 
American Association for the Study of Liver Diseases - Nonprofit Research Organization. 
(14) Gastroscopy following a positive fecal occult blood test and negative colonoscopy: guideline 
recommendations. 2009 Mar 30. NGC:007276 
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. 
(15) Prevention and screening of colorectal cancer. 2002 Apr 27 (revised 2008 May 22). NGC:006598 
Finnish Medical Society Duodecim - Professional Association. 
(16) ASGE guideline: modifications in endoscopic practice for the elderly. 2006 Apr (reaffirmed 2011). 
NGC:004975 
American Society for Gastrointestinal Endoscopy - Medical Specialty Society. 
(17) Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 2009. 
NGC:007630 




(18) Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. 
Sections 137-146: cancer and general health screening. 2003 Sep (revised 2008 Oct). 
NGC:007574 
Children's Oncology Group - Medical Specialty Society. 
(19) Summary of recommendations for clinical preventive services. 1996 Nov (revised 2011 May). 
[NGC Update Pending] NGC:008564 




American Academy of Family Physicians 
American Association for the Study of Liver Diseases 
American Cancer Society  
* American College of Gastroenterology 
American College of Radiology 
* American Gastroenterological Association 
* American Society for Gastrointestinal Endoscopy 
Children's Oncology Group 
Finnish Medical Society Duodecim 
Institute for Clinical Systems Improvement 
Kaiser Permanente Care Management Institute 
Michigan Quality Improvement Consortium 
National Academy of Clinical Biochemistry 
National Institutes of Health Consensus Development Conference 
Program in Evidence-based Care 
U.S. Preventive Services Task Force 
World Gastroenterology Organisation 
 


























Appendix 2: Division of Initial 19 National Guideline Clearinghouse Entries 
 
Included in study: 
 
#1   NIH State-of-the-Science Conference Statement on enhancing use and quality of 
colorectal cancer screening. 2010 Feb. NGC:008272 
National Institutes of Health Consensus Development Conference - Independent Expert 
Panel. 
# 6 Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. 
1996 (revised 2008 Oct). NGC:006722 
U.S. Preventive Services Task Force - Independent Expert Panel. 
#9  Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 
2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology. 2001 (revised 2008 May-Jun). 
NGC:007214 
American Cancer Society - Disease Specific Society; American College of Radiology - Medical 
Specialty Society; U.S. Multisociety Task Force on Colorectal Cancer - Medical Specialty 
Society. 
#19 Summary of recommendations for clinical preventive services. 1996 Nov (revised 2011 May). 
[NGC Update Pending] NGC:008564 
American Academy of Family Physicians - Medical Specialty Society. 
 
 
Excluded from study: 
 
# 2  Colorectal cancer screening clinical practice guideline. 2006 Nov (revised 2008 Dec). 
NGC:007213 
Kaiser Permanente Care Management Institute - Managed Care Organization. Exclusion 
Criterion: Not national in focus. 
# 3  ACR Appropriateness Criteria® colorectal cancer screening. 1998 (revised 2010). 
NGC:007920 American College of Radiology - Medical Specialty Society. Exclusion 
Criterion: Duplicative of joint recommendation in #9 above. 
# 4  Colorectal cancer screening. 1995 May (revised 2010 May). NGC:007960 
Institute for Clinical Systems Improvement - Nonprofit Organization. Exclusion Criterion: Not 
national in focus. 
# 5  Colorectal cancer screening. 2007. NGC:006244 
World Gastroenterology Organisation - Medical Specialty Society. Exclusion Criterion: 
International panel. 
# 7  Guideline Synthesis Screening for Colorectal Cancer. Exclusion Criterion: Guideline 
synthesis conducted by AHRQ regarding 3 recommendations listed above (#2, #6, #9).  
# 8  Preventive services for adults. 1995 Jun (revised 2010 Sep). [NGC Update Pending] 
NGC:008086 
Institute for Clinical Systems Improvement - Nonprofit Organization. Exclusion Criterion: Not 
national in focus. 
#10  Adult preventive services (ages 50 - 65+). 2005 Jul (revised 2011 Apr). NGC:008506 
Michigan Quality Improvement Consortium - Professional Association. Exclusion 
Criterion: Not national in focus. 
#11  Endoscopy by nonphysicians. 2009 Apr. NGC:008327  
American Society for Gastrointestinal Endoscopy - Medical Specialty Society. Exclusion 




#12  Adult preventive services (ages 18 - 49). 2005 Jul (revised 2011 Apr). NGC:008505 
Michigan Quality Improvement Consortium - Professional Association. Exclusion 
Criterion: Not national in focus. 
#13  Diagnosis and management of primary sclerosing cholangitis. 2010 Feb. NGC:007676 
American Association for the Study of Liver Diseases - Nonprofit Research 
Organization. Exclusion Criterion: Focus is primary sclerosing cholangitis not CRC 
screening for people at average risk of colorectal cancer. 
#14  Gastroscopy following a positive fecal occult blood test and negative colonoscopy: 
guideline recommendations. 2009 Mar 30. NGC:007276 
Program in Evidence-based Care - State/Local Government Agency [Non-U.S.]. 
Exclusion Criterion: International panel. 
#15  Prevention and screening of colorectal cancer. 2002 Apr 27 (revised 2008 May 22). 
NGC:006598 
Finnish Medical Society Duodecim - Professional Association. Exclusion Criterion: 
International panel. 
#16  ASGE guideline: modifications in endoscopic practice for the elderly. 2006 Apr 
(reaffirmed 2011). NGC:004975 
American Society for Gastrointestinal Endoscopy - Medical Specialty Society. Exclusion 
Criterion: Duplicative of joint recommendation in #9 above. 
#17  Use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. 2009. 
NGC:007630 
National Academy of Clinical Biochemistry - Professional Association. Exclusion 
Criterion: Does not focus on common screening modalities. 
#18  Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult 
cancers. Sections 137-146: cancer and general health screening. 2003 Sep (revised 2008 
Oct). NGC:007574 
Children's Oncology Group - Medical Specialty Society. Exclusion Criterion: Does not 



























Appendix 3: Organizations, Panels, and Recommendations or Conclusions 
 
Independent Expert Panels and Their Supporting Organizations 
1) The NIH is the nation’s medical research agency and the largest source of funding for medical 
research in the world (NIH, 2014). The ODP is the lead office at NIH “responsible for assessing, 
facilitating, and stimulating research in disease prevention and health promotion, and 
disseminating the results of this research to improve public health” (ODP, 2014a). The ODP’s 
Consensus Development Program convened panels in which members were highly regarded in 
their own fields, but did not have financial or career interests related to conference topics. In 
February 2010, a CDP conference was held to assess the available data on enhancing the use and 
quality of colorectal cancer screening. A one-time, independent State-of-the-Science Panel of 13 
non-federal members reviewed the results of a systematic literature review, listened to 
presentations conducted by experts of CRC issues, participated in public question and answer 
sessions, and deliberated in closed sessions. Afterward, the panel authored a 31-page consensus 
statement. Below are the major CDP recommendations.  
The panel finds that despite substantial progress toward higher colorectal cancer screening rates 
nationally, screening rates fall short of desirable levels. Targeted initiatives to improve screening 
rates and reduce disparities in underscreened communities and population subgroups could 
further reduce colorectal cancer morbidity and mortality. This could be achieved by utilizing the 
full range of screening options and evidence-based interventions for increasing screening rates. 
With additional investments in quality monitoring, Americans could be assured that all screening 
achieves high rates of cancer prevention and early detection. To close the gap in screening, this 
report identifies the following priority areas for implementation and research to enhance the use 
and quality of colorectal cancer screening: 
• Eliminate financial barriers to colorectal cancer screening and appropriate follow-up.  
• Widely implement interventions that have proven effective at increasing colorectal cancer 
screening, including patient reminder systems and one-on-one interactions with 
providers, educators, or navigators.  
• Conduct research to assess the effectiveness of tailoring programs to match the 
characteristics and preferences of target population groups to increase colorectal cancer 
screening.  
• Implement systems to ensure appropriate follow-up of positive colorectal cancer 
screening results.  
• Develop systems to ensure high quality of colorectal cancer screening programs.  
• Conduct studies to determine the comparative effectiveness of the various colorectal 
cancer screening methods in usual practice settings.  
National Guideline Clearinghouse: http://www.guideline.gov/content.aspx?id=25654 
 
 
 2) The Agency for Healthcare Research and Quality (AHRQ), which focuses on research that 
improves informed decision-making and the quality of health care services (AHRQ, 2011a) is 
congressionally mandated to support the U.S. Preventive Services Task Force (USPSTF). The 
USPSTF is an independent panel of 16 non-federal primary care clinicians who are experts in 
prevention and evidence-based medicine. The Task Force “conducts rigorous, impartial 
assessments of the scientific evidence for the effectiveness of a broad range of clinical preventive 




recommendations are considered the “gold standard” for clinical preventive services” (AHRQ, 
2010b). In 1996, the USPSTF recommended screening with gFOBT or FS (Coughlin & 
Thompson, 2005); by 2002 their recommendation included the use of colonoscopy (AHRQ, 
2010b); and by 2008, FIT was added as a recommended screening option (AHRQ, 2008). Below 
is a summary of the 2008 USPSTF recommendations for CRC screening. 
The USPSTF recommends screening for colorectal cancer using fecal occult blood testing, 
sigmoidoscopy, or colonoscopy, in adults, beginning at age 50 years and continuing until age 75 
years. The risks and benefits of these screening methods vary. See Rationale section of the 
original guideline document. This is an A recommendation. 
The USPSTF recommends against routine screening for colorectal cancer in adults 76 to 85 years. 
There may be considerations that support colorectal cancer screening in an individual patient. 
This is a C recommendation. 
The USPSTF recommends against screening for colorectal cancer in adults older than age 85 
years. This is a D recommendation. 
The USPSTF concludes that the evidence is insufficient to assess the benefits and harms of 
computed tomographic colonography and fecal DNA testing as screening modalities for 
colorectal cancer. This is an I “Insufficient Evidence” statement. 
National Guideline Clearinghouse: http://www.guideline.gov/content.aspx?id=13133  
 
 
 3) The Centers for Disease Control and Prevention (CDC), the leading federal division for public 
health, provides scientific, technical, and administrative support to the Community Preventive 
Services Task Force (CDC-Task Force, 2011). This Task Force is an independent panel of 12 
non-federal public health and prevention experts, who are appointed to the Task Force by the 
Director of the CDC (CDC-Task Force, 2010a). The Task Force is charged with conducting 
systematic reviews and issuing findings and evidence-based recommendations to “help inform 
decision making about policy, practice, research, and research funding in a wide range of U.S. 
settings” (CDC-Task Force, 2010a). Below is a summary of the Task Force’s recommendations 
for the CRC screening. 
 
Task Force Findings: 1/1/1997 -7/12/2010 
 
Cancer Prevention and Control: Increasing Colorectal Cancer Screening 
 
Client-Oriented Interventions 
 Client Incentives – Insufficient Evidence 7/12/2010 
 Client Reminders – Recommended (Sufficient Evidence) 2/26/2003 
Group Education – Insufficient Evidence 10/15/2000 
Mass Media - Insufficient Evidence 10/15/2000 
 Small Media - Recommended (Strong Evidence) 12/15/2005 
 One on One Education - Recommended (Sufficient Evidence) 3/31/2010 
Reducing Out-of-Pocket Costs - Insufficient Evidence 10/15/2009 






Provider Assessment and Feedback - Recommended (Sufficient Evidence) 10/15/2009 
 Provider Incentives - Insufficient Evidence 10/15/2009 
 Provider Reminders and Recalls - Recommended (Strong Evidence) 2/16/2006 
 Multicomponent Interventions - Recommended (Strong Evidence) 2/27/2008 
 




Disease Specific Society 
 
 4) The American Cancer Society (ACS), “a nationwide, community-based voluntary health 
organization dedicated to eliminating cancer as a major health problem”, has “13 chartered 
Divisions and more than 3,400 local offices” (ACS, 2010).  Since 1980, with the publishing of 
Guidelines for the Cancer-Related Checkup: Recommendations and Rationale, the ACS has 
conducted assessments of cancer screening tests (Smith et al. 2000). Prior to the mid-2000s, the 
ACS developed CRC screening guidelines through periodic workshops convened by its 
Colorectal Cancer Advisory Group using a nine-step process to review data and establish 
recommendations for target groups (Smith et al. 2000; Smith et al. 2001).  In 2006-2007, the ACS 
joined the U.S. Multisociety Task Force on Colorectal Cancer (MSTF) and the American College 
of Radiology (ACR) to develop guidelines to screen for CRC and its precursor polyps (Levin et 
al. 2008). See Appendix C for the major points of the joint guidelines (NGC, 2008c). 
 
Medical Specialty Societies  
 
5) The American Academy of Family Physicians (AAFP), a national association of family 
doctors with approximately 100,000 members (AAFP, 2012a), has four stated objectives: 
• Advocacy - Shape health care policy through interactions with government, the public, 
business, and the healthcare industry 
• Practice Enhancement - Enhance members’ abilities to fulfill their practice and career 
goals 
• Education - Promote high-quality, innovative education for physicians, residents, and 
medical students that encompasses the art, science, evidence and socioeconomics of 
family medicine 
• Health of the Public - Assume a leadership role in health promotion, disease prevention, 
and chronic disease management. (AAFP, 2012b) 
The AAFP Commission on Health of the Public and Science (CHPS) reviews external 
recommendations and makes its own recommendations, all of which are submitted to the AAFP 
Board of Directors for approval. In most cases the AAFP agrees with the USPSTF; however, 
there are circumstances where there are differences (AAFP, 2011). The 2011 CHPS 
recommendations for CRC screening mirrored those of the USPSTF (NGC, 2011).  
 
6) The American College of Radiology has approximately 34,000 members, including 
“radiologists, radiation oncologists, medical physicists, interventional radiologists and nuclear 
medicine physicians” (ACR, 2011a). The mission of ACR is to maximize the profession’s value 
by advancing radiological science, improving patient care, addressing socioeconomic (i.e., 
reimbursement) issues, and providing continuing education for radiology and allied health 
professionals (ACR, 2011a; 2011b). The ACR Commission on Quality and Safety (CQS), which 
oversees development of the society’s radiology guidelines, tasks the Expert Panel on 




Draft clinical practice guidelines are posted on the ACR website for a 3-week ‘field review’, 
during which time any member of the society can provide comments (ACR, 2011d). These 
comments are collated by ACR staff and reviewed by a subcommittee that adopts or rejects 
suggested changes. Guidelines are then submitted as resolutions to be considered at the ACR 
Annual Meeting and Chapters Leadership Conference. Once adopted, guidelines are posted on the 
ACR website. In 2008, a sub-group of the Expert Panel on Gastrointestinal Imaging (Colon 
Cancer Committee) joined the American Cancer Society and the U.S. Multisociety Task Force on 
Colorectal Cancer to develop guidelines to screen for CRC and it precursor polyps (Levin et al. 
2008). See Table 2 for the major points of the joint guidelines. 
 
7-9) The U.S. Multisociety Task Force on Colorectal Cancer (MSTF) issued CRC screening 
guidelines in 1997, 2003, and 2008.  For the last report, the MSTF issued joint recommendations 
with ACS and ACR (NCG, 2008c).The 2008 MSTF included members representing the 
American Gastroenterological Association, the American College of Gastroenterology, and the 
American Society for Gastrointestinal Endoscopy (Levin et al., 2008; McFarland et al., 2008). 
See Appendix 3 for the major points of the joint ACS, ACR, and MSTF 2008 guidelines, and 
below for descriptions of the three MSTF member organizations.   
 
(7) The American Gastroenterological Association (AGA), representing 17,000 members, 
focuses on the “science, practice and advancement of gastroenterology” (AGA, 2012a). 
The AGA maintains 13 committees, including the 11-member Practice & Quality 
Management Committee which is concerned with: 
• Developing evidence-based clinical practice guidelines; policy statements; consensus 
statements, etc., for gastroenterologists and primary care physicians with respect to 
the management and treatment of patients with various digestive diseases and 
conditions 
• Developing priorities, standards and processes for development of standards of 
practice (development of which shall be the responsibility of the AGA Council) 
(AGA, 2012b). 
 
(8) The American College of Gastroenterology (ACG) has 12,000 members and directs its 
efforts toward continuing medical education (through publications, meetings, and web-
based resources), health care policy, clinical research, and patient advocacy (ACG, 
2012a). The ACG Practice Parameters Committee follows specific steps when creating 
the organization’s clinical guidelines: 
• A subgroup of the committee holds a conference call to isolate 8-12 central issues in 
diagnosis and management of a disease. 
• Clinical questions are developed and applicable systematic reviews of evidence are 
identified. 
• Evidence from systematic reviews is linked to certain questions. When a clinical 
question is not addressed by a systematic review, an ‘explicit review of the literature’ 
is conducted, which may take cohort studies and case series findings under 
consideration. 
• Recommendations are generated using nominal group technique and are graded for 
both strength of evidence and strength of recommendation.  
• Flow diagrams demonstrating algorithms are created. 
• The ACG Board of Trustees reviews all recommendations, which are then published 
in the peer-reviewed American Journal of Gastroenterology for member comment. 
(ACG, 2012b). 





(9) The American Society for Gastrointestinal Endoscopy (ASGE), which has 12,000 
members, is dedicated to advocacy, education, practice, and research that enhances 
digestive tract endoscopy (ASGE, 2012a). Physician members are required to have 
documented special training in gastrointestinal endoscopic procedures, such as flexible 
sigmoidoscopy and colonoscopy (ASGE, 2012a). The ASGE Standards of Practice 
Committee develops the organization’s clinical practice guidelines (ASGE, 2012b). The 
Standards of Practice Committee routinely includes three representatives from other 
professional societies (i.e. Society of Gastroenterology Nurses and Associates (SGNA), 
Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) and North 
American Society for Pediatric Gastroenterology, Hepatology and Nutrition 
(NAPSGHAN)) when authoring clinical recommendations (NGC, 2006 &2009).  
Below are the MSTF Guidelines for Screening for the Early Detection of Colorectal Cancer and 
Adenomas for Average-Risk Women and Men Aged 50 Years and Older 
The following options are acceptable choices for colorectal cancer screening in average-risk 
adults beginning at age 50 years. Since each of the following tests has inherent characteristics 
related to prevention potential, accuracy, costs, and potential harms, individuals should have an 
opportunity to make an informed decision when choosing one of the following options. 
In the opinion of the guidelines development committee, colon cancer prevention should be the 
primary goal of colorectal cancer screening. Tests that are designed to detect both early cancer 
and adenomatous polyps should be encouraged if resources are available and patients are willing 
















Tests that Detect Adenomatous Polyps and Cancer 
Test Interval Key Issues for Informed Decisions 
Flexible sigmoidoscopy 
(FSIG) with insertion to 
40 cm or to splenic 
flexure 
Every 5 years • Complete or partial bowel prep is required  
• Sedation usually is not used, so there may be some discomfort during 
the procedure  
• The protective effect of sigmoidoscopy is primarily limited to the 
portion of the colon examined  
• Patients should understand that positive findings on sigmoidoscopy 
usually result in a referral for colonoscopy 
Colonoscopy Every 10 
years 
• Complete bowel prep is required  
• Conscious sedation is used in most centers; patients will miss a day of 
work and will need a chaperone for transportation from the facility  
• Risks include perforation and bleeding, which are rare but potentially 
serious; most of the risk is associated with polypectomy 
Double contrast barium 
enema (DCBE) 
Every 5 years • Complete bowel prep is required  
• If patients have one or more polyps ≥6 mm, colonoscopy will be 
recommended; follow-up colonoscopy will require complete bowel 
prep  
• Risks of DCBE are low; rare cases of perforation have been reported 
Computed tomographic 
colonography (CTC) 
Every 5 years • Complete bowel prep is required  
• If patients have one or more polyps ≥6 mm, colonoscopy will be 
recommended; if same day colonoscopy is not available, a second 
complete bowel prep will be required before colonoscopy  
• Risks of CTC are low; rare cases of perforation have been reported  
• Extracolonic abnormalities may be identified on CTC that could 
require further evaluation 
Tests that Primarily Detect Cancer 
Test Interval Key Issues for Informed Decisions 
Guaiac-based fecal occult 
blood test (gFOBT) with 
high sensitivity for cancer 
Annual • Depending on manufacturer's recommendations, 2 to 3 stool samples 
collected at home are needed to complete testing; a single sample of 
stool gathered during a digital exam in the clinical setting is not an 
acceptable stool test and should not be done  
• Positive tests are associated with an increased risk of colon cancer and 
advanced neoplasia; colonoscopy should be recommended if the test 
results are positive  
• If the test is negative, it should be repeated annually  
• Patients should understand that one-time testing is likely to be 
ineffective 
Fecal immunochemical 
test (FIT) with high 
sensitivity for cancer 
Annual 
Stool DNA (sDNA) with 
high sensitivity for cancer 
Interval 
uncertain 
• An adequate stool sample must be obtained and packaged with 
appropriate preservative agents for shipping to the laboratory  
• The unit cost of the currently available test is significantly higher than 
other forms of stool testing  
• If the test is positive, colonoscopy will be recommended  





Note: In this update of the CRC screening guidelines, the guideline authors have focused on screening in 
average-risk adults and have not reviewed recent literature on CRC screening or surveillance for 
individuals at increased and high risk. Individuals at increased risk due to a history of adenomatous polyps; 
a personal history of curative-intent resection of CRC; a family history of either CRC or colorectal 
adenomas diagnosed in a first-degree relative before age 60 years; or high risk due to a history of 
inflammatory bowel disease of significant duration or the presence of one of two hereditary syndromes 
should continue to follow recommendations issued previously by the American Cancer Society (ACS) or 
U.S. Multi-Society Task Force (USMSTF). 





10) The Cochrane Collaboration is an international, nonprofit organization that conducts 
systematic reviews of research in health care and health policy to help clinicians, patients, 
advocates, and policymakers make well-informed decisions based on the best available evidence 
(Cochrane Collaboration, 2012a & 2012b). The Cochrane Colorectal Cancer Group (CCCG) is 
one of the organization’s 52 collaborative review groups (Cochrane Collaboration, 2009). The 
CCCG is composed of 13 editors, 2 consumer representatives, 600 reviewers, 120 external peer 
referees, and 21 searchers. A search of The Cochrane Library, using the search term “colorectal”, 
yielded 89 reviews and protocols. Of the 89, five were related to colorectal cancer screening of 
asymptomatic, average-risk adults; one review and four protocols (Cochrane Collaboration, 
2012c). A plain language summary for the published 2011 review on FOBT highlights the 
following evidence-based findings: 
• Regular screening of faeces for blood can detect colorectal cancer earlier and hence may 
reduce mortality.  
• If the FOBT is positive, the bowels are examined closely with further diagnostic testing 
(coloscopy, flexible sigmoidoscopy, double-contrast barium enema), but these tests often 
cause discomfort and can cause serious adverse consequences. As blood identified in 
faeces may be due to several reason (unrelated to cancer), it may cause people 
unnecessary stress and expose them to possible harm.  
• FOBT screening is likely to avoid approximately 1 in 6 colorectal cancer deaths. 
(Cochrane Collaboration, 2008, 2)  
 
11) The Institute of Medicine (IOM), the health arm of the National Academy of Sciences, is an 
independent, nonprofit organization that works to provide unbiased and authoritative advice about 
health and health care to decision-makers and the public (IOM, 2010).  Many studies that the 
IOM conducts are congressionally mandated; however, federal agencies and independent 
organizations can also request an IOM review through consensus committee, standing committee, 
workshop, forum, or roundtable (IOM, 2010). In 2008, the IOM’s National Cancer Policy Forum 
(NCPF) convened a workshop on CRC screening to discuss the next steps to be taken by clinics, 
communities, and health systems to overcome screening barriers and prevent CRC deaths (IOM, 
2008). The NCPF consists of 20 members, representing cancer centers, advocacy organizations, 
industry, academia, and components of the U.S. Department of Health and Human Services. The 
Forum’s 2008 evidence-based report from the workshop was independently reviewed by five 
experts to ensure the manuscript met the IOM’s standards for objectivity, evidence, and 
responsiveness (IOM, 2008). Although the report did not layout specific guidelines to follow, it 
did identify several themes that required additional attention: 
• Although the incidence of CRC has declined since the 1980s, too many diagnoses are for 




• Messages about colorectal cancer screening are complicated by heterogeneity in testing 
methods and intervals at which tests are to be performed. 
• Improved referral of patients from primary care providers to clinicians who directly 
screen for CRC would improve screening rates. (IOM, 2008) 
 
Below are the IOM’s conclusions on specific issues. 
 
• Colorectal cancer: The incidence of colorectal cancer has declined since screening was 
first recommended in 1980. Even so, too many colorectal cancer diagnoses are for late-
state disease, and screening rates are still too low.  
•  Screening tests: A fair amount of consensus exists on the current guidelines for colorectal 
cancer screening. However, the message is complicated by the different tests and 
intervals at which the tests are performed. Even though there seems to be movement 
toward colonoscopy as the preferred test, this is not necessarily based on evidence of 
better test sensitivity or specificity. Additional concerns arise as new tests are developed 
that provide only incremental benefit, but confuse the message to the public about 
colorectal cancer screening. 
•  Quality of screening: For colonoscopy, in particular, screening often takes place outside 
the primary care physician’s practice. Improving the referral process so that patients are 
not lost would improve screening rates. Regarding the quality of the testing itself, 
speakers discussed variability in test results due to different readers for multiple test types 
and quality of bowel preparation for endoscopic screening. Nonadherence to screening 
guidelines results in inadequate promotion of screening or the use of non-evidence based 
screening tests. 
•  Primary care system: Primary care physicians and their staff are critical to the 
implementation of colorectal cancer screening. However, the primary care system is 
under enormous pressure. These physicians deal with significant time constraints due to a 
large preventive, chronic, and acute care agenda. Financial stability of the practices and 
incentives for preventive care in primary care practices are also important considerations. 
•  Workforce capacity: It is unclear whether the capacity to fully implement colorectal 
cancer screening is currently available. On one hand, primary care physicians do not have 
time to fully implement preventive care in their practices, and there may be long waits for 
colonoscopy appointments. On the other hand, there may be overuse of colonoscopy. The 
medical home concept was introduced as a possible route to address workforce issues. 
•  Metrics and measurements: “We often hear from community programs and organizations, 
which is for some advice on what we should be measuring to know whether we are 
getting where we want to be.” Datasets such as HEDIS are helpful in addressing these 
concerns. Errors and quality of measurements, data standards, and reporting methods 
were discussed, as well as the apparent spectrum between 
privacy protections and transparent systems. 
•  Costs: Cost of screening and cost-effectiveness were common themes throughout the 
workshop: not only the monetary costs of the testing itself, but also the time costs of staff, 
particularly for small practices. Financial incentives and disincentives to physicians were 
also seen as affecting colorectal cancer screening implementation. 
•  Coverage: Colorectal cancer screening is generally covered by traditional health 
insurance plans and Medicare. Beyond lack of coverage for uninsured and underinsured 
individuals, however, “We seem to be hearing more and more about the affordability of 
insurance and the trend to shift more of the cost burden on the employee.” This may 
result in lack of coverage for colonoscopy for more people. “This is at the same time we 




in screening offerings was highlighted on a state-to-state level, among practice types, and 
on practice-to-practice and even physician-to-physician levels. 
•  Communications: The content of the message to the public was discussed, as was its 
place in the general preventive care agenda. Communications between health plans and 
providers can be improved, as can communications to providers about screening 
guidelines. Community- and practice-based interventions were shown to be successful, 
although the data focused on interventions to increase FOBT screening. Data from state 
and federal demonstration programs showed that large screening initiatives are useful in 
increasing screening rates and decreasing the incidence of colorectal cancer. 
•  Disparities: During the workshop, several issues of disparities were discussed, including 
race, gender, age, and insurance coverage. For example, African Americans experience 
earlier onset of colorectal cancer, suggesting that different screening guidelines might 
better serve this group. Another topic covered was difference between genders: 
depending on the setting and types of intervention, there are different screening rates and 
disease outcomes to be addressed. 
 
Institute of Medicine of the National Academies. (October 2008). Implementing Colorectal 




Appendix 4: Summary of IOM Standards for Developing Trustworthy Clinical Practice 
Guidelines  
 
1. Establishing Transparency 
1.1  The processes by which a CPG is developed and funded should be detailed explicitly and 
publicly accessible. 
2. Management of Conflict of Interest (COI) 
2.1  Prior to selection of the guideline development group (GDG), individuals being 
considered for membership should declare all interests and activities potentially resulting 
in COI with development group activity, by written disclosure to those convening the 
GDG: 
•  Disclosure should reflect all current and planned commercial (including services 
from which a clinician derives a substantial proportion of income), non-commercial, 
intellectual, institutional, and patient–public activities pertinent to the potential scope 
of the CPG. 
2.2 Disclosure of COIs within GDG: 
•  All COI of each GDG member should be reported and discussed by the prospective 
development group prior to the onset of his or her work. 
•  Each panel member should explain how his or her COI could influence the CPG 





• Members of the GDG should divest themselves of financial investments they or their 
family members have in, and not participate in marketing activities or advisory 
boards of, entities whose interests could be affected by CPG recommendations. 
2.4 Exclusions 
• Whenever possible GDG members should not have COI. 
  
• In some circumstances, a GDG may not be able to perform its work without members 
who have COIs, such as relevant clinical specialists who receive a substantial portion 
of their incomes from services pertinent to the CPG. 
  
• Members with COIs should represent not more than a minority of the GDG. 
  
• The chair or cochairs should not be a person(s) with COI. 
  
• Funders should have no role in CPG development. 
3. Guideline Development Group Composition 
3.1 The GDG should be multidisciplinary and balanced, comprising a variety of 
methodological experts and clinicians, and populations expected to be affected by the 
CPG. 
3.2 Patient and public involvement should be facilitated by including (at least at the time of 
clinical question formulation and draft CPG review) a current or former patient, and a 
patient advocate or patient/consumer organization representative in the GDG. 
3.3 Strategies to increase effective participation of patient and consumer representatives, 
including training in appraisal of evidence, should be adopted by GDGs. 
4. Clinical Practice Guideline–Systematic Review Intersection 
4.1 Clinical practice guideline developers should use systematic reviews that meet standards 
set by the Institute of Medicine’s Committee on Standards for Systematic Reviews of 
Comparative Effectiveness Research. 
4.2 When systematic reviews are conducted specifically to inform particular guidelines, the 
GDG and systematic review team should interact regarding the scope, approach, and 
output of both processes. 
5. Establishing Evidence Foundations for and Rating Strength of Recommendations 
 5.1 For each recommendation, the following should be provided: 




○ a clear description of potential benefits and harms; 
○ a summary of relevant available evidence (and evidentiary gaps), description of 
the quality (including applicability), quantity (including completeness), and 
consistency of the aggregate available evidence; 
○ an explanation of the part played by values, opinion, theory, and clinical 
experience in deriving the recommendation. 
• A rating of the level of confidence in (certainty regarding) the evidence underpinning 
the recommendation. 
• A rating of the strength of the recommendation in light of the preceding bullets. 
• A description and explanation of any differences of opinion regarding the 
recommendation. 
6. Articulation of Recommendations 
6.1 Recommendations should be articulated in a standardized form detailing precisely what 
the recommended action is, and under what circumstances it should be performed. 
6.2 Strong recommendations should be worded so that compliance with the 
recommendation(s) can be evaluated. 
7. External Review 
7.1 External reviewers should comprise a full spectrum of relevant stakeholders, including 
scientific and clinical experts, organizations (e.g., health care, specialty societies), 
agencies (e.g., federal government), patients, and representatives of the public. 
7.2 The authorship of external reviews submitted by individuals and/or organizations should 
be kept confidential unless that protection has been waived by the reviewer(s). 
7.3 The GDG should consider all external reviewer comments and keep a written record of 
the rationale for modifying or not modifying a CPG in response to reviewers’ comments. 
7.4 A draft of the CPG at the external review stage or immediately following it (i.e., prior to 
the final draft) should be made available to the general public for comment. Reasonable 
notice of impending publication should be provided to interested public stakeholders. 
8. Updating 
8.1 The CPG publication date, date of pertinent systematic evidence review, and proposed 
date for future CPG review should be documented in the CPG. 
8.2 Literature should be monitored regularly following CPG publication to identify the 





8.3 CPGs should be updated when new evidence suggests the need for modification of 
clinically important recommendations. For example, a CPG should be updated if new 
evidence shows that a recommended intervention causes previously unknown substantial 
harm; that a new intervention is significantly superior to a previously recommended 
intervention from an efficacy or harms perspective; or that a recommendation can be 


























Appendix 5: Medical and Nursing Professional Societies/Organizations Identified in Initial 
Internet Search  
 
Medical Organizations  
 
*American Academy of Family Physicians 
† American Academy of Home Care Physicians  
§ American Academy of Physician Assistants 
† American Association of Public Health Physicians 
† American College of Osteopathic Family Physicians 
*American College of Physicians 
*American Congress of Obstetricians and Gynecologists 
† American Holistic Medical Association 
*American Medical Association 
*American Medical Women's Association 
*American Osteopathic Association 
† Association of American Indian Physicians 
† Association of Departments of Family Medicine 
† Association of Family Practice Physician Assistants 
† Association of Family Practice Residency Directors 
† Association of Program Directors in Internal Medicine  
† Catholic Medical Association 
† Christian Medical & Dental Associations 
† Fellowship of Christian Physician Assistants 
† National American Arab Medical Association 
† National Commission on Certification of Physician Assistants 
† National Hispanic Medical Association 
† National Medical Association 
† Physician Assistant Education Association 
† Society of Army Physician Assistants 
† Society of General Internal Medicine 
 
Nursing Organizations  
 
† Alpha Tau Delta National Fraternity for Professional Nurses 
† American Academy of Ambulatory Care Nursing 
§ American Academy of Nurse Practitioners 
† American Academy of Nursing 
† American Assembly for Men in Nursing 
† American College of Nurse Practitioners 
† American Holistic Nurses Association 
† American Nurses Association 
† Association of Family Practice Residency Nurses 
† Association of Women's Health, Obstetric and Neonatal Nurses 
† Gerontological Advanced Practice Nurses Association 
† National Alaska Native American Indian Nurses Association 
† National American Arab Nurses Association 
† National Association of Catholic Nurses 




† National Association of Hispanic Nurses 
† National Association of Nurse Practitioners in Women's Health 
† National Black Nurses Association 
† National Coalition of Ethnic Minority Nurse Associations Inc. 
† National Gerontological Nursing Association 
† National League for Nursing Inc. 
† Nurse Practitioner Healthcare Foundation 
† Nurses Christian Fellowship 
† Nurses Organization of Veteran Affairs 
† Philippine Nurses Association of America, Inc. 
† Samoan National Nurses Association 
† Sigma Theta Tau International 
 
* Organization met all study criteria:  
 U.S.-based primary care professional society (or a professional society with a primary 
care segment)  
 National in focus 
 Addressed colorectal cancer screening issues through position statements or clinical 
recommendations.  
 
† Organization was excluded from the study because it did not address colorectal cancer 
screening issues through position statements or clinical recommendations.  
 
§ Organization did not address colorectal cancer screening issues through position statements or 
clinical recommendations, but was included in the study because it was the largest organization 









































Study Title: Moving Research Into Practice: The Diffusion of Evidence-based 
Recommendations Through Professional Societies 
Principal Investigator: Elizabeth Neilson 
 
 
What you should know about this study 
 
• You are being asked to join a research study. 
• You are a volunteer. You can choose not to take part; if you join, you may quit at any 
time. There will be no penalty if you decide to quit the study. 
• During the study, we will tell you if we learn any new information that might affect 
whether you wish to continue to be in the study. 
 
Purpose of research project 
 
The National Institutes of Health (NIH), Office of Disease Prevention’s Consensus Development 
Program (CDP) convenes scientific panels yearly to assess complex medical issues and develop 
recommendations to increase understanding and assist health professionals and other stakeholders 
in decisionmaking. The purpose of this study is to explore how professional societies (and their 
members) view scientific panels and disseminate or implement evidence-based recommendations 
(e.g., colorectal cancer screening). The knowledge gained from this study will be used to 
strengthen the CDP and enhance its panel recommendations so they are more accessible, 
pertinent, and actionable for professional societies and their members. Data will also be utilized 
as part of a dissertation project at the Johns Hopkins School of Public Health. 
 
Why you are being asked to participate 
 
You are being asked to take part in an NIH research study because of your position or 
membership in a professional society. We anticipate that 30 people, involved in several 




Here is a list of what will happen if you join this study: 
 
• You will take part in a one-time 1-hour telephone interview. 
• At the beginning of the interview, you will be asked to confirm your name and provide 
your address. This information will be used to process an honorarium ($60) to thank you 
for your time. Your name and address will be removed from the interview transcript 




• You will also be asked about your professional society and your role in the organization. 
This information will be de-identified for data analysis and presentation.   
• During the interview, you will be asked about your professional society’s support and 
dissemination of clinical recommendations (including colorectal cancer screening). 
• The interview will be audio-recorded. The recording will be destroyed within 30 days of 




There are minimal risks to you for participating. There is a possible risk of discomfort in sharing 
your views during the interview.  
 
Every effort will be made to keep the information you give us private. Your name will never be 
linked to any comments nor will it appear in any written reports or publications. It is very 




There is no direct benefit to you for being in this study, but the answers you provide may help the 
NIH in developing and disseminating evidence-based recommendations that are of use to 




A $60 honorarium is provided to study participants. 
 
Protecting your privacy 
 
The information you provide will be kept private to the furthest extent provided by law. Interview 
transcripts will be marked by a unique code number. Transcripts and the link between code 
number and identifiable information will be kept on a password-protected server. Other study 
information (e.g., the processing of your honorarium) will be stored in a locked filing cabinet 
within a secure office at NIH’s study contractor—IQ Solutions, Inc.  
 
Access to the information we collect will be limited to study analysts and people in charge of 
making sure the research is done correctly. This might include people from the NIH Office of 
Human Research Protections. All of these people are required to keep your information private. 
 




You do not have to take part in this study. There will be no penalty if you decide not to be in the 
study. If you decide not to be in the study, you will not lose any benefits you would otherwise 
receive. 
 
Cost of participation in the study 
 





What happens if you leave the study early? 
 
Your participation in this research study is completely voluntary. You have the right to withdraw 
from the research study at any time. Even if you do not want to join the study, or if you withdraw 
from the study, it will not affect your relationship with the NIH.  
 
You may leave this study early if you so chose. Under some circumstances, the principal 
investigator or the sponsor (NIH Office of Disease Prevention) may ask you to leave the study 
early. In either case, there will be no consequence to you. 
 
Whom to call if you have questions 
 
If you have any questions about the research, please call the principal investigator, Elizabeth 
Neilson, at 301–496–4999 or the NIH Office of Human Subjects Research Protections (OHSRP) 
at 301–402–3444 or Fax 301–402–3443. (See below for address and additional information.) 
 
Call or contact the NIH OHSRP if you have questions about your rights as a study participant. 
Contact information is provided below. 
 
 
 National Institutes of Health 
 Office of Human Subjects Research Protections 
 Building 10, Room 2C116 
 Bethesda, Maryland 20892-1154 
 Telephone: 301–402–3444 
 Fax: 301–402–3443 














































Appendix 10: Consent Form 
 
 
INFORMED CONSENT DOCUMENT 
 
Qualitative Interviews  
 
Study Title: Moving Research Into Practice: The Diffusion of Evidence-based Recommendations 
Through Professional Societies 
Principal Investigator: Elizabeth Neilson 
IRB No.: 11735 
PI Version Date: Version 2 / February 5, 2013 
 
 
What you should know about this study 
 
• You are being asked to join a research study. 
• This consent form explains the research study and your part in the study. 
• Please read it carefully and take as much time as you need. 
• You are a volunteer. You can choose not to take part; if you join, you may quit at any 
time. There will be no penalty if you decide to quit the study. 
• During the study, we will tell you if we learn any new information that might affect 
whether you wish to continue to be in the study. 
 
Purpose of research project 
 
The National Institutes of Health (NIH), Office of Disease Prevention’s Consensus Development 
Program (CDP) convenes scientific panels yearly to assess complex medical issues and develop 
recommendations to increase understanding and assist health professionals and other stakeholders 
in decision-making. The purpose of this study is to explore how professional societies (and their 
members) view scientific panels and disseminate or implement evidence-based recommendations 
(e.g., colorectal cancer screening). The knowledge gained from this study will be used to 
strengthen the CDP and enhance its panel recommendations so they are more accessible, 
pertinent, and actionable for professional societies and their members. Data will also be utilized 
as part of a dissertation project at the Johns Hopkins School of Public Health. 
 
Why you are being asked to participate 
 
You are being asked to take part in an NIH research study because of your position or 
membership in a professional society. We anticipate that 30 people, involved in several 




Here is a list of what will happen if you join this study: 
 




• At the beginning of the interview, you will be asked to confirm your name and provide 
your address. This information will be used to process an honorarium ($60) to thank you 
for your time. Your name and address will be removed from the interview transcript 
before any data analysis.  
• You will also be asked about your professional society and your role in the organization. 
This information will be de-identified for data analysis and presentation.   
• During the interview, you will be asked about your professional society’s support and 
dissemination of clinical recommendations (including colorectal cancer screening). 
• The interview will be audio-recorded. The recording will be destroyed within 30 days of 




There are minimal risks to you for participating. There is a possible risk of discomfort in sharing 
your views during the interview.  
 
Every effort will be made to keep the information you give us private. Your name will never be 
linked to any comments, nor will it appear in any written reports or publications. It is very 




There is no direct benefit to you for being in this study, but the answers you provide may help the 
NIH in developing and disseminating evidence-based recommendations that are of use to 




A $60 honorarium is provided to study participants. 
 
Protecting your privacy 
 
The information you provide will be kept private to the furthest extent provided by law. Interview 
transcripts will be marked by a unique code number. Transcripts and the link between code 
number and identifiable information will be kept on a password-protected server. Other study 
information (e.g., the processing of your honorarium) will be stored in a locked filing cabinet 
within a secure office at NIH’s study contractor—IQ Solutions, Inc.  
 
Access to the information we collect will be limited to study analysts and people in charge of 
making sure the research is done correctly. This might include people from the NIH Office of 
Human Subjects Research Protections. These people are required to keep your information 
private. 
 




You do not have to take part in this study. There will be no penalty if you decide not to be in the 






Cost of participation in the study 
 
There will be no monetary cost to you for taking part in this study. 
 
What happens if you leave the study early? 
 
Your participation in this research study is completely voluntary. You have the right to withdraw 
from the research study at any time. Even if you do not want to join the study, or if you withdraw 
from the study, it will not affect your relationship with the NIH. You should ask the principal 
investigator listed below any questions you may have about this research study. You may ask her 
questions in the future if you do not understand something that is being done.  
 
You may leave this study early if you so chose. Under some circumstances, the principal 
investigator or the sponsor (NIH Office of Disease Prevention) may ask you to leave the study 
early. In either case, there will be no consequence to you. 
 
Whom to call if you have questions or problems 
 
If you have any questions, concerns, or complaints about the research study, please call the 
principal investigator, Elizabeth Neilson, at 301–496–4999 or the NIH Office of Human Subjects 
Research Protections (OHSRP) at 301–402–3444 or Fax 301–402–3443. (See below for address 
and additional information.) Either the principal investigator or staff from OHSRP will answer 
your questions and/or help you find care if you feel you have suffered an injury as a result of this 
study. The Federal Government does not have any program to provide compensation to you if 
you experience injury or other bad effects which are not the fault of the investigators. 
 
Call or contact the NIH OHSRP if you have questions about your rights as a study participant, if 
you feel you have not been treated fairly, or if you have other concerns.  
 
 Office of Human Subjects Research Protections 
 National Institutes of Health 
 Building 10, Room 2C116 
 Bethesda, Maryland 20892-1154 
 Telephone: 301–402–3444 
 Fax: 301–402–3443 
 Email: ohsr_nih_ddir@od.nih.gov  
 
 
What does your signature on this consent form mean? 
 
Your signature on this form means: 
 
• You have been informed about this study’s purpose, procedures, possible benefits, and 
risks. 
• You have been given the chance to ask questions before you sign. 
• You have voluntarily agreed to be in this study. 
 
_____________________                  ____________________________               __________ 







____________________                    _____________________________        __________ 





Please check either Yes or No before placing your signature and date below. 
 
� Yes � No  I may be contacted in the future regarding this study, if clarification is requested 
regarding a response from the interview and/or for more detailed information. 
 
 
______________________                 __________________ 
Participant’s Signature                                   Date 
 
 




































Appendix 11: Response Sheet 
 
 
 [Study #] 
 
NIH Study Response Sheet 
 
Study Title: Moving Research Into Practice: The Diffusion of Evidence-based Recommendations 
Through Professional Societies 
 
 
Please check the appropriate response below and mail this form in the stamped return 
envelope that has been provided. 
 
 
_________ Yes, I would like to participate in this research study. I am also including a signed 
consent form in the stamped return envelope. 
 
_________ Yes, I am interested in participating in this research study, but I would like more 
information. Please contact me with additional details. I can be reached at this 
telephone number____________________________ or email 
address_____________________________________________. 
 
_________ No, I am not interested in participating in this research study. 
 
_________ No, I am not interested in participating in this research study, but I have a colleague 
who may be interested in participating. Please contact   ______________________ 























Appendix 12: Physician Leadership Interview Guide 
 
 
Semi-Structured Interview with 
Physician Professional Society Leaders 
American Academy of Family Physicians (AAFP) 
American College of Physicians (ACP) 
American Congress of Obstetricians and Gynecologists (ACOG) 
American Medical Association (AMA) 
American Medical Women’s Association (AMWA) 
American Osteopathic Association (AOA) 
 
 
Hi.  My name is ____________ and I am calling to conduct an interview for the NIH Consensus 
Development Program study that you agreed to participate in.  _________, who will be taking 
notes, joins me on the telephone. With your permission we would like to record the interview to 
assist us with our analysis. To help protect your confidentiality, we will code answers so that no 
responses are attributed to a particular person or organization.   
 
The purpose of this study is to explore how professional societies (and their members) view 
scientific panels and disseminate or implement evidence-based recommendations (for example, 
colorectal cancer screening). The knowledge gained from this study will be used to strengthen the 
NIH Consensus Development Program and enhance its panel recommendations so they are more 
accessible, pertinent, and actionable for professional societies and their members. 
 
You are being asked to take part in this study because of your role in a professional society. Our 
focus today will be on your perspective as a leader in a [INSERT PROFESSIONAL SOCIETY]. 
 







Do you have any questions before we begin? 
 
I. Background on physician professional societies 
 
Great. I would like to start by asking you a little about your organization. 
 
1. Can you briefly describe the [INSERT PROFESSIONAL SOCIETY]?  
PROBE for size (both members and staff), goals, organizational structure, 
centralization of decision-making, and the formalization of rules and regulations 
 
II. Scientific panels and evidence-based practice and recommendations  
 





2. We are interested in understanding the role that primary care professional societies 
play in promoting evidence-based practice. So first, I would like to know how you 
define evidence-based practice and evidence-based recommendations.  
 
3. Does the [INSERT PROFESSIONAL SOCIETY] have a role in promoting evidence-
based recommendations and practice? If so, what is that role and how is it carried 
out? 
 
Now I’d like to discuss scientific panels that develop evidence-based recommendations.  
4.   Are you familiar with organizations or scientific panels that assess clinical issues 
and/or develop recommendations? If so, what do you know about them? (If not, skip 
to section IV.) 
PROBE for non-profit groups (e.g., Institute of Medicine, Cochrane Collaboration), 
disease specialty societies (e.g., American Cancer Society), and other professional 
societies (e.g., American College of Radiology) 
 
5. Is a scientific panel’s organizational affiliation important to the [INSERT 
PROFESSIONAL SOCIETY]? If so, how?  
 
PROBE the USPSTF as an independent scientific panel supported by the federal 
Agency for Healthcare Research and Quality (AHRQ) and the U.S. Multi-Society 
Task Force on Colorectal Cancer as a group of medical specialty societies (i.e., 
American Gastroenterological Association, American College of Gastroenterology, 
American Society for Gastrointestinal Endoscopy) 
 
6.   What makes you trust or distrust a scientific panel? Are there specific panels you trust 
or distrust? 
 
7. Scientific panels vary in their composition and methods. Do the following influence 
your views about their recommendations?  
 
a. Source of funding 
b. Composition of panel members - PROBE expert, multidisciplinary, lay or patient 
perspectives  
c. Reporting of member conflicts of interest – PROBE financial or intellectual 
interests 
d. Methods used to analyze evidence – PROBE expert opinion, systematic review 
e. Methods of validating panel recommendations – PROBE external review, 
internal review 
 
8.   Are the needs of your organization for clinical assessments and recommendations 
being met by external scientific panels? If so, how? If not, what needs are not being 
met?  
 
Now I’d like to focus specifically on colorectal cancer screening recommendations. 
 






a. [For American Academy of Family Physicians] supports colorectal cancer 
screening recommendations developed by the U.S. Preventive Services Task 
Force. 
b. [For American College of Physicians] published a guidance statement in 2012 
that supports colorectal cancer screening recommendations developed by the 
U.S. Preventive Services Task Force. 
c. [For American Congress of Obstetricians and Gynecologists] posted an opinion 
that supports joint colorectal cancer screening recommendations developed by 
the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radiology.   
d. [For American Medical Association] supports the general recommendations of 
“major healthcare organizations” and are consistent with the recommendations 
developed by the American Cancer Society, the U.S. Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology.   
e. [For American Medical Women’s Association] has a position paper that 
supports colorectal cancer screening recommendations developed by the 
American Cancer Society. 
f.  [For American Osteopathic Association] has a 2011 Policy Compendium that 
supports colorectal cancer screening reimbursement based on American Cancer 
Society recommendations.  
 
9.  What do you know about the [INSERT ORGANIZATION OR PANEL NAME] and 
how they develop recommendations? 
10. Do you trust or distrust [INSERT ORGANIZATION OR PANEL NAME]? What 
makes you trust or distrust them? 
 
11. Do you have anything else to add about scientific panels and their recommendations? 
 
III.  Professional societies’ support and dissemination of recommendations.  
 
Now let’s focus on how the [INSERT PROFESSIONAL SOCIETY] chooses to support and 
disseminate clinical recommendations. 
 
12. How does the [INSERT PROFESSIONAL SOCIETY] decide which clinical topics 
and issues to address?  
 
PROBE who makes decisions, if steps are taken to get buy-in throughout leadership, if 
organizational characteristics are influential  
 
13. How does the [INSERT PROFESSIONAL SOCIETY] choose which 
recommendations to support on a particular issue? 
 
PROBE who makes decisions, if steps are taken to get buy-in throughout leadership, 
if organizational characteristics are influential  
 
14. When deciding on which recommendations to support, how do the following issues 
impact your decisions?  
a. Insurance coverage for an intervention  
b. Patient access to an intervention 




d. Encouragement of shared decision-making between provider and patient 
e. Implementation costs for providers 
f. Provider preferences 
g. Whether a recommendation is controversial  
h. Other factors 
 
15. When various panels issue different recommendations, how does the [INSERT 
PROFESSIONAL SOCIETY] reconcile the differences and choose which 
recommendation to support? 
 
16. Does the [INSERT PROFESSIONAL SOCIETY] have a relationship with [INSERT 
PANEL] or other external recommendation developers? If so, can you describe the 
nature of these relationships and how they are developed and sustained?  
 
17. Would you characterize your organization as being a trail blazer when supporting 
recommendations, or do you generally wait for other organizations to go first?  
 
18. How does the [INSERT PROFESSIONAL SOCIETY] disseminate information about 
recommendations to its members? 
PROBE for newsletters, published statements, journal articles, presentations at annual 
meetings, online CME courses) 
IV. Developing recommendations 
 
19. Does the [INSERT PROFESSIONAL SOCIETY] ever develop their own clinical 
recommendations?  (If not, skip to section V; if yes, continue) 
 
a. What processes are in place to identify problems or needs? 
b.  To research solutions?   
c.  To construct a recommendation? 
 
V.  The NIH Consensus Development Program’s (and the Federal government’s) contribution 
to evidence-based practice.  
 
The remaining questions focus on the NIH Consensus Development Program and the federal 
government’s role in developing and disseminating recommendations. 
 
20. Have you heard of the NIH Consensus Development Program or other federally 
supported recommendation developers? If yes, what do you know about them? (If 
not, skip to question 23) 
 
PROBE for USPSTF, CDC Preventive Services Task Force  
 
21. Have you or someone representing your organization ever received a panel statement 
from the NIH Consensus Development Program? Do you routinely get their 
statements?  
 
22. Have you or someone representing your organization ever attended a Consensus 





23. Are there any specific characteristics of the NIH Consensus Development Program or 
other federally supported recommendation developers that make them uniquely 
trustworthy or untrustworthy sources? If so, what are they? 
 
 PROBE for panel composition, funding sources, financial/intellectual conflicts, 
transparency, methods of analysis, and validation of recommendations 
 
24. In what ways could the NIH Consensus Development Program and other federally 
supported recommendation developers enhance their credibility with professional 
societies and providers? 
 
25. What steps should be taken to make recommendations more pertinent and usable for 
providers and professional societies? 
 
26. In what ways could federally-supported panels better partner with stakeholders (such 
as professional societies, Congress and payers) to develop and disseminate their 






































Appendix 13: Physician Membership Interview Guide 
 
 
Semi-Structured Interview with  
Physician Society Members 
American Academy of Family Physicians (AAFP) 
American College of Physicians (ACP)  
American Congress of Obstetricians and Gynecologists (ACOG) 
American Medical Association (AMA) 
American Medical Women’s Association (AMWA) 
American Osteopathic Association (AOA) 
 
 
Hi.  My name is ____________ and I am calling to conduct an interview for the NIH Consensus 
Development Program study that you agreed to participate in.  _________, who will be taking 
notes, joins me on the telephone. With your permission we would like to record the interview to 
assist us with our analysis. To help protect your confidentiality, we will code answers so that no 
responses are attributed to a particular person or organization.   
 
The purpose of this study is to explore how professional societies (and their members) view 
scientific panels and disseminate or implement evidence-based recommendations (for example, 
colorectal cancer screening). The knowledge gained from this study will be used to strengthen the 
NIH Consensus Development Program and enhance its panel recommendations so they are more 
accessible, pertinent, and actionable for professional societies and their members. 
 
You are being asked to take part in this study because of your membership in a professional 
society. Our focus today will be on your perspective as a physician and member of the [INSERT 
PROFESSIONAL SOCIETY]. 
 





Membership in Professional Societies: 
Years Serving as a Physician: 
Type of Physician:  
Type of Practice: PROBE for solo practice, group practice, HMO, teaching hospital   
Role in Practice: PROBE for academician/researcher, administrator, practitioner 
 
Do you have any questions before we begin? 
I. Gaining knowledge and communication preferences 
 
Great. I’d like to start with questions about how you, as a physician, gather and learn new 
clinical information. 
 
1. How are you usually exposed to new medical ideas or clinical recommendations? 
 





PROBE for reading, attending conferences, interactive media, one-to-one learning with 
trained individuals 
 
3. How do you receive information from [INSERT PROFESSIONAL SOCIETY]? 
 
4. Do you read the [INSERT PROFESSIONAL SOCIETY]’s journal or newsletters, or 
participate in its annual meetings, scientific forums, and CME activities? If so, which 
ones? 
 
PROBE for  
g. [For American Academy of Family Physicians] Annals of Family Medicine, 
American Family Physician, Family Practice Management, and FP Essentials  
h. [For American College of Physicians] Annals of Internal Medicine, ACP 
Internist, and ACP Hospitalist  
i. [For American Congress of Obstetricians and Gynecologists] Green Journal 
(aka, Obstetrics & Gynecology) 
j. [For American Medical Association] Journal of the American Medical 
Association, Archives of Internal Medicine, and American Medical News 
k. [For American Medical Women’s Association] bi-weekly Newsflash and 
quarterly newsletter 
l.  [For American Osteopathic Association] Journal of the American Osteopathic 
Association, The DO, and AOA Health Watch 
 
5. Do you see the [INSERT PROFESSIONAL SOCIETY] as a trusted source for 
information?  
 
6. Are you satisfied with the clinical information you receive from [INSERT 
PROFESSIONAL SOCIETY]? If so, how? If not, what aspects are you dissatisfied with?  
 
II. Knowledge and beliefs about scientific panels and evidence-based practice and 
recommendations 
 
Now I’d like to discuss evidence-based practice and evidence-based recommendations. 
 
7. We are interested in understanding the role that physicians play in providing evidence-
based care. So first, I would like to know how you define evidence-based practice. 
 
PROBE for research evidence, expert opinion of others, personal experience, patient 
values and circumstances  
 
8. How do you define evidence-based recommendations? Can you describe how evidence-
based recommendations are generally developed?  
 
9. Is it important to you that your work be guided by evidence-based information? If so, 
how? 
 





10. Are you familiar with organizations or scientific panels that assess clinical issues and/or 
develop recommendations? If so, what do you know about them? (If not, skip to section 
III.) 
PROBE for non-profit groups (e.g., Institute of Medicine, Cochrane Collaboration), 
disease specialty societies (e.g., American Cancer Society), and other professional 
societies (e.g., American College of Radiology) 
 
11. What makes you trust or distrust a scientific panel? Are there specific panels you trust or 
distrust? 
 
12. Is a scientific panel’s organizational affiliation important to you? If so, how?  
 
PROBE the USPSTF as an independent scientific panel supported by the federal Agency 
for Healthcare Research and Quality (AHRQ) and the U.S. Multi-Society Task Force on 
Colorectal Cancer as a group of medical specialty societies (i.e., American 
Gastroenterological Association, American College of Gastroenterology, American 
Society for Gastrointestinal Endoscopy) 
 
13. Scientific panels vary in their composition and methods. Do the following influence your 
views about their recommendations?  
 
a. Source of funding 
b. Composition of panel members - PROBE expert, multidisciplinary, lay or patient 
perspectives – which are credible 
c. Reporting of member conflicts of interest – PROBE financial or intellectual 
interests 
d. Methods used to analyze evidence – PROBE expert opinion, systematic review 
e. Methods of validating panel recommendations – PROBE external review, 
internal review 
 
14. What other factors increase or decrease a scientific panel’s credibility?  
 
15. Do you believe that clinical recommendations enhance professional practice and 
satisfaction or impede it? How?  Do clinical recommendations affect your professional 
autonomy? If so, how?  
 
16. Healthcare recommendations can affect groups differently. What are the benefits and 




o Health care delivery organizations and their administrators (hospitals, clinics) 
o Insurance Companies  
o Researchers 
 
17. How do you feel about the large number of clinical recommendations that are developed 
each year?  
 





I reviewed the [INSERT PROFESSIONAL SOCIETY] website and it appears your 
organization: 
 
a. [For American Academy of Family Physicians] supports colorectal cancer 
screening recommendations developed by the U.S. Preventive Services Task 
Force. 
b. [For American College of Physicians] published a guidance statement in 2012 
that supports colorectal cancer screening recommendations developed by the 
U.S. Preventive Services Task Force. 
c. [For American Congress of Obstetricians and Gynecologists] posted an opinion 
that supports joint colorectal cancer screening recommendations developed by 
the American Cancer Society, the U.S. Multi-Society Task Force on Colorectal 
Cancer, and the American College of Radiology.   
d. [For American Medical Association] supports the general recommendations of 
“major healthcare organizations” and are consistent with the recommendations 
developed by the American Cancer Society, the U.S. Multi-Society Task Force on 
Colorectal Cancer, and the American College of Radiology.   
e. [For American Medical Women’s Association] has a position paper that 
supports colorectal cancer screening recommendations developed by the 
American Cancer Society. 
f.  [For American Osteopathic Association] has a 2011 Policy Compendium that 
supports colorectal cancer screening reimbursement based on American Cancer 
Society recommendations.  
 
18. What do you know about the [INSERT ORGANIZATION OR PANEL NAME] and how 
they develop recommendations?  
 
19. Do you trust or distrust [INSERT ORGANIZATION OR PANEL NAME]? What makes 
you trust or distrust them? 
 
20. Do you have anything else to add about scientific panels and their recommendations? 
 
III.   Use of evidence-based recommendations. 
 
21. Do you follow clinical recommendations when caring for patients?  What influences your 
decision to follow [or not follow] recommendations? (If not, skip to section IV.) 
 
22. In general, what clinical recommendations do you support and/or follow? Are there 
specific cancer screening recommendations you follow? What factors led you to support 
these recommendations? 
 
PROBE for professional society recommendations, workplace guidelines, and other tools 
(DynaMed, Up-to-Date) 
 
PROBE for CRC, breast, and prostate cancer screening 
 
23. Do you ever receive conflicting recommendations? If so, how do decide which 
recommendation to follow?  
 
24. Do you have opportunities to try new recommendations on a probationary basis? If yes, 





25. When deciding on which recommendations to support, how do the following issues 
influence clinical decision-making and your ability to implement recommendations? 
a. Patient insurance coverage for an intervention  
b. Patient access to an intervention (availability of specialists or equipment) 
c. Patient knowledge, attitudes and preferences 
d. Patient compliance 
e. Your preferences 
f. Your implementation costs 
g. Your resources (electronic health records, built-in reminder systems) 
h. Whether a recommendation is controversial  
i. Other factors 
 
26. Are you able to influence any of these factors? If so, how? 
 
27. Is shared decision-making with patients a part of your practice? If so, how do you balance 
shared decisionmaking on one hand, and the following of explicit recommendations on 
the other?  
28. When thinking of your professional characteristics, would you characterize yourself as a 
trailblazer when supporting and following recommendations, or do you generally wait for 
other providers to go first?   
 
IV.  The NIH Consensus Development Program’s (and the federal government’s) contribution 
to evidence-based practice. 
The remaining questions focus on the NIH Consensus Development Program and the Federal 
Government’s role in developing and disseminating recommendations. 
 
29. Have you heard of the NIH Consensus Development Program or other federally 
supported recommendation developers? What do you know about them? (If not, skip to 
question 32.) 
 
PROBE for USPSTF, CDC Preventive Services Task Force  
 
30. Have you ever received a panel statement from the NIH Consensus Development 
Program? Do you routinely get their statements?  
 
31. Have you ever attended a Consensus Development Conference or viewed one on 
videocast?  Do you do so frequently?  
 
32. Do you consider the NIH Consensus Development Program, or other federally supported 
recommendation developers, a trustworthy or untrustworthy source? If so, what factors 
influence this opinion? 
 
 PROBE for panel composition, funding sources, financial/intellectual conflicts, 
transparency, methods of analysis, and validation of recommendations 
 
33. In what ways could the NIH Consensus Development Program and other federally 





34. What steps should be taken to make recommendations more pertinent and usable for 
physicians? 
 
35. In what ways could federally-supported panels better partner with stakeholders (such as 
patients, professional societies, Congress and payers) to develop and disseminate their 
assessments and recommendations? 
 
 














































Appendix 14: Nurse Practitioner/Physician Assistant Leadership Interview Guide 
 
Semi-Structured Interview with  
Physician Assistant and Nurse Practitioner  
Professional Society Leaders 
American Academy of Physician Assistants (AAPA) 
American Academy of Nurse Practitioners (AANP) 
 
 
Hi.  My name is ____________ and I am calling to conduct an interview for the NIH Consensus 
Development Program study that you agreed to participate in.  _________, who will be taking 
notes, joins me on the telephone. With your permission we would like to record the interview to 
assist us with our analysis. To help protect your confidentiality, we will code answers so that no 
responses are attributed to a particular person or organization.   
 
The purpose of this study is to explore how professional societies (and their members) view 
scientific panels and disseminate or implement evidence-based recommendations (for example, 
colorectal cancer screening). The knowledge gained from this study will be used to strengthen the 
NIH Consensus Development Program and enhance its panel recommendations so they are more 
accessible, pertinent, and actionable for professional societies and their members. 
 
You are being asked to take part in this study because of your role in a professional society. Our 
focus today will be on your perspective as a leader in a [INSERT PROFESSIONAL SOCIETY]. 
 







Do you have any questions before we begin? 
 
I. Background on professional societies 
 
Great. I would like to start by asking you a little about your organization. 
 
4. Can you briefly describe the [INSERT PROFESSIONAL SOCIETY]?  
PROBE for size (both members and staff), goals, organizational structure, 
centralization of decision-making, and the formalization of rules and regulations 
 
II. Scientific panels and evidence-based practice and recommendations  
 
Now I’d like to discuss evidence-based practice and evidence-based recommendations. 
 
5. We are interested in understanding the role that professional societies play in 
promoting evidence-based practice. So first, I would like to know how you define 





6. Does the [INSERT PROFESSIONAL SOCIETY] have a role in promoting evidence-
based recommendations and practice? If so, what is that role and how is it carried 
out? 
 
Now I’d like to discuss scientific panels that develop evidence-based recommendations.  
4.   Are you familiar with organizations or scientific panels that assess clinical issues 
and/or develop recommendations? If so, what do you know about them? (If not, skip 
to section IV.) 
PROBE for non-profit groups (e.g., Institute of Medicine, Cochrane Collaboration), 
disease specialty societies (e.g., American Cancer Society), and other professional 
societies (e.g., American College of Radiology) 
 
5.   Does the [INSERT PROFESSIONAL SOCIETY] consider and/or support 
recommendations from external scientific panels? If so, which ones and how? (If not, 
skip to section IV.) 
 
PROBE for recommendations on colorectal cancer screening 
 
6. Is a scientific panel’s organizational affiliation important to the [INSERT 
PROFESSIONAL SOCIETY]? If so, how?  
 
PROBE the USPSTF as an independent scientific panel supported by the federal 
Agency for Healthcare Research and Quality (AHRQ) and the U.S. Multi-Society 
Task Force on Colorectal Cancer as a group of medical specialty societies (i.e., 
American Gastroenterological Association, American College of Gastroenterology, 
American Society for Gastrointestinal Endoscopy) 
 
7.   What makes you trust or distrust a scientific panel? Are there specific panels you trust 
or distrust? 
 
8. Scientific panels vary in their composition and methods. Do the following influence 
your views about their recommendations?  
 
a. Source of funding 
b. Composition of panel members - PROBE expert, multidisciplinary, lay or patient 
perspectives  
c. Reporting of member conflicts of interest – PROBE financial or intellectual 
interests 
d. Methods used to analyze evidence – PROBE expert opinion, systematic review 
e. Methods of validating panel recommendations – PROBE external review, 
internal review 
 
9.   Are the needs of your organization for clinical assessments and recommendations 
being met by external scientific panels? If so, how? If not, what needs are not being 
met? 
 
10. Do you have anything to add about scientific panels and their recommendations? 
 





Now let’s focus on how the [INSERT PROFESSIONAL SOCIETY] chooses to support and 
disseminate clinical recommendations. 
 
11. How does the [INSERT PROFESSIONAL SOCIETY] decide which clinical topics 
and issues  
to address?  
 
PROBE who makes decisions, if steps are taken to get buy-in throughout leadership, 
if organizational characteristics are influential  
 
12. How does the [INSERT PROFESSIONAL SOCIETY] choose which 
recommendations to support on a particular issue? 
 
PROBE who makes decisions, if steps are taken to get buy-in throughout leadership, 
if organizational characteristics are influential  
 
13. When deciding on which recommendations to support, how do the following issues 
impact your decisions?  
a. Insurance coverage for an intervention  
b. Patient access to an intervention 
c. Patient attitudes and compliance 
d. Encouragement of shared decision-making between provider and patient 
e. Implementation costs for providers 
f. Provider preferences 
g. Whether a recommendation is controversial  
h. Other factors 
 
14. When various panels issue different recommendations, how does the [INSERT 
PROFESSIONAL SOCIETY] reconcile the differences and choose which 
recommendation to support? 
 
15. Does the [INSERT PROFESSIONAL SOCIETY] have a relationship with [INSERT 
PANEL] or other external recommendation developers? If so, can you describe the 
nature of these relationships and how they are developed and sustained?  
 
16. Would you characterize your organization as being a trail blazer when supporting 
recommendations, or do you generally wait for other organizations to go first?  
 
17. How does the [INSERT PROFESSIONAL SOCIETY] disseminate information about 
recommendations to its members? 
PROBE for newsletters, published statements, journal articles, presentations at 
annual meetings, online CME courses) 
 
IV. Developing recommendations 
 
18. Does the [INSERT PROFESSIONAL SOCIETY] ever develop their own clinical 
recommendations?  (If not, skip to section V; if yes, continue) 
 




e.  To research solutions?   
f.  To construct a recommendation? 
 
V.  The NIH Consensus Development Program’s (and the Federal government’s) contribution 
to evidence-based practice.  
 
The remaining questions focus on the NIH Consensus Development Program and the federal 
government’s role in developing and disseminating recommendations. 
 
19. Have you heard of the NIH Consensus Development Program or other federally 
supported recommendation developers? If yes, what do you know about them? (If 
not, skip to question 23) 
 
PROBE for USPSTF, CDC Preventive Services Task Force  
 
20. Have you or someone representing your organization ever received a panel statement 
from the NIH Consensus Development Program? Do you routinely get their 
statements?  
 
21. Have you or someone representing your organization ever attended a Consensus 
Development Conference or viewed one on videocast?  Do you do so frequently? 
 
22. Are there any specific characteristics of the NIH Consensus Development Program or 
other federally supported recommendation developers that make them uniquely 
trustworthy or untrustworthy sources? If so, what are they? 
 
 PROBE for panel composition, funding sources, financial/intellectual conflicts, 
transparency, methods of analysis, and validation of recommendations 
 
23. In what ways could the NIH Consensus Development Program and other federally 
supported recommendation developers enhance their credibility with professional 
societies and providers? 
 
24. What steps should be taken to make recommendations more pertinent and usable for 
providers and professional societies? 
 
25. In what ways could federally-supported panels better partner with stakeholders (such 
as professional societies, Congress and payers) to develop and disseminate their 
assessments and recommendations? 
 
 












Appendix 15: Nurse Practitioner/Physician Assistant Membership Interview Guide  
 
 
Semi-Structured Interview with  
Physician Assistant & Nurse Practitioner Society Members 
American Academy of Physician Assistants (AAPA)  
American Academy of Nurse Practitioners (AANP)  
 
 
Hi.  My name is ____________ and I am calling to conduct an interview for the NIH Consensus 
Development Program study that you agreed to participate in.  _________, who will be taking 
notes, joins me on the telephone. With your permission we would like to record the interview to 
assist us with our analysis. To help protect your confidentiality, we will code answers so that no 
responses are attributed to a particular person or organization.   
 
The purpose of this study is to explore how professional societies (and their members) view 
scientific panels and disseminate or implement evidence-based recommendations (for example, 
colorectal cancer screening). The knowledge gained from this study will be used to strengthen the 
NIH Consensus Development Program and enhance its panel recommendations so they are more 
accessible, pertinent, and actionable for professional societies and their members. 
 
You are being asked to take part in this study because of your membership in a professional 
society. Our focus today will be on your perspective as a [INSERT PHYSICIAN ASSISTANT OR 
NURSE PRACTITIONER] and member of the [INSERT PROFESSIONAL SOCIETY].  
 





Membership in Professional Societies: 
Years Serving as a [INSERT PHYSICIAN ASSISTANT OR NURSE PRACTITIONER]:   
Area of Specialty: 
Type of Practice: PROBE for group practice, HMO, teaching hospital   
Role in Practice: PROBE for academician/researcher, administrator, practitioner 
 
Do you have any questions before we begin? 
 
 
III. Gaining knowledge and communication preferences 
 
Great. I’d like to start with questions about how you gather and learn new clinical information. 
 
11. How are you usually exposed to new clinical ideas or recommendations? 
 
12. How do you prefer to learn about new clinical ideas and recommendations?  
  
PROBE for reading, attending conferences, interactive media, one-to-one learning with 
trained individuals 
 





14. Do you read the [INSERT PROFESSIONAL SOCIETY]’s journal or newsletters, or 
participate in its annual meetings, scientific forums, and CME activities? If so, which 
ones? 
 
PROBE for  
m. [For American Academy of Physician Assistants] Journal of the American 
Academy of Physician Assistants, PA Professional, PA Pro Now 
n. [For American Academy of Nurse Practitioners] Journal of the American 
Academy of Nurse Practitioners, AANP SmartBrief 
 
15. Do you see the [INSERT PROFESSIONAL SOCIETY] as a trusted source for 
information?  
 
16. Are you satisfied with the clinical information you receive from [INSERT 
PROFESSIONAL SOCIETY]? If so, how? If not, what aspects are you dissatisfied with? 
 
IV. Knowledge and beliefs about scientific panels and evidence-based practice and 
recommendations 
 
Now I’d like to discuss evidence-based practice and evidence-based recommendations. 
 
17. We are interested in understanding the role that [INSERT PHYSICIAN ASSISTANTS 
OR NURSE PRACTITIONERS] play in providing evidence-based care. So first, I would 
like to know how you define evidence-based practice. 
 
PROBE for research evidence, expert opinion of others, personal experience, patient 
values and circumstances  
 
18. How do you define evidence-based recommendations? Can you describe how evidence-
based recommendations are generally developed?  
 
19. Is it important to you that your work be guided by evidence-based information? If so, 
how? 
 
Now I’d like to discuss scientific panels that develop evidence-based recommendations. 
 
20. Many organizations have scientific panels that assess clinical issues and/or develop 
recommendations. Are you familiar with any? If so, what do you know about them? (If 
not, skip to section III.) 
 
PROBE for federally-supported panels (e.g., USPSTF), non-profit groups (e.g., Institute 
of Medicine, Cochrane Collaboration), disease specialty societies (e.g., American Cancer 
Society), and professional societies (e.g., U.S. Multi-Society Task Force on Colorectal 
Cancer, American College of Radiology)  
 






22. Is a scientific panel’s organizational affiliation important to you? If so, how?  
 
PROBE the USPSTF as an independent scientific panel supported by the federal Agency 
for Healthcare Research and Quality (AHRQ) and the U.S. Multi-Society Task Force on 
Colorectal Cancer as a group of medical specialty societies (i.e., American 
Gastroenterological Association, American College of Gastroenterology, American 
Society for Gastrointestinal Endoscopy) 
 
23. Scientific panels vary in their composition and methods. Do the following influence your 
views about their recommendations?  
 
a. Source of funding 
b. Composition of panel members - PROBE expert, multidisciplinary, lay or patient 
perspectives – which are credible 
c. Reporting of member conflicts of interest – PROBE financial or intellectual 
interests 
d. Methods used to analyze evidence – PROBE expert opinion, systematic review 
e. Methods of validating panel recommendations – PROBE external review, 
internal review 
 
24. What other factors increase or decrease a scientific panel’s credibility?  
 
25. Do you believe that clinical recommendations enhance professional practice and 
satisfaction or impede it? How?  Do clinical recommendations affect your professional 
autonomy? If so, how?  
 
26. Healthcare recommendations can affect groups differently. What are the benefits and 




o Health care delivery organizations and their administrators (hospitals, clinics) 
o Insurance Companies  
o Researchers 
 
27. How do you feel about the large number of clinical recommendations that are developed 
each year?  
 
28. Are you aware of policy statements, recommendations, or guidelines that the [INSERT 
PROFESSIONAL SOCIETY] supports? If yes, are you aware of how they are 
developed?  
 
III.   Use of evidence-based recommendations. 
 
29. Do you follow clinical recommendations when caring for patients?  What influences your 
decision to follow [or not follow] recommendations? (If not, skip to section IV.) 
 
30. In general, what clinical recommendations do you support and/or follow? Are there 






PROBE for professional society recommendations, workplace guidelines, and other tools 
(DynaMed, Up-to-Date) 
 
PROBE for CRC, breast, and prostate cancer screening 
 
31. Do you ever receive conflicting recommendations? If so, how do decide which 
recommendation to follow?  
 
32. Do you have opportunities to try new recommendations on a probationary basis? If yes, 
please explain the circumstances around doing so.  
 
33. When deciding on which recommendations to support, how do the following issues 
influence clinical decision-making and your ability to implement recommendations? 
a. Patient insurance coverage for an intervention  
b. Patient access to an intervention (availability of specialists or equipment) 
c. Patient knowledge, attitudes and preferences 
d. Patient compliance 
e. Your preferences 
f. Your implementation costs 
g. Your resources (electronic health records, built-in reminder systems) 
h. Whether a recommendation is controversial  
i. Other factors 
 
34. Are you able to influence any of these factors? If so, how? 
 
35. Is shared decision-making with patients a part of your practice? If so, how do you balance 
shared decisionmaking on one hand, and the following of explicit recommendations on 
the other?  
36. When thinking of your professional characteristics, would you characterize yourself as a 
trailblazer when supporting and following recommendations, or do you generally wait for 
other providers to go first?   
 
 
IV.  The NIH Consensus Development Program’s (and the federal government’s) contribution 
to evidence-based practice. 
The remaining questions focus on the NIH Consensus Development Program and the Federal 
Government’s role in developing and disseminating recommendations. 
 
37. Have you heard of the NIH Consensus Development Program or other federally 
supported recommendation developers? What do you know about them?  
(If not, skip to question 31.) 
 
PROBE for USPSTF, CDC Preventive Services Task Force  
 
38. Have you ever received a panel statement from the NIH Consensus Development 
Program? Do you routinely get their statements?  
 
39. Have you ever attended a Consensus Development Conference or viewed one on 





40. Do you consider the NIH Consensus Development Program, or other federally supported 
recommendation developers, a trustworthy or untrustworthy source? If so, what factors 
influence this opinion? 
 
 PROBE for panel composition, funding sources, financial/intellectual conflicts, 
transparency, methods of analysis, and validation of recommendations 
 
41. In what ways could the NIH Consensus Development Program and other federally 
supported recommendation developers enhance their credibility with [INSERT 
PHYSICIAN ASSISTANTS OR NURSE PRACTITIONERS]?  
 
42. What steps should be taken to make recommendations more pertinent and usable for 
[INSERT PHYSICIAN ASSISTANTS OR NURSE PRACTITIONERS]? 
 
43. In what ways could federally-supported panels better partner with stakeholders (such as 
patients, professional societies, Congress and payers) to develop and disseminate their 
assessments and recommendations? 
 
 


































Appendix 16: Codebook 
 
 
List of Codes 
1. Eb   Evidence-based Practice, Assessments, and Recommendations 
2. Know  Knowledge of Organizations and Scientific Panels  
3. Att  Attitudes and Beliefs about Organizations and Scientific Panels 
4. PrUt  Provider Utilization of Panel Outputs 
5. InO   Innovation in Organizations 
6. Value  Value Federal Government Contributes to Evidence-based Practice by 
Developing and Disseminating Assessments and recommendations 
7. Sugg  Suggestions for Federally-Sponsored Panels to Consider for the Development of 
More Trustworthy, Feasible, and Pertinent Outputs 
8. Feed  Feedback on this study 
 
Eb  Evidence-based Practice, Assessments, & Recommendations 
 Eb-P Evidence-based Practice 
 Eb-Out Evidence-based Outputs 
 
Know  Knowledge of Organizations and Scientific Panels 
 Know-A Awareness of Organizations and Scientific Panels 
Know-U Understanding of Organization and Panel Composition, Processes, & 
Outputs  
 Know-U/Back Background of Members 
 Know-U/Fund Source of Panel Funding 
 Know-U/Ana Compiling & Analyzing Evidence 
Know-U/Form  Methods Used to Formulate Assessments &   
Recommendations 
 Know-U/Rec Assessments & Recommendations 
 Know-U/Rev Review of Assessments & Recommendations 
 Know-U/Het Heterogeneity 
 
Att Attitudes and Beliefs about Organizations and Scientific Panels 
 
 Att-TM Trust and Mistrust of Organizations and Scientific Panels 
  Att-TM/Cred   Credibility of Composition, Processes, & Outputs 
    Att-TM/Cred/COI  Promoting Objectivity and Effective 
Panel Composition While Managing 
Conflict of Interest 
    Att-TM/Cred/Rig  Methodological Rigor  
    Att-TM/Cred/Tran Transparency 
    Att-TM/Cred/Het Heterogeneity  
  Att-TM/FP Feasibility & Pertinence of Outputs  





 Att-BD  Benefits and Drawbacks of Outputs 
 Att-BD/High High Volume of Outputs and Information Overload 
 Att-BD/IPP Impact on Professional Practice 
  Att-BD/IPP/Sat  Satisfaction 
 Att-BD/IPP/Cont Professional Control 
ATT-BD/IPP/Cont/Auto   Tension between 
Outputs and Autonomy 
ATT-BD/IPP/Cont/Ten     Tension between Elite, 
and Rank and File 
ATT-BD/IPP/Cont/PCvS   Tension between 
Specialists and Primary 
Care Providers 
 Att-BD/IPP/Qual Quality of Care 
 Att-Meet Meeting Professional Society and Health Care Provider Needs for Evidence-
based Outputs 
  Att-Meet/CFP Availability of Trustworthy, Feasible, & Pertinent 
Outputs 
 
PrUt  Provider Utilization of Panel Outputs 
 PrUt-Use Use of Outputs 
 PrUt-Het  Heterogeneity 
PrUt-Fact  Factors Associated with Utilization of Services 
  PrUt-Fact/Sys  Healthcare System 
  PrUt-Fact/EE  External Environment 
  PrUt-Fact/PCh  Predisposing Characteristics 
  PrUt-Fact/ER  Enabling Resources 
  PrUt-Fact/Need Need 
  PrUt-Fact/HB  Health Behavior 
 PrUt-Inf Provider Influence over Utilization Factors 
InO  Innovation in Organizations 
 InO-PR Innovation Process for Organizations 
  InO-PR/Ini Initiation 
   InO-PR/Ini/AS     Agenda Setting 
   InO-PR/Ini/Mat Matching 
  InO-PR/Imp   Implementation 
InO-PR/Imp/Rout Routinizing/Dissemination Though 
Communication Channels 
InO-PR/Imp/Rout/External Non-Organizational 
Channels of Information for 
Members 
InO-PR/Imp/Rout/Pref Members’ Preferred 
Channels of Communication  
InO-PR/Imp/Rout/Sat    Member Satisfaction    
with Dissemination  




InO-Ch/Over  History/Mission 
InO-Ch/Cent  Centralization 
InO-Ch/Comp Complexity 
InO-Ch/Formal  Formalization 
InO-Ch/Inter  Interconnectedness 
InO-Ch/Size  Size 
InO-Ch/Open System Openness 
 InO-RIn Perceived Relative Innovativeness 
 
Value  Value Federal Government Contributes to Evidence-based Practice by Developing & 
Disseminating Assessments & Recommendations 
 Value-Tran Transparency 
 Value-Obj   Objectivity 
 Value-Rig   Methodological Rigor 
 
 
Sugg  Suggestions for Federally-Sponsored Panels to Consider for the Development of More 
Trustworthy, Feasible, & Pertinent Outputs 
 Sugg-TW   Trustworthy Assessments & Recommendations  
 Sugg-Pert  Pertinent Assessments & Recommendations 
 Sugg-Feas  Feasible Recommendations 
 
Feed    Feedback on Study 
Codes & Definitions 
 
Eb  Evidence-based Practice, Assessments, & Recommendations 
 
Eb-P Evidence-based Practice 
Evidence-based practice (EBP) means different things to different people; therefore, a variety of 
responses are expected. We view EBP as an integration of the best research evidence with clinical 
expertise and the patient's unique values and circumstances. Best research evidence is clinically 
relevant research that has been critically appraised and found to be the finest in scientific merit. 
By clinical expertise, we mean the ability to use our clinical skills and past experience to rapidly 
identify each patient's unique health state and diagnosis, their individual risks and benefits of 
potential interventions, and their personal values and expectations. By patient values we mean the 
unique preferences, concerns, and expectations each patient brings to a clinical encounter and 
which must be integrated into clinical decisions if they are to serve the patient. By patient 
circumstances we mean their individual state and the clinical setting. This code also covers 
discussions of “standards of care” and if these are based on evidence or other factors. 
 
Eb-Out Evidence-based Outputs 
Assessments and recommendations informing decision-makers, which are based on “rigorous, 
comprehensive syntheses and analyses of the scientific literature” and is accompanied by 





Know  Knowledge of Organizations and Scientific Panels 
When an individual or professional society learns of a panel’s or organization’s existence and 
gains some understanding of its structure, how it functions, and its outputs.  
 
Know-A Awareness of Organizations and Scientific Panels 
When an individual or professional society learns of a panel’s or organization’s existence. 
 
Know-U Understanding of Organization and Panel Composition, Process, & Outputs 
When an individual or professional society comprehends the function, structure, processes, and 
outputs of a panel. Understanding often occurs as a result of direct experience (e.g., attending a 
panel meeting, reviewing panel statements, etc.) 
 
Know-U/Back Background of Members 
Refers to the professionals serving as members of the scientific panel or organization (examples 
include methodologists, clinicians with experience in prevention and primary care [family 
medicine, internal medicine, nursing, obstetrics/gynecology, pediatrics, and behavioral medicine]; 
clinical subspecialists, those with experience in relevant field [policymakers, payers, ethicists], 
and consumers/patients). Panels may be multidisciplinary or consist of representatives from a 
single field. 
 
Know-U/Fund Source of Panel Funding 
The entities which provide the necessary resources for panels and organizations to conduct their 
activities. Examples include the federal government, industry, and professional societies through 
membership fees. 
 
Know-U/Ana Compiling & Analyzing Evidence 
The selection of evidence (based on a priori inclusion/exclusion criteria) and a critical appraisal 
of its quality (internal validity), generalizability to the U.S. primary care population (external 
validity), and applicability to target populations, situations, and settings). This includes 
consideration of the "hierarchy of research design" (RCTs, cohort studies, case-control studies, 
case series, case reports, ideas and opinions), methods to assess quality and strength of evidence 
(expert consensus [committee, Delphi review], rating scheme (GRADE), subjective review), and 
approaches to analysis (systematic review, meta-analysis, general review). 
 
Know-U/Form Methods Used to Formulate Assessments & Recommendations 
This involves examining and judging the cumulative evidence presented to it, and making 
recommendations. It include assessing the evidence at the Key Question level and across an entire 
Analytic Framework, assessing both the certainty of the evidence about, and the magnitude of, 
the harms and benefits of the service, estimating the magnitude of the net benefit for the service, 
and the certainty of that estimation, and finally arriving at a recommendation grade for that 
service in the relevant population Examples include expert consensus (Delphi, CDP, Nominal 
Group Technique), informal consensus, and balance sheets. 
 
Know-U/Rec Assessments & Recommendations 






Know-U/Rev Review of Assessments & Recommendations 
A limited number of experts and perspectives can be represented within a panel or organizational 
leadership; hence, development groups committed to ensuring the balance, comprehensiveness, 
and quality of their assessments and recommendations often share drafts with a spectrum of 
external reviewers expected to be evaluate the panel’s evidence characterization, 
recommendations, etc. These reviewers may be able to challenge the logic applied by the panel in 
translating the evidence into recommendations; call attention to biases, political pressure, or other 
factors that may be coloring panelist judgments; provide suggestions for improving and clarifying 
messages; and allow for debate about the finding’s or recommendation’s rationale.  
 
Know-U/Het Heterogeneity 
Dissimilar or conflicting panel composition, processes, or outcomes. 
 
Att Attitudes and Beliefs about Organizations and Scientific Panels 
These are the evaluative and probable dimensions of panels and their outputs. Beliefs are 
cognitive content held to be probable and true while attitudes are reflect positive or negative 
feelings. Examples of attitudes include “Is the recommendation good or bad?"; "Do I support or 
oppose this recommendation?”; "Do I trust or mistrust this panel?" Examples of beliefs include "I 
think there are tensions between administrators and frontline clinicians"; "Guidelines improve 
quality of care." 
 
Att-TM Trust and Mistrust of Organizations and Scientific Panels 
An overall confidence and reliance (trust) or lack of confidence and suspicion (mistrust) in panels 
and their assessments and recommendations. 
 
Att-TM/Cred   Credibility of Composition, Processes, and Outputs 
When composition, processes, and their outputs are considered worthy of trust and held in high 
regard specifically because of their promotion of objectivity, methodological rigor, and 
transparency.   
 
Att-TM/Cred/COI    Promoting Objectivity and Effective Composition While Managing 
Conflict of Interest 
Conflict of Interest (COI) is a set of circumstances that creates a risk that professional judgment 
regarding a primary interest will be unduly influenced by a secondary interest. Strategies for 
managing potential COI and heightening objectivity "range from exclusion of conflicted 
members from direct participation or restriction of roles, to formal or informal consultation, to 
participation in certain exclusive recommendations, to simple disclosure of COI." COI, or the 
appearance of COI, can also occur because of funding mechanisms. Effective composition is 
attained when members approach the recommendation process in a manner that is objective, 
scientifically valid, and consistent and members create recommendations that are credible and 
pertinent to key affected groups. 
 
Att-TM/Cred/Rig  Methodological Rigor  
The striving for excellence in research through the use of discipline, scrupulous adherence to 
detail, and strict accuracy. This includes compiling and analyzing data and formulating and 






When funding, composition, and processes are detailed explicitly and are publicly accessible. 
 
Att-TM/Cred/Het Heterogeneity  
Dissimilar or conflicting panel composition, processes, or outcomes. 
 
Att-TM/FP Feasibility & Pertinence of Outputs  
 
Pertinent Assessments & Recommendations 
Pertinent assessments and recommendations are applicable or relevant to professional societies 
and their members. These outputs "should be as inclusive of appropriately defined patient 
populations as scientific and clinical evidence and expert judgment permit, and they should 
explicitly state the populations to which statements apply." 
 
 Feasible Recommendations 
Feasible recommendations can be successfully implement in the context of a provider’s 
professional practice. Examples of variables that may influence feasibility include adequacy of 
the health care system (e.g., availability of equipment, volume & distribution of providers; 
external environment (e.g., political and economic conditions; and population characteristics of 
both providers and patients (e.g., knowledge; beliefs; personal, family, and community resources, 
which include decision-support tools and other knowledge couplers for providers. 
 
Att-TM/Care General Population vs. Unique, Individualized Care 
A tension that exists when evidence for clinical decision-making is focused on a particular study 
population, often to the exclusion of patients with comorbidities or those from socially and 
economically disadvantaged backgrounds. Consequently, many recommendations "either do not 
address or apply to a significant number of patients." 
 
Att-BD  Benefits and Drawbacks of Outputs 
Advantages and disadvantages to the volume of assessments and recommendations and their 
impact on professional practice and stakeholder groups (e.g., patients, researchers, payers, etc.). 
 
Att-BD/High High Volume of Outputs and Information Overload 
The rapidly expanding health literature (which grew from 5,000 published RCT per year from 
1978-1985 to 25,000 per year from 1994-2001) and the difficulty professional societies and 
clinicians face in appraising the research and making the information "relevant to the individual 
patient encounter."  
 
Att-BD/IPP Impact on Professional Practice 
The effects of assessments and recommendations on professional attributes, such as expert 
knowledge, autonomy, satisfaction, and status, as well as the quality of care provided. 
Professionals are "distinguished from ordinary rank and file workers because they are expected to 
exercise judgment and discretion on a routine, daily basis in the course of performing their work, 
i.e. discretion is a recognized and legitimate part of their work role. This characteristic, along 
with such others as their common training, credentials, and pay differential, is considered 





Att-BD/IPP/Sat        Satisfaction 
The degree to which assessments and recommendation affect a provider’s contentment with their 
work. 
 
Att-BD/IPP/Cont Professional Control 
Among professions – professional control dictates who does what, under which circumstances, 
and for what purpose. 
 
ATT-BD/IPP/Cont/Auto   Tension between Outputs and Autonomy 
A state of opposition between recommendations and the independence and authority health care 
providers wish to exercise in their own practice. Some question whether recommended 
interventions-tested under ideal circumstances with patients who met strict and narrow eligibility 
criteria-are relevant to certain subpopulations to certain subpopulations (e.g., patients with 
comorbidities and those socially and economically disadvantaged) and practice settings. Some 
providers complain of "cookbook medicine" (the "simplistic algorithms that fail to recognize the 
complexity of medical decision making and the need for individual clinical judgment"). 
 
ATT-BD/IPP/Cont/Ten     Tension between Elite, Rank, and File 
A state of opposition among three types of professionals "involving differences in official 
authority and power that in turn produce varying perspectives on the professional enterprise."  For 
example, rank and file professionals are primarily preoccupied with "performing their work 
according to their own view of the intrinsic practical problems and the necessary means of coping 
with them on a day-to-day basis," while "supervisory professionals are accountable for the 
aggregate performance of workers under them and they tend to have an organizational 
perspective."  
 
ATT-BD/IPP/Cont/PCvS    Tension between Specialists and Primary Care Providers 
A state of opposition between disease specialists and primary care providers, based on their 
differing education and experiences, regarding prioritization and data interpretation.  
 
Att-BD/IPP/Qual Quality of Care 
The degree of excellence in clinical practice across the care continuum. 
 
Att-Meet Meeting Professional Society and Health Care Provider Needs for Evidence-based 
Outputs 
The extent to which professional societies and providers have access to trustworthy, feasible, and 
pertinent assessments and recommendations. 
 
Att-Meet/CFP Availability of Trustworthy, Feasible, & Pertinent Outputs  
 
Trustworthy Assessments and Recommendations 
When outputs are considered credible and held in high regard.  
 
Pertinent Assessments & Recommendations 
Pertinent assessments and recommendations are applicable or relevant to professional societies 




populations as scientific and clinical evidence and expert judgment permit, and they should 
explicitly state the populations to which statements apply." 
 
 Feasible Recommendations 
Feasible recommendations can be successfully implement in the context of a provider’s 
professional practice. Examples of variables that may influence feasibility include adequacy of 
the health care system (e.g., availability of equipment, volume & distribution of providers; 
external environment (e.g., political and economic conditions; and population characteristics of 
both providers and patients (e.g., knowledge; beliefs; personal, family, and community resources, 
which include decision-support tools and other knowledge couplers for providers. 
 
PrUt  Provider Utilization of Panel Outputs and Other Evidence-based Information 
A provider's use or implementation of assessments and recommendations which are influenced by 
factors that enable or impede utilization. 
 
PrUt-Use  Use of Outputs 
Whether or not a provider reports following recommendations or using evidence-based 
information in their practice. 
 
PrUt-Use/Het  Heterogeneity 
Reactions of providers when faced with dissimilar or conflicting panel composition, processes, or 
outcomes. 
 
PrUt-Fact Factors Associated with Utilization of Services 
Contextual variables that influence the use of recommended health care services. These variables 
include the health care system, external environment, predisposing characteristics, enabling 
resources, need, and health behaviors.  
 
PrUt-Fact/Sys  Healthcare System 
These variables involve the labor and capital dedicated to healthcare (e.g., volume and 
distribution of providers, equipment, and health facilities; consideration of implementation costs 
in decisions to provide care) and their organization, or the manner in which resources are 
coordinated in the process of providing care (e.g., waiting times for appointments and office 
waiting times in reception areas). 
 
PrUt-Fact/EE  External Environment 
These variables relate to broader social, physical, political, and economic conditions, such as 
societal norms, national health policies, national or regional standards of care, and economic 
prosperity. Broad controversy regarding recommendations would be covered by this code. 
 
PrUt-Fact/PCh  Predisposing Characteristics 
Predisposing Characteristics – These variables include age, education, ethnicity, gender, 
occupation, religion, ethnicity, and health knowledge and beliefs. For patients, these variables 
describe the ‘propensity’ of individuals to use [or not to use] services. For providers, predisposing 
characteristics “are intrinsic to who they are as people and how they view themselves and their 




and agreement with clinical guidelines and protocols and assumptions about patients and their 
adherence.”  
 
PrUt-Fact/ER  Enabling Resources 
These reflect a patient’s means of obtaining needed healthcare using personal, family, and 
community resources (e.g., health insurance, income, and a regular source of care). For clinicians, 
enabling resources influence their capacity to provide care and include items such as reminder 
systems, electronic health records, and decision-support tools. Trialability- the degree to which an 
innovation may be experimented with on a limited basis may also be viewed as an enabling 
influence. 
 
PrUt-Fact/Need  Need  
This involves perceived need (i.e., a patient’s self-perception of a health condition) and objective 
or evaluated need (i.e. a provider’s medical diagnosis, which provides external validation). 
Evaluated need is not simply, or even primarily, a valid and reliable measure from biological 
science. It also has a social component, and varies with the changing state of the art and science 
of medicine as well as according to the training and competency of the professional expert doing 
assessment. Perceived clinical impact as well as clinical guidelines and recommendations can 
also affect the determination of need, by setting expectations that can influence a provider’s 
judgment. 
 
PrUt-Fact/HB  Health Behavior 
This domain refers to the direct actions taken by both patients and providers to maintain or 
improve health and is divided into two elements. Personal Health Behaviors – Variables in this 
group include patient compliance with diet, exercise, and self-care regimens and physician 
recommendations for screening and other services. Willingness of both patients and providers to 
participate in shared decision-making is another example of behavior that can affect health. 
 
PrUt-Inf    Provider Influence over Utilization Factors 
A provider’s ability to have an effect on health care utilization factors  
 
InO   Innovation in Organizations 
When professional societies and their members adopt ideas or practices captured within scientific 
panel assessments or recommendations. There is a 5-stage innovation process for organizations 
(i.e., agenda setting, matching, redefining/restructuring, clarifying, routinizing) and several 
independent variables related to organizational innovativeness (e.g., centralization, complexity, 
formalization, interconnectedness, size).  
 
InO-PR   Innovation Process for Organizations 
The sequence of decisions, actions, and events that take place when an innovation is introduced 
into organization. This is not a description of strategic priorities, but may include how priorities 
are identified and applicable innovations are developed. 
 
InO-Proc/Ini Initiation 
"The information gathering, conceptualizing, and planning for the adoption of an innovation, 
leading up to the decision to adopt." Initiation includes the process of agenda setting and 




InO-PR/Ini/AS  Agenda Setting 
"This occurs when a general organizational problem is defined that creates a perceived need for 
an innovation." This stage consists of (1) identifying and prioritizing needs and problems and (2) 
searching for innovations to resolve needs and problems 
 
InO-PR/Ini/Mat Matching 
"Matching is defined as the stage in the innovation process at which a problem from the 
organization's agenda is fit with an innovation, and this match is planned and designed…At this 
second stage in the innovation process, conceptual matching of the problem with the innovation 
occurs in order to establish how well they fit. In this reality testing, the organization's members 
attempt to determine the feasibility of the innovation in solving the organization's problems. Such 
planning entails anticipating the benefits and problems that the innovation will encounter when it 
is implemented. The organization's decision-makers may conclude that the innovation is 
mismatched with the problem....terminating the innovation process prior to the new idea's 
implementation." Matching involves learning about the innovation (or creating it), developing 
attitudes & beliefs, and deciding to support or not support a recommendation, and developing 
policies to support it. 
 
InO-Proc/Imp  Implementation 
"All of the events, actions, and decisions involved in putting an innovation into use." 
Implementation includes restructuring the innovation and modifying the organization's structure 
to create a good fit and disseminating the innovation through various communication channels. 
 
InO-PR/Imp/Rout  Routinizing/Dissemination Though Communication Channels 
This “occurs when an innovation has become incorporated into the regular activities of the 
organization and has lost its separate identify." This also involves disseminating assessments and 
recommendations through various communication channels. 
 
InO-PR/Imp/Rout/External  Non-Organizational Channels of Information for Members 
These communication channels are not hosted by the professional society, but do serve as sources 
of information for professional society members, and can include other professional society 
journals, newsletters, Listservs, Up-to-Date, Dynamed, the National Guideline Clearinghouse, the 
general media, and other sources. 
 
InO-PR/Imp/Rout/Pref   Members Preferred Channels of Communication  
The communication channels (e.g., journals, newsletters, conferences, webinars) professional 
society members' favor when receiving information. 
 
InO-PR/Imp/Rout/Sat    Member Satisfaction with Dissemination 
The degree to which members are content with the dissemination of assessments and 
recommendations by professional societies and other evidence-based information through other 
channels. This may be influenced by impressions of the organization’s trustworthiness or 
pertinence. This code may include coverage of specific topics which are satisfying or unsatisfying 
to members.  
 




This provides information on the organizational setting (e.g., history, mission) as well as 
independent variables related to innovativeness (e.g., centralization, complexity, formalization, 
interconnectedness, organizational slack, size). 
 
InO-Ch/Over  Overview/History/Mission 
Background information on the history of the organization and a general overview of the 
professional society and its mission, goals, priorities, and programs. 
 
InO-Ch/Cent  Centralization 
The degree to which power and control in a system are concentrated in the hands of a relatively 
few individuals and the structure that permits decision-making and governance.  
 
InO-Ch/Comp Complexity 
The degree to which an organization's members possess a relatively high level of knowledge and 
expertise, usually measured by the member's range of occupational specialties and their degree of 
professionalism (expressed by formal training). 
 
InO-Ch/Formal   Formalization 
The degree to which an organization emphasizes its members' following rules and procedures. 
 
InO-Ch/Inter   Interconnectedness 
The degree to which units in a social system are linked by interpersonal networks. 
 
InO-Ch/Size   Size 
The number of members and staff in a professional society. 
 
InO-RIn   Perceived Relative Innovativeness 
The degree to which individuals view themselves or their professional society as adopting new 
ideas earlier than others in the system. 
 
Value  Value Federal Government Contributes to Evidence-based Practice by Developing & 
Disseminating Assessments & Recommendations 
The distinct benefit contributed to evidence-based practice by federal scientific panels. 
 
Value-Tran Transparency 
When panel funding, composition, and processes are detailed explicitly and are publicly 
accessible. 
 
Value-Obj   Objectivity 
When panel member decisions and panel processes are based on a primary interest and not 
influenced by secondary financial or intellectual concerns. 
 
Value-Rig   Methodological Rigor 
The striving for excellence in research through the use of discipline, scrupulous adherence to 





Sugg  Suggestions for Federally-Sponsored Panels to Consider for the Development of More 
Trustworthy, Feasible, & Pertinent Outputs 
Ideas for the NIH to consider to strengthen panel composition and processes so that assessments 
and recommendations can be more trustworthy, pertinent, and feasible.  
 
Sugg-TW   Trustworthy Assessments & Recommendations  
When outputs are considered credible and held in high regard. 
 
Sugg-Pert   Pertinent Assessments & Recommendations 
Pertinent assessments and recommendations are applicable or relevant to professional societies 
and their members. These outputs "should be as inclusive of appropriately defined patient 
populations as scientific and clinical evidence and expert judgment permit, and they should 
explicitly state the populations to which statements apply." 
 
Sugg-Feas   Feasible Recommendations 
Feasible recommendations can be successfully implement in the context of a provider’s 
professional practice. Examples of variables that may influence feasibility include adequacy of 
the health care system (e.g., availability of equipment, volume & distribution of providers; 
external environment (e.g., political and economic conditions; and population characteristics of 
both providers and patients (e.g., knowledge; beliefs; personal, family, and community resources, 
which include decision-support tools and other knowledge couplers for providers. 
 
Feed    Feedback on Study 




































Appendix 18: Acronyms 
AACR  American Association for Cancer Research 
AAFP  American Academy of Family Physicians  
AANP  American Association of Nurse Practitioners  
AAP  American Academy of Pediatrics 
AAPA  American Academy of Physician Assistants 
ACA  Affordable Care Act 
ACG  American College of Gastroenterology  
ACIP  Advisory Committee on Immunization Practices 
ACOG  American College of Obstetricians and Gynecologists  
ACP  American College of Physicians  
ACR  American College of Radiology 
ACS  American Cancer Society 
AGA  American Gastroenterological Association 
AHRQ  Agency for Healthcare Research and Quality 
AMA  American Medical Association 
AMWA American Medical Women’s Association 
AOA  American Osteopathic Association 
ASGE  American Society for Gastrointestinal Endoscopy 
CAT  Computerized axial tomography 
CDC  Centers for Disease Control and Prevention 
CDP  Consensus Development Program 
CHR  Committee on Human Research 
CIPP  Context-Input-Process-Products 




CMSS  Council of Medical Specialty Societies  
COPD  Chronic obstructive pulmonary disease 
CRC  Colorectal cancer 
CRS  Congressional Research Office  
CT  Computed tomography 
CTC  Computed tomographic colonography  
DCBE  Double contrast barium enema 
DNA  Deoxyribonucleic acid 
DO  Doctor of Osteopathic Medicine 
DRE  Digital rectal exam 
EHR  Electronic health record 
FBOT  Fecal occult blood test 
FDA  U.S. Food and Drug Administration  
FIT  Fecal immunochemical test 
FS  Flexible sigmoidoscopy  
GAO  Government Accountability Office 
gFBOT Guaiac-based fecal occult blood test 
GIN  Guidelines International Network 
GRADE Grading of Recommendations Assessment, Development and Evaluation 
HMO  Health maintenance organization 
HRSA  Health Resources and Services Administration  
IOM  Institute of Medicine 
JNC Joint National Committee on Prevention, Detection, and Treatment of High 
Blood Pressure 
LSU  Louisiana State University 




MSTF  U.S. Multi-Society Task Force 
NAS  National Academy of Sciences 
NCI  National Cancer Institute 
NGC  National Guideline Clearinghouse 
NHLBI National Heart, Lung, and Blood Institute 
NIDDK National Institute of Diabetes and Digestive and Kidney Diseases 
NIH  National Institutes of Health 
NP  Nurse Practitioner 
ODP Office of Disease Prevention 
OHSR Office of Human Subjects Research 
ONC-NLC Office of the National Coordinator for Health Information Technology and 
 National Learning Consortium 
OTA  Congressional Office of Technology Assessment  
P2P  Pathways to Prevention program 
PA  Physician Assistant  
PSA  Prostate specific antigen  
QALY  Quality adjusted life years 
RCT  Randomized controlled trial 
UCS  Union of Concerned Scientists 
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